Fallbrook Technologies ... Farodox Energy Storage ... FarSounder ... FastCAP Systems ... Fate Therapeutics ... FEI ... Femta Pharmaceuticals ... Feuz Manufacturing ... Fiber Materials ... Fiber&Sensor  Fibersense ... Fibrocell Science ... FibroGen ... Filter Sensing Technologies ... Finisar ... Firefly BioWorks ... Firefly Energy .... Firefly LED ... First Solar ... Fisker Automotive ... Flex Biomedical ... Flexion Therapeutics .. FLIR Systems ... FloDesign Wind Turbine ... FlowCardia ... FlowMedica ... FlowMetrix ... FluGen ... Fluidigm ... Fluid Innovation Group ... Fluidnet ... FluoroPharma ... Follica ... FoldRx Pharmaceuticals ... Footnote ... F-Origin ... Forma Therapeutics ... Forus Health ... Foster-Miller... Foundation Medicine ... Fractal Antenna Systems ... Free Flow Power ... FTL Solar ... FuelCell Energy ... Fuel Tech ... Fusion Coolant Systems ... Galenea ... Galleon Pharmaceuticals ... Gamma Medica Ideas ... Gelesis ... GelTech ... Gemin X Pharmaceuticals ... GEMFIRE ... Gemmus Pharma ... Gen9 ... Genaera ... Genelabs Technologies ... Gene Logic ... General Compression ... Generex Biotechnology ... Genesis Laboratories ... Genetix Pharmaceuticals ... Genex ... Genocea Biosciences ... Genomatica ... Genomic Health ... GenomeQuest ... Genoptix Medical Laboratory ... Genor ... Gen-Probe ... GenSpera ... GenTel BioSciences ... Genzyme ... Geomagic ... GeoMed Analytical ... Geospiza ... GeoVax Labs ... GenVec ... Geron ... GI Dynamics ... GigOptix ... Giner ... Ginkgo BioWorks ... GlideLine Systems ... Gliknik ... GlobalPositions ..  Gloucester Pharmaceuticals ... GlucaGo ... GlycoFi ... GlyGenix ... GlySens ... GnuBio ... Good Start Genetics ... Gore Photonics ... GPC-Rx ... gRadiant Research ... Graphene Energy ... Graphic Surgery ... GreatPoint Energy ... GreenFuel Technologies ... GreenTech America ... Grove Instruments ... GSI Technology ... GT Advanced Technologies .... GTC Biotherapeutics ... GT Equipment .... GTI Diagnostics ... Guided Therapeutics ...G-Zero Therapeutics ... H2Pump ... H3 Biomedicine ... HNC Software ... Halozyme ... Hana Biosciences ... Hansen Medical ... Harbor Technologies ... Hardcore Computer ... Harvard Bioscience ... Harvest Automation ... Harvest Power ... Healionics ...HealthTronics ... Hearforward ... Heartland Robotics ... HeartWare International .... HeatGenie ... Helicos BioSciencesHeliovolt ... Helix Therapeutics ... HemaQuest Pharmaceuticals ... Hepregen ... Herley Industries ... Hermes Biosciences ... Hibernaid ... High Performance Technologies ... Histogenics ... HistoRx ... Hitite Microwave ...Hoku Scientific ... Hollis-Eden Pharmaceuticals ... Hontek ...Hoppe Tool ... HTSS ... Humacyte ... Human Genome Sciences ... Hybrivet ...HYCOR Biomedical ... Hydra Biosciences ... HydroCision ... Hydrogen Safety ... Hygeia Therapeutics ... HyperBranch Medical Technologies ... Hyperion Therapeutics ... HyperMed ... Hypres ... Hy-SyEnce ... IAP Research ... IBC Advanced Technologies ... Ibis Technology ... iBLogix ... IBT Laboratories ... Icagen ... ICx Technologies ... Idaho Technology ... Ideal Power Converters ... IdeaPaint ... II-IV .. Ikaria... Ikonisys ...Illinois Superconductor ... Illumigen Biosciences ... Illumina ... IlluminOss Medical ... Illumitex ... Imaging Biometrics ... Imago Scientific Instruments ... Immersion ... Immtech ... Immune Control ... Immune Design ... Immunetics ... ImmuneWorks ... Immunicon ... ImmunoGen ... Immunomedics ... ImmuRx .... ImmusanT ... II-VI ... Impact Science & Technology ... Imperium Renewables.. Impinj<.a> ... Implant Sciences ... Impulse Monitoring ... ImThera Medical ... i-Nalysis .. . INC Research ... Incelldx ... Incyte ... Indiana Nanotech ...Infinera ... Infinia ... Infinity Pharmaceuticals ... Inform Genomics ... Infoscitex ... Inframat ... InfraReDx ... InfraScan ... Inhibitex ... INI Power ... InnerOptic Technology ... InnerPulse ... Innography ... InnoPad ... Innovalight ... Innovari Energy ... Innovative Microplate ... Innov-X ...Innovative Silicon ... Innovative Spinal Technologies .... Innovative Technologies ... InnovaWave ... Inorganic Specialists ... Inotek Pharmaceuticals ... Inovio Biomedical ... InPhase ... Inphi ... Insight...InSite Vision ... Insitu ... Inspire Medical Systems ... Inspire Pharmaceuticals ... Insulet ... IntAct Labs ... Intaglio ... Intalio ... Integra Group ... IntegenX ... Integrated Fuel Cell Technologies ... Integration Associates ... Intelleflex ... Intelligent Automation .. Intelect Medical ... Intelligent Medical Devices ... Intelliphage ... Intellisense... Interactive Supercomputing ... Interlace Medical ... Intermagnetics General ... Intermolecular ... InterMune ... Intersense ... Intersystems ... International Stem Cell ... Intevac ... IntraLase ... Intrinsity ... Introgen Therapeutics ... Intuitive Surgical ... Invensense ... Inverness Medical Innovations ... InView Technology ... Inviragen ... InVisage Technologies ... Invitrogen ... Invivosciences ... Iomai ... Iomed .. Ion America ... Ion Optics ... Ion Torrent ... Iovation ... Iowa Thin Film Technologies ... IPG Photonics ... IQuum ... iRobot ... Ironbridge Technologies ... Ironwood Pharmaceuticals ... Irvine Sensors... Isis Biopolymer ... Isis Pharmaceuticals ... Island Data ... Isogenis ... IsoRay ... Isothermal Systems ... Itaconix ... I-Therapeutix ... Itherx Pharmaceuticals ...iWalk ... J&Y International ... Janus Biotherapuetics ... Javelin Pharmaceuticals ... Jennerex ... Joule Biotechnologies ... Joyent

Fallbrook Technologies (San Diego, CA)

Fallbrook Technologies (San Diego, CA; no SBIR) has raised another $6 million in venture capital, according to an amended IPO registration form the company filed with government regulators Friday. Fallbrook, which is developing an innovative continuously variable transmission (CVT) for a variety of applications, originally filed for an IPO in February ...  launched the first version of its NuVinci transmission for bicycles in 2007 ... With the most recent Series E venture investment, entities associated with Rabobank of The Netherlands, have a 24.6 percent stake ... cleantech venture firm NGEN Partners increased its ownership to 24.2 percent. Both groups provided $2 million in additional venture funding, as did a third, unidentified venture investor. The company says it has raised a total of $62 million to develop its core CVT technology and develop products for various markets, and has a combined total of 365 patents and patent filings [Bruce Bigelow, signonsandiego.com, Sep 18, 10]

Farodox Energy Storage

Nanohmics (Austin, TX; $16M SBIR)  was among 44 companies nationwide recognized for success in commercializing science and technology innovations with the help of [SBIR] Nanohmics President and co-founder Mike Mayo was at the White House last week to receive the Tibbetts Award, which recognizes companies that have achieve excellence using SBIR. ... founded in 2002, created two new companies to commercialize unique technologies. ... The SBIR program "allowed three first-time entrepreneurs to take the risk of creating a new venture," Mayo said. So far, he said, that has led to the creation of 30 jobs in the Austin area.  Faradox Energy Storage develops high-performance capacitors that can operate in high temperatures. GlideLine Systems develops parachute navigation systems for military special forces personnel.  [Austin American Statesman, Feb 22, 11] Believe what you will about what the Tibbetts Award actually recognizes.  Roland Tibbetts had an interesting idea of an SBIR for NSF which had never funded much small for profit business. But by the time the politicians and the federal agencies captured SBIR for their purposes, the idea had been mangled by self-serving federal management. Nearly thirty years later, it still cannot show any net economic gain over what would have happened if the federal agencies just spent their R&D unmolested by such social programs. Nevertheless, the SBIR advocates hold the principle that anecdote is the singular of data, and if you accept the anecdotes, the whole data must be a mere multiple of them. 

The Texas Emerging Technology Fund is pumping more money into Central Texas technology startups.  Six more Austin companies have won grants totaling $5.3 million.  Among the six new grant winners is year-old NanoMedical Systems (no SBIR) which will use its $3.5 million to develop a tiny implantable capsule that delivers drugs a few molecules at a time, with the dosage controlled precisely for each patient. The company is completing a prototype using $4 million from a private investor, said co-founder and chief executive Randy Goodall. The grant will help fund it through the complex and time-consuming process of seeking Food and Drug Administration approval, Goodall said. ...... Farodox Energy Storage  (no SBIR), which has developed a new fabrication process for high-performance electrical capacitors, $250,000; ...  Ironbridge Technologies (no SBIR), which is developing self-heating food packaging technology, $250,000;  ... Merkatum (no SBIR), which is developing fingerprint and facial recognition identity technologies, $250,000;   .....  Stellarray (no SBIR), which is commercializing flat-panel radiation source technology, $750,000; ...  Sunrise Ridge Algae (no SBIR), which is commercializing technology to turn algae into a renewable energy source. [Lori Hawkins, Austin  American-Statesman, Nov 17, 08]

FarSounder (Warwick, RI)

FarSounder (Warwick, RI; one SBIR) also got a $2M NIST grant to develop a navigation sonar system.

FastCAP Systems (Cambridge, MA)

several Massachusetts projects will receive a total of $33.2 million in federal funding for energy research.  1366 Technologies (Lexington) $4 million; , Agrivida (Medford; $300K SBIR) $4.6 million for efforts to cut the costs of cellulosic biofuels and chemicals; MIT $7 million on all-liquid metal grid-scale batteries; FastCAP Systems (Cambridge) $5.3 million to reduce the cost of hybrid and electric vehicles and of grid-scale storage; FloDesign Wind Turbine (Wilbraham) on new high efficiency shrouded wind turbines that could reduce noise and safety concerns $8.3 million ; Sun Catalytix (Cambridge) $4 million for a novel catalyst to enhance the efficiency of splitting water into hydrogen and oxygen. [Boston Globe, Oct 27, 09]

Fate Therapeutics

Fate Therapeutics (San Diego, CA; no SBIR) on a quest to develop techniques that make stem cell research practical for the pharmaceutical industry, has raised $30 million in a Series B round of venture financing.  [Xconomy.com, Nov 16, 09]

A group of venture capitalists is investing $12M to launch Fate Therapeutics, a biotech company aiming to develop drugs that spur dormant adult stem cells to regenerate damaged tissue. The budding biotech expects to have a product in early-stage clinical trials by next year [Angel Gonzalez, Seattle Timers, Nov 30]

FEI (Hillsboro, OR)

FEI up 14% [Oct 28, 11]

FEI  down 10% [Oct 3, 11]

FEI up 16% [Feb 4, 11]

FEI up 10% [Nov 3, 10]

FEI (Hillsboro, OR; $300K SBIR) up 5% authorized a buyback program of four million shares, citing its strong cash flow and positive outlook. [Wall Street Journal, Sep 21, 10]

FEI  said that its fourth-quarter bookings beat its forecast by more than 13 percent.  [The Oregonian, Jan 6, 09]

The vanguard of Oregon's nanotechnology industry was the state's best-performing stock in the first quarter. Shares of FEI Co. leapt 37% as it shocked investors with unexpectedly strong sales and a profit surge. [Oregonian, Apr 1, 07]

FEI lost 14% after reporting a fourth-quarter loss and saying it ended merger talks with Germany's Carl Zeiss.  FEI had one Navy SBIR Phase 2 in 1993 five years after the Phase 1. Note: the SBIR law imposes no time limit on Phase 2.

Femta Pharmaceuticals (San Diego, CA)

Femta Pharmaceuticals (San Diego, CA; no SBIR)  raised $2.2 million in equity and options financing ... to develop antibody drugs with super-high affinity, meaning they bind tightly to their chosen target on cells, and can be effective at tiny doses  [Luke Timmerman, signonsandiego, com, Jul 15, 10]

Feuz Manufacturing (Rotterdam NY)

GE is suing a former supplier from  for allegedly stealing trade secrets ... Feuz Manufacturing (Rotterdam NY; no SBIR), made parts that GE Energy used in the manufacturing of gas turbines, including pins, rotors and other turbine parts.  GE claims that Feuz used GE's engineering designs to make parts that it sold to GE competitors. [Albany Times-Union, Sep 29]

Fiber & Sensor Technologies (Blacksburg, VA)

Though Murphy had flunked out of Virginia Western Community College three times when he first started working with glass and light, he was smart. He had a knack for making things work better and was notorious for juicing up motorcycles he raced with friends. A would-be electrical engineer who skipped his own studies, Murphy was known as a slacker who would shout out answers to complicated math problems as he wandered the halls of his high school, from which he graduated third from the bottom in class of 430. [Nicholas Johnston, Washington Post, Dec 16,02]  Not an auspicious start for an entrepreneur, or is it notice that the education system lacks something? This Murphy founded Luna Innovations (Blacksburg, VA) to mine technology from Va Tech. It started in 1990 as Fiber & Sensor Technologies which submitted lots of SBIR proposals to embed optical fibers in almost anything, winning at least 22 Phase 2s and another 15 or so recent Phase 1s which are candidates for Phase 2. .Why not?  Feeding 100 employees is no small task. He also has five commercial companies funded privately with another 50 employees. Murphy paid hsi dues to the academics by eventually getting an MEE from Virginia Tech. Whether his tech transfer entrepreneuring returns much to Tech remains to be seen, but it at least makes a good human interest story. Like most TT stories, the emotional outweigs the economic.

Fiber Materials (Biddeford, ME)

former president of Fiber Materials (Biddeford, ME; $13M SBIR) agreed to plead guilty to federal charges arising from a bribery scheme ....  accused of orchestrating a conspiracy that involved two officials at the Army Space and Missile Defense Command. He faces up to 20 years in prison. ... Prosecutors say [he] and the officials agreed to split and personally use money earmarked for missile defense contracts. [They] have pleaded guilty and are awaiting sentencing. .... Most of the material delivered by [sub-contractor] was worthless, a fact that [the Army officials] covered up while continuing to funnel earmarked money to [his] sham companies in return for a share of the gains  [AP, Jan 24]  Fiber had a very nice business in ICBM nose cones until the Cold War stopped.

Earmarks Too Tempting.  Two former missile-command officials pleaded guilty early this year in federal court to public-corruption and conspiracy charges. Their plea agreements detail a conspiracy in which politically connected defense contractors that lobbied for congressional funding, called earmarks, bribed the officials to steer the funds to sham subcontractors.... The Army Space and Missile Defense Command (the Army's Star Wars component) awards some $500 million a year in research work. In some years as much as one-third of the funds is directed by members of Congress through earmarks or other means to contractors in this military boomtown.   Two SBIR firms have been named in news reports of the ongoing probe: Vicus Technologies (Kennebunk, ME; $2M SBIR), and Fiber Materials (Biddeford, ME; $13M SBIR)  [John Wilke, Wall Street Journal, Apr 14]

Intermat (Biddeford, ME; $400K SBIR) landed a $12M contract for materials science R&D for the U.S. Navy. [Mass High Tech, Jan 23, 08]  The company is a subsidiary of nosecone materials expert Fiber Materials (17 Phase 2 SBIRs and counting) whose prospects were substantially dimmed by the standown of US ICBMs after the Cold War. 

Fibersense (Canton, MA)

Fibersense had three SBIR Phase 1s to engineer GPS navigation units for missiles, was bought by Northrop Grumman for $44M. (Jan 03)

Fibrocell Science (Exton, PA)

Fibrocell Science (formerly Isolagen, Exton, PA; no SBIR) signed an agreement to establish a joint venture with Hefei Meifu Bio-Tech Ltd. Co. of China to market Fibrocell’s cellular therapy products in Asia, except for Japan.  [John George, Philadelphia Business Journal, Nov 3, 10]  Hefei is twice the size of Houston and who every heard of it? 

Fibrocell Science (Exton, PA; no SBIR) entered into a $3.8 million securities purchase agreement with unidentified accredited investors. .... developing regenerative cell therapy treatments for aesthetic, medical and scientific applications. [John George, Philadelphia Business Journal, Mar 3, 10]

FibroGen (South San Francisco, CA)

San Francisco hopes to develop the commercial zone around UCSF's Mission Bay campus with help from biotech firm FibroGen (South San Francisco, CA; $1.3M SBIR), which is participating in an incubator to help medical startups become companies.....  moved to San Francisco last year and now has 250 employees, has devoted some unused space at its Mission Bay headquarters to the incubator, which has signed up five startups and has room for more, company officials said  [Tom Abate, San Francisco Chronicle, Jul 15, 09]

Filter Sensing Technologies (Cambridge, MA)

Finisar (Sunnyvale, CA)

Finisar  (Sunnyvale, CA; one SBIR) said it plans to offer $75 million of convertible senior notes.  [Silicon Valley/San Jose Business Journal, Oct 7, 09]

Firefly BioWorks (Cambridge, MA)

Firefly Energy

Big Yellow Batteries.  Firefly Energy [Barbara Rose, Chicago Tribune, Oct 14]

Firefly LED (Austin, TX)

FireFly LED (Austin, TX; no SBIR) startup that makes LED light bulbs, will receive a $3 million grant from the Texas Emerging Technology Fund.  ...  housed in the Austin Technology Incubator, says its bulbs use less energy, generate less heat and last longer than traditional lighting.  ...  is working with the University of Texas on commercializing the product.   ...   last year raised $300,000 in seed money from angel investors [Austin American Statesman, Feb 10, 11]

First Solar (Tempe, AZ)

First Solar up 11% [Nov 28, 11]

First Solar up 15% [Oct 27, 11]

First Solar down 25% [Oct 25, 11]

The U.S. Energy Department said it is offering to guarantee about $4.5 billion in loans for First Solar  to finance three renewable energy projects in California that the solar-panel maker is developing ... will supply thin-film solar panels for the plants from an existing manufacturing facility in Ohio as well as a new plant in Arizona.   [Ryan Tracy, Wall Street Journal, Jul 1, 11]

First Solar Chairman Michael Ahearn may be taking a dimmer view of the solar-power company these days, having cut his stake by nearly half in the past month. Mr. Ahearn, who has led the board since 2000 and was chief executive for nine years, dumped 800,000 shares valued at $118.9 million ... Before this spate of transactions, Mr. Ahearn last sold shares in early 2010, nearly halving his holdings at that time as well. [Melissa Korn, Wall Street Journal, Mar 30, 11]

First Solar said it is working with China Guangdong Nuclear Solar Energy Development Co. to revive a project to build what it expects to be the world's largest solar-energy plant in China's Inner Mongolia region. .... China aims to generate 20% of its power from renewable sources by 2020.  [Wall Street Journal, Jan 6, 11]  Unlike the give and take of American government plans, if China's government wants to do something, it simply draws a line on the map.

investment-advisory firm, Alan B. Lancz & Associates ...  is currently shorting ...First Solar whenever the solar-panel maker is trading over $150 a share, according to Mr. Lancz.  "A lot of First Solar's business is based on subsidies which may be pulled back by governments, particularly in Europe," said Mr. Lancz. A First Solar representative referred to relevant portions of the company's recent third-quarter earnings conference call that showed the company's strategy in subsidized markets is to price for the long term and in transition markets is to drive down the levelized cost of energy by pricing and anticipation of cost declines. [Alejandro Martinez, Wall Street Journal, Nov 26, 10]

First Solar up 18% [Apr 29, 10]

In the nearby city of Frankfurt/Oder, the factory that made the solar cells used at Lieberose, owned by First Solar, an American firm, cannot keep up with demand as one sheet of glass after another rolls down its production line.  In Germany this is seen as vindication of an industrial policy that has nurtured solar power for almost a decade with incentives known as feed-in tariffs.  [The Economist, Jan 9, 10]

only one American company (First Solar) among the top 10 worldwide in photovoltaic-cell production in 2008. But the European Commission does not even classify First Solar as being an "American" company, instead labeling it "international" because it does most of its production in Asia. The U.S. federal government has invested hundreds of millions of dollars in photovoltaics research and development, yet the United States accounted for only 5.6 percent of global production of photovoltaics in 2008, down from 30 percent in 1999. Chinese production, by contrast, represented only 1 percent of global output of photovoltaics in 1999. By 2008, its output had risen to 32 percent of global production.  [Richard McCormack, The American Prospect, Dec 21]

First Solar down 17% [Oct 29, 09]  third-quarter profit jumped 54% as the maker of thin-film solar-power modules posted higher revenue, but margins slumped on pricing pressures. As revenue missed Wall expectations,  [Wall Street Journal, Oct 30]

First Solar will enter the Standard & Poor's 500 index.  [Oct 1, 09]

First Solar up 11% [Sep 8, 09]

First Solar down 11% [Jul 31, 09]

FBR Capital Markets analyst Mehdi Hosseini said [First Solar's] stock will be pressured by the decline in polysilicon prices amid weak demand in Europe. [Wall Street Journal, May 27]

First Solar  up 23% [Apr 30, 09] first-quarter net income more than tripled on surging revenue and margins [Wall Street Journal, May 1]

First Solar  up 11% [Mar 26, 09]

First Solar up 11% [Mar 10, 09]

An Earnings Eclipse at First Solar  Shares of First Solar , the Tempe (Ariz.)-based maker of photovoltaic cells, had been holding up somewhat better than the rest of the solar industry—at least until Feb. 24. That's when the company reported fourth-quarter earnings, along with a startlingly glum outlook for 2009. First Solar said it would have to help some of its customers finance upcoming projects, cutting into 2009 revenue. CEO Michael Ahearn also noted that 10% to 15% of current orders could vanish if clients default. Shares plummeted 20% over the next week and dragged down the sector. "First Solar is not immune from absolute demand destruction that is materializing in the wake of the global economic malaise," wrote Jonathan Hoopes, an analyst at research firm ThinkEquity. He recommends investors sell the stock. [Aaron Pressman, Business Week, Mar 16]

The financial crisis has wreaked havoc on the big-swinging solar stocks. Since September, solar energy stocks have lost 79% of their value, according to the Claymore/MAC Global Solar Energy Index exchange-traded fund. ....  First Solar is another hot company due to its unique manufacturing process. Unlike SunPower's conventional crystalline silicon-based solar products, First Solar uses thin-film technology, which is cheaper. As a result, the Tempe, Ariz.-based company saw earnings and revenue double in 2008. For the year, First Solar reported net income of $348 million on revenues of $1.25 billion. ....  Energy Conversion Devices also uses thin-film technology, but its product is different in interesting ways. Most solar panels are hard, flat planes, but ECD's product can be rolled onto roofs in strips, are lightweight, and can become part of the physical roof. ....   But the nascent market likely will benefit from a number of trends, including the reduction of carbon sources, resistance to nuclear energy and the potential for renewable mandates and carbon dioxide regulations.  Industry observers say those trends will lead to higher costs for conventional energy sources, while solar energy prices decrease. Says O'Rourke: "When that happens, it will be potentially explosive."  [Carl Gutierrez, Forbes, Mar 6, 09]

First Solar, the darling of the photovoltaic industry, confronts new competition and a bum economy....  In an industry marked by broken promises, First Solar has been a success story. It delivered growth and big, uninterrupted profits. .... More than 100 startups are trying to bring to fruition a thin-film technology called CIGS ...  Meanwhile, the cost of making traditional crystalline cells is dropping, making it easier for companies like Q-Cells and Suntech to compete with First Solar on price. Those companies saw the price of polysilicon triple to $450 per kilogram in 2008. The price is now near $100, and some expect it to fall as low as $30. ... It doesn't help build confidence that First Solar insiders are getting out. Ahearn sold half his shares over the past two years, for $380 million. [Jonathan Fahey, Forbes, Mar 16, 09]

First Solar down 22% [Feb 25, 09]  fourth-quarter earnings more than doubled, but management's cautious tone during an earnings conference call dragged down shares  [Wall Street Journal, Feb 26]

First Solar  up 10% [Feb 24, 09]

First Solar up 10% [Jan 2, 09]

First Solar up 12% [Dec 17, 08]

First Solar up 14% [Dec 16, 08]

Green Goes Dark. One of the best-performing stocks of 2007 was none other than First Solar, up an incredible 795%.  ... But wait!  First, there's significant government involvement in the sector that distorts market forces. That is an immediate red flag for prospective investors. Whenever the government is involved in something, there can be no certainty.  Second, green tech development cycles are becoming increasingly rapid. What seems like a great idea today could be obsolete tomorrow. For an investor in an early-stage company, your product may never get to market -- so you're staring down a significant risk of total capital loss.   Finally, though we can expect more "green" spending in an Obama administration, our country still hasn't decided what the goal of green tech is  [Tim Hanson, Motley Fool, Dec 9]

First Solar down 13% [Dec 9, 08]

Solar Stocks. a few standouts may shine in the long run.... the Solar Power International 2008 convention drew attendees from 70 countries and generated lines stretching out the door for parking, food, and just about everything else.  ... With subsidies, First Solar's products can compete in many parts of the world with a natural gas or coal-fired power plant.  ... SunPower claims the most efficient. ... Suntech Power offers  scale ...  But for now, The shares of even the best solar companies have fallen on hard times.  [Michael Copeland, Fortune, Nov 10]

First Solar up 15% [Dec 3, 08]

First Solar  down 12% [Dec 1, 08]  On a stock bloodbath day

First Solar up 21% [Nov 24, 08]

First Solar up 12% [Nov 13, 08]

First Solar down 16% [Nov 12, 08]

First Solar down 14% [Nov 5, 08]

First Solar up 10% [Nov 4, 08]

First Solar up 13% [Nov 3, 08]

First Solar capitalized on the growing sustainability trend and increased production at its plants to more than double its net income and revenue in the third quarter.   ... investing $25 million in installer SolarCity Corp. and signing a deal to supply the company with more than 100 megawatts of panel generation capacity. [Phoenix Business Journal, Oct 29, 08]

First Solar up 24% [Oct 30, 08]

First Solar down 10% [Oct 27, 08]

First Solar up 15% [Oct 16, 08]

First Solar down 14% [Oct 15, 08]

First Solar down 20% [Oct 7, 08]

First Solar down 10% [Oct 2, 08]

First  Solar down 13% [Sep 29, 08]

First Solar down 11% [Sep 9, 08]

Thin Is In. from the Southwest to Silicon Valley to Germany. Everywhere you look, thin-film solar companies are opening new, more efficient factories. .... As First Solar scaled production up, it was able to bring its costs down. Solar producers measure their costs in terms of dollars per watt of energy produced, a formula that's a combination of the cost of producing a module and its power efficiency. Right now the best crystalline-silicon makers can sell modules at $3 to $4 a watt; First Solar can sell at around $2.40 a watt, a price the company expects to reduce steadily. ... Nanosolar announced it would begin profitably selling thin-film panels at $1 a watt. ... says he can achieve radical cost savings by directly applying photoactive chemicals with an ink composed of nanoparticles. ... [dubious] competitors pointing out that the cost of raw materials alone should make it impossible to produce $1-a-watt panels profitably.   [Bryan Walsh, Time, Jun 23, 08]

First Solar stock has risen dramatically since its initial public offering in November 2006, but the threat of stiffer competition could take some of the shine off of its shares. ... trading at a price/earnings ratio of about 97.50 ... the company is vulnerable to new thin-film entrants and a potentially large drop in manufacturing costs for traditional solar makers," wrote Kaufman Bros. analyst Theodore O'Neill ...  module manufacturing costs were $1.14 per watt in the first quarter, while conventional solar cells cost about $3 per watt to produce, according to Raymond James analyst Pavel Molchanov. The company said it aims to get its costs down to 65 cents to 70 cents per watt by 2012 at the latest  [Riva Richmond, Wall Street Journal, Jun 11]

First Solar down 10% [May 1, 08]

While all the presidential candidates were railing about lost manufacturing jobs in Ohio, no one noticed that America’s premier solar company, First Solar, from Toledo, Ohio, was opening its newest factory in the former East Germany — 540 high-paying engineering jobs — because Germany has created a booming solar market and America has not.  [Tom Friedman, New York Times, Apr 30]

I Saw it on TV.  First Solar up 10% [Apr 4, 08] after Street wag Jim Cramer told viewers of his "Mad Money" TV show, "When it comes to solar stocks, there's only going to be one winner,"  Thursday. And that winner is First Solar " [theStreet.com, Apr 4]

First Solar up 12% [Mar 11, 08]

First Solar down 10% [Mar 10, 08]

First Solar up 30% [Feb 13, 08] as fourth-quarter net income surged amid falling manufacturing costs and soaring demand [Wall Street Journal, Feb 14]

First Solar up 10% [Feb 11, 08]

First Solar down 10% [Jan 23, 08]

First Solar down 11% [Jan 16, 08]

First Solar up 10% [Nov 29, 07] to 173 times earnings.

First Solar up 11% [Nov 16, 07]

First Solar down 15% [Nov 12, 07].

First Solar up 34% as blasted past its earning estimates and drew cheers from analysts. [MarketWatch, Nov 8, 07]

First Solar up 14% as investors sang "Good Day Sunshine" upon learning that the solar energy company's new deals will bring more sales. ... First Solar's thin film solar panels use Cadmium Telluride. Others use mixtures of other materials, such as copper, indium and gallium. [Carl Gutierrez, Forbes, Nov 6, 07]

refined silicon, the most costly and crucial element in solar panels, has been in short supply for the past four years. There are only about a half-dozen companies world-wide that purify silicon .. and they haven't built new refineries fast enough to keep up with rising demand.  ... First Solar  recently came to market with the first "thin-film" solar panels that use only 1% of the silicon found in conventional solar panels. The firm's revenues are booming ... Despite decades of hype and hope, solar still accounts for less than 1% of the world's energy needs and is significantly more expensive than coal-generated power. It costs 35 to 45 cents to produce a kilowatt-hour of electricity from solar panels, compared with about three to five cents burning coal  [Leila Abboud, Wall Street Journal, Sep 21]

Overpriced and dependent on subsidy said Barron's about First Solar stock prospects. [its] technology is more cost-effective than competitors, it still falls short of the huge potential for Solar 2.0, a thin-solar energy technology based on chemicals and vapor deposition. First Solar is also highly dependent on European government subsidies, especially in Germany, which said two weeks ago it wants to cut subsidies further for solar ... Barron's also identified five 'green' stocks to watch that it believes may either be acquisition targets or become household names in their own right. SunPower, Environmental Power, Fuel Tech, Pico Holdings, and Composite Technology  [Reuters, Jul 15]  At 500 times earnings, it's easy to see overpricing.

First Solar rocketed 24% after announcing $1.6B in new business. [Jul 9, 07]

Motley Fool is flogging First Solar as an Unloved Growth Stock with a low short interest and a 65% expected annual profit growth rate. And SunPower for a 40% growth rate. Thatsalotta growth. [Jun 07]

Investors took a shine to First Solar, lifting its shares a day after the solar-cell maker said it swung to a quarterly profit that trumped Wall Street's expectations. [AP, May 4, 07]

First Solar up 11%. [Mar 12, 07]  after being included in NASDAQ Clean Edge Index.

First Solar jumped 28% on surprise high profits and plans to supply products for a solar-power plant in Germany. It started life in Toledo with a 1999 DOE Phase 2 SBIR (just one, thank you, we're a serious business) for its CdTe technology and now has a $3B market cap in Phoenix (where the sun shines more). The stock price is now up 75% from its first trading three months ago.

First Solarrose 23% after its IPO [Nov 17, 06]. The new technology is photovoltaics from CdTe, a favored material for IR sensors. Good news for American jobs from the one Phase 2 SBIR? Not quite. Earlier this year FSLR got 45M euros worth of breaks to build a 400-worker plant in Germany.

Fisker Automotive

Uncle VC. DOE had a bolder idea ...  Fisker Automotive, a two-year-old business that has yet to sell a car, won loans from the federal government totaling $528 million. Fisker had joined a flock of other businesses seeking cash from the biggest venture capitalist of all, the U.S. government. The DOE hopes to lend or give out more than $40 billion to businesses working on "clean technology," ...  In the first nine months of 2009, the DOE doled out $13 billion in loans and grants to such firms. By contrast, venture-capital firms .. poured just $2.68 billion into the sector in that time, according to data tracker Cleantech Group. ... The result is an intertwining of public and private-sector interests in an arena where politics is never far from the surface.  [Neil King, Wall Street Journal, Dec 15]  Government's track record as a VC doesn't suggest much hope for success in picking economic "winners". Its two-plus decades of SBIR deliberately shuns any economic evaluation, and the $500+ million to the start-up auto company is to re-open a big Delaware (home of the VPOTUS) auto assembly factory amid a world over-capacity for auto production.

Flex Biomedical (Madison, WI)

Flex Biomedical  (Madison, WI; one SBIR) that is developing treatments for orthopedic diseases said Wednesday that it has raised $866,000 of outside funding. ....  to further develop its lead product, said Sal Braico, chief executive officer. Called Flex Polymer, the product is a synthetic, injectable substance with the potential to relieve pain and protect cartilage from further degradation  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 26]

At least 14 [Wisconsin] biotech companies have received more than $3 million in grants ($240K each) from the Internal Revenue Service as part of a federal program to spur job growth at smaller firms and advance the country's life sciences prowess, according to a BioForward survey. ....  More than 5,600 companies applied for the grants and at least 4,000 companies were expected to receive them, according to BIO, the national trade organization for the biotech industry. .... The Qualifying Therapeutic Discovery Project was part of health care reform legislation passed earlier this year. The program provides grants or tax credits to companies of fewer than 250 employees to help create and sustain high-paying jobs and to advance the nation's competitiveness in life sciences. [Kathleen Gallagher, Milwaukee Journal Sentinel, Nov 2] Flex Biomed (Madison, WI; one SBIR) ;  NanoMedex Pharmaceuticals (no SBIR); FluGen (no SBIR).  BTW, BIO is the political champion of VC in SBIR awards, a barrier to House-Senate agreement on SBIR re-authorization, which will be up in the air again as the House committees change leadership.

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] ....  founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers.  ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

Six start-ups will be recognized for making strides to commercialization at a biotech industry summit in October. ... part of a one-day Biotechnology Vision Summit 2009 that is being run by BioForward, an organization that represents Wisconsin's biotech industry. AquaMost LLC (Madison, WI; one SBIR) , Echometrix  (Madison, WI; no SBIR), Flex Biomedical Inc(Madison, WI; one SBIR), Semba Biosciences (Madison, WI; no SBIR),  Invivosciences LLC (Wauwatosa, WI; no SBIR), and Rapid Diagnostek Inc  (Hudson, WI; no SBIR).  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 22, 09]

Flex Biomedical (Madison, WI; one SBIR)  developing treatments and diagnostics for orthopedic diseases, said that it has raised $985,000, including a $150,000 loan from the state's Technology Venture Fund, and that it is moving its operations from Boston to Madison. [Guy Boulton, Milwaukee Journal Sentinel, Aug 12, 09]

Flexion Therapeutics (Woburn, MA)

Flexion Therapeutics (Woburn, MA; no SBIR)  has closed a first round of venture capital financing worth $42 million. The company also announced that it has acquired four potential drugs from large pharmaceutical companies. [Mass High Tech, Jan 29, 10]

Flexion Therapeutics (Woburn, MA; no SBIR) said it has completed a Series A financing round totaling $33 million. "The funds will be used to advance a number of promising drug candidates through clinically meaningful proof of concept and beyond," Flexion said in a press release. [Boston Globe, Oct 16, 09]

FLIR Systems

[The Army] announced Wednesday that Flir Systems had won an uncontested contract to provide 48 of its Star Safire II night vision and infrared camera systems to the Army. But the announcement was accompanied by a solicitation number that the Army Contracting Command says doesn't exist in its database.  As a result, the Army couldn't say how the Safire II systems would be used. [Mike Francis, The Oregonian, Sep 15, 11]

The Navy will pay a little more than $750,000 each for 34 of Flir Systems Inc.'s Star Safire 380 high-definition camera systems under a $25.51 million fixed-price contract ... [DOD] said 60 percent of the work will be performed in Afghanistan and 40 percent in Wilsonville [Mike Francis, The Oregonian, Aug 29, 11]

Flir said it has bought infrared and laser component maker Aerius Photonics (Ventura, CA; $14M SBIR) for $27 million. The seven-year-old company makes infrared detectors, lightweight laser rangefinders and infrared illuminators and pointers. [Brent Hunsberger, Oregonlive.com, Jul 22,11]

FLIR Systems to provide sensor systems and service as part of the Naval Shipboard Protection System program. Flir won a $7,785,143 firm, fixed-price indefinite delivery contract for its systems after a noncompetitive bidding process.  [The Oregonian, Jul 15, 11]

FLIR Systems to provide surveillance equipment and technology to the Customs and Border Protection Division working to stiffen the border between Mexico and the United States. The big prize was a five-year contract worth up to $101.9 million to a FLIR subsidiary via a recent acquisition, ICx Technologies (Arlington, VA).  ....  Also this week, the Defense Department said it had awarded FLIR a $15.9 million, one-year contract to provide 36 night-vision systems and training classes to the Army Aviation & Missile Command [oregonlive.com, Jan 6, 11]

Homeland-security products maker ICx Technologies (no SBIR) rose 14% after saying it has agreed to be acquired by large-cap Flir Systems for about $274 million. [Wall Street Journal, Aug 17, 10]

Flir Systems said it will buy troubled British marine GPS maker Raymarine for $180 million, outbidding GPS giant Garmin, and effectively entering the marine electronics industry. .... will give it access to more than 1,000 retail outlets in which it can distribute its new handheld night-vision cameras for boaters. [Brent Hunsberger, The Oregonian, May 13, 10]

Flir Systems fell 8% as quarterly earnings fell 7.3% on lower margins and weak business in its government segment. Also, its 2010 per-share earnings forecast was below analysts' expectations.  [Wall Street Journal, Feb 12, 10]

Flir Systems said it has acquired Directed Perception (Burlingame, CA; no SBIR) for $20 million in an all-stock deal. ... Directed Perception makes pan-tilt motion control systems for commercial and military markets. [Portland Business Journal, Dec 27, 09]

A federal judge in Texas on Monday threw out most of a trade secret theft case brought by defense giant Raytheon Co. against a subsidiary of Wilsonville-based Flir Systems, Inc. Raytheon sued Indigo Systems Corp. in March 2007 claiming it had hired dozens of Raytheon employees over time to learn trade secrets of its infrared cameras. Flir bought Goleta, Calif.-based Indigo in 2004.  [Brent Hunsberger, The Oregonian, Sep 1, 09]

Flir Systems has been chosen for inclusion in the Standard & Poor’s 500 index. [Portland Business Journal, Dec 31, 08]

FLIR Systems will replace National City in the Nasdaq bellwether index.

InsiderInsights.com is keeping 30% of his model portfolio in cash and adding a short position in Flir Systems, maker of thermal imaging systems for military, law-enforcement and commercial uses.  Starting in late October, Flir insiders, including Chairman and Chief Executive Earl Lewis, sold 430,000 shares through option exercises as Flir's stock price declined -- "a very bearish signal" that Mr. Moreland calls "selling on weakness."  [David Reynolds, Wall Street Journal, Dec 3]

FLIR Systems received an $96.6 million U.S. Army contract for its stabilized multi-sensor systems. [Boston Globe, Sep 11]

War Brings Profit. Flir Systems which makes infrared night-vision cameras and heat-detection products, said first-quarter profit rose 42% on higher government-sector sales. The results, announced before markets opened Thursday, sent its shares soaring 10%. [The Oregonian, Apr 25, 08]

A federal appeals court threw out a lower court ruling that the U.S. attorney's office in Portland used tricks and deception in the prosecution of three former executives of Flir Systems ($1.6M SBIR) [The Oregonian, Apr 5, 08]

Flir Systems reported a 43% leap in sales, and announced plans to acquire Extech Instruments (Waltham MA; no SBIR) [ for $40M cash] and split Flir's stock. ... Flir is among many companies benefiting from the U.S. military's increased demand for battlefield tools and weapons [Joe Rojas-Burke, The Oregonian, Oct 26]

FLIR Systems up 14% [Oct 25, 07]

FLIR Systems landed a $25M Navy deal for handheld, thermal imaging binoculars. [Mass High Tech, Jun 18, 08]

Spending on products suited for deployed troops in harm’s way remained the most dominant spending driver for the group. Companies such as FLIR (FLIR) and AeroVironment (AVAV) continued to see strong order flow, deliver strong results, and have exceptionally optimistic outlooks for 2008. [Jeff Saut, minyanville.com, Oct 22]

Forbes's annual list of the best 200 small companies had several SBIR awardees: Ceradyne #12, Flir Systems 37, II-IV 58, ATMI 69, ViaSat 90, Surmodics 105, Micrel 149, OPNET Tech 167.

Flir Systems was rated number 3 among mid-cap public companies by Forbes magazine. Cymer was #44. [Sep 07]

Flir Systems (Wilsonville OR; $1.6M SBIR in the 1990s) won a $47.6M Navy contract to develop up to 700 handheld imagers for U.S. Special Operations forces. ... From its 24 employees when it won its first SBIR, it has grown to 1900 employees with a $3.6B market cap. [Mass High Tech, Sep 25]

 Flir Systems [$1.5M SBIR in the 1990s] said it believes company stock options that vested between 1996 and 2001 were improperly recorded [The Oregonian, Nov 10]

FloDesign Wind Turbine (Wilbraham, MA)

Using features from jet engines, FloDesign Wind Turbine (Wilbraham, MA; one SBIR on gun muzzle flash suppression) created a compact prototype three times more efficient at turning wind into electricity than today's three-bladed windmills. ...  also received funding from the U.S. Energy Dept., hopes to raise an additional $25 million later this year.  [Business Week, Oct 29]

several Massachusetts projects will receive a total of $33.2 million in federal funding for energy research.  1366 Technologies (Lexington) $4 million; , Agrivida (Medford; $300K SBIR) $4.6 million for efforts to cut the costs of cellulosic biofuels and chemicals; MIT $7 million on all-liquid metal grid-scale batteries; FastCAP Systems (Cambridge) $5.3 million to reduce the cost of hybrid and electric vehicles and of grid-scale storage; FloDesign Wind Turbine (Wilbraham) on new high efficiency shrouded wind turbines that could reduce noise and safety concerns $8.3 million ; Sun Catalytix (Cambridge) $4 million for a novel catalyst to enhance the efficiency of splitting water into hydrogen and oxygen. [Boston Globe, Oct 27, 09]

FlowCardia

FlowCardia, a medical-device maker building catheter systems that bore holes in blood clots, raised $30 million in a third funding round; [Matt Marshall, Venture Beat, Sep 5, 07]

FlowMedica (Fremont,CA)

AngioDynamics (Queensbury, NY; no SBIR) a medical device manufacturer paid $1.75 million for the assets of a similar, smaller company in California.  ... the assets of FlowMedica (Fremont,CA; no SBIR),  backed by venture capitalists. FlowMedica, founded in 2002, is developing ways to deliver drugs to kidneys to keep the organs functioning after certain medical procedures.  [The Business review (Albany), Jan 13, 09]

FlowMetrix (Maynard, MA)

Flow Metrix (Maynard MA)  is being bought by Itron for its advanced leak detection systems for underground pipelines of which the US has 900,000 miles of buried water pipe that lose about 10% of their treated water through pipeline leaks.  [Itron Press release, Aug 16, 06]  Flow had two Phase 2 SBIRs from NSF. Sale price a secret.

FluGen (Madison, WI)

FluGen (Madison, WI; no SBIR) landed $7.8 million that should help bring one of its leading technologies into human clinical trials this year.  ....   to fund a Phase I clinical trial for its vaccine delivery device, a poker chip-sized, micro-needle skin patch the company says is more effective and less painful than standard needle injections.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Feb 21, 11]

At least 14 [Wisconsin] biotech companies have received more than $3 million in grants ($240K each) from the Internal Revenue Service as part of a federal program to spur job growth at smaller firms and advance the country's life sciences prowess, according to a BioForward survey. ....  More than 5,600 companies applied for the grants and at least 4,000 companies were expected to receive them, according to BIO, the national trade organization for the biotech industry. .... The Qualifying Therapeutic Discovery Project was part of health care reform legislation passed earlier this year. The program provides grants or tax credits to companies of fewer than 250 employees to help create and sustain high-paying jobs and to advance the nation's competitiveness in life sciences. [Kathleen Gallagher, Milwaukee Journal Sentinel, Nov 2] Flex Biomed (Madison, WI; one SBIR) ;  NanoMedex Pharmaceuticals (no SBIR); FluGen (no SBIR).  BTW, BIO is the political champion of VC in SBIR awards, a barrier to House-Senate agreement on SBIR re-authorization, which will be up in the air again as the House committees change leadership.

FluGen (Madison, WI; no SBIR) has gotten rights from the Wisconsin Alumni Research Foundation to further develop a new class of antiviral drugs with the potential to stop viruses after a patient has been infected [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 8, 10]    Last month, FluGen announced that its CHO-cell (Chinese hamster ovary) system had, indeed, generated the 2009 H1N1 influenza virus without using eggs. The 10-employee company is ramping up its capability to type and bank cells next year in advance of seeking a clinical trial for its cell-based system, licensed last year to the company last year by the Wisconsin Alumni Research Foundation (WARF). [Lynn Welch, Wisconsin Tech Network News, Nov 16, 09]

Fluidic Energy (Scottsdale, AZ)

 Zinc-air batteries, which use zinc metal as the anode and an alkaline paste as the electrolyte, are simple, inexpensive, nontoxic, and long-­lasting. But engineers haven't been able to figure out how to recharge them. Cody Friesen, an associate professor of materials science at Arizona State University, solved the problem by using a porous electrode and a liquid solution of zinc ions and additives as the electrolyte. He cofounded Fluidic Energy (Scottsdale, AZ; no SBIR) in 2007 to commercialize the design, and outside testing of its commercial prototype is planned for late fall.  [Neil Savage, MIT Tech Review, Sep/Oct09]

Fluidigm (South San Francisco, CA)

Fluidigm (South San Francisco, CA) priced its IPO of up to $77.6 million  .... makes and develops microfluidic systems used in life sciences and agricultural biotech

Fluidigm (South San Francisco, CA; $1.1M SBIR), which makes equipment to control fluids in small volumes for applications such as genetic analysis, plans to raise up to $86.3 million in its [IPO] ...  company said it has sold systems to over 200 customers in over 20 countries worldwide. It had $25.4 million in revenue in 2009 and customers include Genentech, which is now part of Swiss drug developer Roche, and Novartis.   [AP, Dec 7, 10]

The California Institute for Regenerative Medicine, the state stem cell agency, has awarded $1B so far in research money.  SBIR companies got $10M of it.  Bio Time (Berkeley, CA; $300K SBIR)  $4.7M;   Vistagen Therapeutics (Burlingame, CA; $600K SBIR)  $970K; Gamma Medica Ideas  (Northridge, CA; $2.8M SBIR) $950K; Vala Sciences (San Diego, CA; $3M SBIR)  $900K; Invitrogen (Carlsbad, CA; $4M SBIR) $870K SBIR;  Fluidigm (South San Francisco, CA: $1.2M SBIR) [CIRM press release, Oct 28]  

Fluid Innovation Group

Austin startup Fluid Innovation (no SBIR) is making a game out of the arduous task of software commercialization.  VirtualVentures.com combines aspects of fantasy football and social networking, letting players become venture capitalists who make virtual investments. ...  has five employees and an offshore development team in Brazil, is backed by $1M from private investors. [Lori Hawkins, Austin American Statesman, Sep 24]

Austin-based Fluid Innovation Group has completed a software commercialization deal with Lockheed Martin Aeronautics.  Founded in 2005, Fluid Innovation works with businesses and institutions to transform their software into commercial products. [Austin American-Statesman, Jan 29, 07]

Fluidnet (Amesbury, MA)

FluoroPharma (Boston, MA)

FluoroPharma Medical (Boston, MS; no SBIR), a PET imaging product developer in Boston, has raised $2.36 million of a planned $6 million financing ... products are designed to detect acute and chronic coronary artery disease and Alzheimer’s disease. It currently has clinical trials underway for two products aimed at myocardial cell activity and inflamed plaques within the coronary arteries.  [Michelle Lang, Mass High Tech, Jul 8,11]

FluoroPharma (Boston, MA; no SBIR) , developing molecular imaging agents for the Positron Emission Tomography market, said it has been issued a patent covering methods of imaging cardiovascular plaque formation.  [Chris Reidy, Boston Globe, Jan 27, 09]

FoldRx Pharmaceuticals

Pfizer says it will buy  FoldRx Pharmaceuticals (Cambridge, MA; no SBIR) for an undisclosed amount, expanding its pipeline of potential products. .... developing potential treatments for diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases.[AP, Sep 1, 10]

FoldRx Pharmaceuticals (Cambridge, MA; no SBIR), a small molecule therapeutics firm ... completed a $29 million funding round that it said would support the development and commercialization of tafamidis, its treatment for a genetic and potentially fatal neurodegenerative disease called TTR amyloid polyneuropathy.  [Michelle Lang, Mass High Tech, Jun 15, 10]

EnVivo Pharmaceuticals (Redwood City, CA; one SBIR) and FoldRx Pharmaceuticals (no SBIR) will share with four other companies a $2.1 million grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). [Mass High Tech, Jan 26, 10]

Follica (Boston, MA)

Follica (Boston, MA; no SBIR) announced a $5.5M financing to develop a novel therapy for androgenetic alopecia - male and female pattern hair loss caused by androgens in genetically susceptible men and women - and other hair follicle disorders [Boston Globe, Jan 5, 08] Not to be confused with internet hair products retailer Folica.

Footnote (Linden UT)

 A tiny company is out to digitize the world, one historical document and photograph after another. And in so doing, Footnote Inc (Linden UT; no SBIR) hopes to accomplish a couple of things - bring easy Internet access to millions of documents and tap a bunch of niche populations willing to pay for that access.  In January, Footnote Inc. signed a deal with the National Archives and Records Administration, the small agency that cares for billions of documents generated by the federal government since its inception. Footnote agreed to produce digital copies for the National Archives for free in exchange for allowing it to make the images available for a charge on www.footnote.com. ...  Footnote is but the latest incarnation of the company that began as Automated Solutions Inc., cofounded in 1994 by David Norton but which was foundering by the end of the 1990s. Norton also was one of the founders of Iomega, a computer storage company. [Tom Harvey, Salt Lake Tribune, Sep 11]

F-Origin (Morrisville, NC)

A developer of touch-screen technology plans to use $5 million in recently raised venture capital to release its first products next year. F-Origin  (Morrisville, NC; no SBIR), currently at 10 employees, expects to expand to 70 full-time workers over four years if its products take off. The company designs touch screens called "AnyTouch" that are activated by contact from an any object, such as finger, pen or piece of clothing. The screens are being designed for GPS systems, electronic books and cell phones.  [Raleigh News & Observer, Jun 24]

Forma Therapeutics (Cambridge, MA)

small-molecule therapeutics developer Forma Therapeutics (Cambridge, MA; no SBIR) has partnered with Emerald BioStructures for the structure-based development of potential cancer drug targets.The partnership uses Bainbridge Island, Wash.-based Emerald BioStructures’ X-ray crystallography in combination with Forma Therapeutic’s Diversity Oriented Synthesis (DOS) chemistry.  [Michelle Lang, Mass High Tech, Jun 28, 10]

Emerald BioStructures (Bainbridge, WA; $2M SBIR) and FORMA Therapeutics, (Cambridge, MA; no SBIR) drug discovery company, announced the signing of a strategic partnership for the structure-based design of cancer drug candidates for FORMA's pipeline.[Boston Globe, Jun 28, 10]

FORMA Therapeutics (Cambridge, MA; no SBIR) said that it has signed a collaboration agreement with Cubist Pharmaceuticals to leverage [whatever that means] FORMA's chemistry platform to discover novel antibacterial compounds for development by Cubist.  [Chris Reidy, Boston Globe, Jan 27, 09]

oncology treatment startup company Forma Therapeutics (Cambridge, MA; no SBIR) has announced that it raised $25 million to fund its expansion. Forma also announced this week its formal debut as a global drug discovery company. Forma, founded in May 2007 by researchers from the Broad Institute of Harvard and MIT, seeks to integrate transformative biology and chemistry to create new oncology treatments.  [Marc Songini, Mass High Tech, Jan 6, 09]

Forma Therapeutics (Cambridge, MA; no SBIR)., a stealth biotech start-up trying to develop cancer drugs, is lifting its corporate veil. The one-year-old  company, which has previously been secretive about its mission and finances, plans to disclose today it has raised $25 million in venture capital, grants, loans, and other funding over the past year - a feat that has become increasingly rare [Boston Globe, Jan 6, 09]

Chelmsford-based Mercury Computer Systems Inc. has announced its sale of the assets and intellectual property of its biotech venture, SolMap Pharmaceuticals  (one SBIR), to Cambridge startup Forma Therapeutics (no SBIR) ... SolMap is a spinout from the structural bioinformatics laboratory of Sandor Vajda, a professor at Boston University. It focuses on computational and experimental fragment-based drug design to develop small-molecule, therapeutic drugs.  [Mass High Tech, Oct 2, 08]

Forus Health

“We work with a Dutch company on optics, and the University of Texas supports us in business development,” Chandrasekhar adds. “We are talking to a Brazilian company that is interested in manufacturing our technology and selling in Latin America.” Outsourcees are becoming outsourcers.No SBIR, no apparent government subsidy to Forus Health which invented “a single, portable, intelligent, noninvasive, eye prescreening device” that can identify all five of these major ailments and also provide an automated “Normal or Needs to See a Doctor” report; it can be run by a trained technician, who through telemedicine connects patients to a doctor.  [Thomas Friedman, New York Times, Nov 5] 

Foster-Miller (Waltham, MA)

Protonex Technology (Southborough, MA; $2M SBIR) said its fuel-cell power system has been successfully tested in a Talon military robot from Foster-Miller. [Boston Globe, Apr 21]

Foster-Miller  has been awarded $58.5 million in funding for additional Talon military robots and replacement parts, its parent company, QinetiQ North America, said today.  The total represents awards from the US Army and Navy made during the six-month period from May 1 to Nov. 1,  [Boston Globe, Dec 2, 08]

Foster-Miller (Waltham, MA; 8 tons of SBIR) landed a $400 M deal from the Army for Talon robots, parts and services. [Mass High Tech, May 29,08]

Foster-Miller sold the Navy another $51M worth of robots. [Aug 10, 07]

Foster-Miller got another $18M robot order from the Navy. [Mass High-Tech, Jun 11, 07]

Foster-Miller acquired robotics companies Automatika Inc. and Applied Perception Inc. -- both based in Pittsburgh for an undisclosed price.  [Mass High Tech, Apr 24]

Foster Miller got another robot contract: Navy, $26M in an installment on the $257M 2005 defense contract.

The Talon by Foster-Miller has emerged as one of stars of this new class of robots. ...  Marine Colonel Edward Ward is division chief in the Robotic Systems Joint Project Office...said that his group has put 400 Talons into service, while the company said that other military purchases of the systems, which cost more than $100,000 apiece, put the number of its robots sent to Iraq and Afghanistan above 800  ... Talon's biggest competitor is the better-known iRobot   [Jeffrey Krasner, Boston Globe, Mar 12]  Did SBIR help Talon substantially?  Hard to tell since Foster-Miller had so-o many SBIRs. 

Foster-Miller, formerly of SBIR notoriety, got a $10M UKMOD subcontract for armor. Foster-Miller was founded in 1956 by three MIT graduates, and is now a subsidiary of U.K.-based QinetiQ Holdings Ltd.

Foster-Miller, the former SBIR consumption champ,  got a $64 M and a $28 M Navy contract, the larger to build robots and robotic parts for U.S. Navy repair teams deployed in Iraq and Afghanistan.  [Mass High Tech, May 23]

Foster-Miller got a $133M order for spare parts and service for its Talon robot. That's on top of  a recent deal of $96M for up to 1,200 robots over seven years, with a total award of $124 million, then the largest order in the company’s history.  Foster-Miller is a leading supplier of explosive ordnance robots for missions in Iraq and Afghanistan, completing more than 50,000 missions.  [Mass High Tech, Sep 20] FMI was the undisputed champion of collecting SBIR money before it was bought out by a large firm.

Foster-Miller plans to buy PSI (Reston, VA) $42M in a move to be a bigger DOD contractor, pushing 700 folks. Foster-Miller was the champion SBIR harvester until being bought by a British firm which is apparently looking for a bigger footprint in DOD business. Three MIT graduates founded Foster-Miller nearly 50 years ago. [story in Mass High Tech, Aug 2, 05]$152,596,023 is how much Foster-Miller got in DOD SBIRs by Sep 8 postings in the DOD database according to a spreadsheet painstakingly assembled for 678 line-by-lines by an interesting observer.  SBA records show 679 projects (lumping Phase 1 and Phase 2 as one project) of which about 80% are DOD. That's about another $35M for a grand total approaching $200M. Maybe the best economic story to emerge from all that money was when Parvis Tayebati left FMI to start his own company, got a couple of SBIRs, and five years later sold his company for $1.6B in overvalued stock of an info-tech biggie. Would such economic success have ever happened if he had stayed at FMI with those same SBIR awards? As Fox News would say, "We Report, You Decide". 

Heavyweight Champ to Retire.  Foster-Miller, the biggest user of SBIR, will sell itself to a British organization for $163M by Britain's QinetiQ Group PLC, a public-private partnership with the United Kingdom Ministry of Defense. If the SBA would publish what the Brits call league tables, we would see that FMI has had about three gazillion dollars in mostly defense SBIR money since SBIR began in 1983. SBA doesn't publish such stats because it would reveal how concentrated the SBIR money is in companies who live on SBIR, although FMI relied on regular SBIR for only a part of its revenue and accepted the relatively low net profit margin to get another foot in the DOD door. Tons of startup companies can rejoice that the champ has liberated a lot of SBIR money for them.   The buyer QinetiQ is now one-third owned by Carlyle Group, the Washington investment firm whose executives include many retired US officials. Carlyle's role is to help QinetiQ prepare for an initial public offering of stock by 2007. [Ross Kerber, Boston Globe, Sep 8]

Foster-Miller  (the SBIR champ) got a $9M contract from the Federal Railroad Administration for more work in locomotive crashworthiness and fuel tank safety. Foster-Miller has been creating computerized simulations of collisions involving rail equipment since 1995. These simulations are used to analyze different types of railroad accidents so that designers are able to minimize injury and improve crash worthiness through design modifications. In 2000, Foster-Miller opened a 5,000-square-foot, full-scale Locomotive Test Facility in Fitchburg, with a 1-million-pound loading test fixture capable of handling 40,000-pound test locomotives. Following modeling and testing in Fitchburg, Foster-Miller conducts full-scale railroad crash tests at a government facility in Pueblo, Colo.  [Mass High-Tech, Dec 23]  Foster Miller is a regular winner of the few DOT SBIRs awarded. 

When rescue conditions are too unsafe for dogs or humans, send in a robot. In the WTC clean-up one robot was supplied by SBIR champ Foster-Miller (Waltham, MA), says Ryan Malkin in Smart Money (Dec 01). I suppose SBIR could take some credit, at least for keeping FMI alive and well for two decades of SBIR totalling well over $100M.

Coming soon to a pub near you: beer in a plastic-screw top bottle. Rick Lusignea, president of Superex Polymer Inc.. a subsiudiary of SBIR champ Foster-Miller., said the Waltham company is working with a consortium of beer bottlers and brewing companies to apply its specialized polymer film in creating the world’s first plastic beer bottles. The whole idea of packaging beer in plastic bottles has been on the shelf for 10 years, Lusignea said. Superex’s innovative way to make a polymer known as liquid crystal polymers (LCPs). In the past, plastic bottles have been shunned by brewers because oxygen seeping through the plastic changes the flavor of the beer long before its carbonation is surrendered. LCPs, however, have a much stronger barrier to keep out oxygen than previous plastics; ... LCPs were developed by Air Force engineers 20 years ago. Their stiffness, strength and resistance to water and vapor infiltration made LCPs an attractive candidate for a diverse set of products. The early process for making the polymers, however, was troublesome. Under a federal grant, many SBIR's that is, Foster-Miller began exploring ways to solve the problem in 1983. Foster-Miller created Superex in 1993 and assigned Lusignea to begin exploring the market opportunities of the technology. The first real-world application of Superex’s LCP technology is in the medical device field, where a New York company called Precision Extrusions is making and selling LCP tubular products for endoscopic instruments. The product has attracted interest from device makers because it is five times stronger than conventional tubing and has electrical insulating qualities. The big market opportunity, however, is plastic beer bottles. The U.S. produces some 54 million units of beer per year; the worldwide market is three times larger. Lusignea does not expect LCP-lined plastic bottles to compete head-on with glass bottles and cans that are cheap, but he said it does offer advantages that have brewers and packagers interested. [Mass High-Tech, Jan 17] With enough SBIR and enough time, many things are possible. Especially if the supplier of the R&D funds has no economic goals and no need for an ROI.The gripe from the SBIR rejectees is that they could have gotten a much larger ROI with a lot less money. But the funding source, your USAF, ignores such arguments.

Not Just the Army Loves Foster-Miller. A quick look at the Navy's SBIR Data Base shows that 1991-1997 Foster-Miller has won 67 Phase 1s and 15 Phase 2s. And across all DOD 1983-1996, 101 Phase 2s and 180 Phase 1s, for a total something like $70M of innovation. A start-up needing government succor? As an FMI manager said at a recent SPIE Conference Foster-Miller is a 40-year old engineering services firm. Could your start-up stand that much prosperity and do you think you might be getting crowded out by FMI, however competent. Has the Law of Diminishing Returns been repealed in Massachusetts and the results accepted by the DOD?

Foster-Miller Suit
(Oct 27) Foster-Miller (Waltham, MA) has a product. Actually FMI has quite a few products after $70M of SBIR handout. The latest product is an air-conditioned firefighter's suit pictured in The Futurist November 1997. What FMI doesn't have is any visible and compelling evidence that all that money was a smart investment by the government in a competitive investment program. Nor does the government seem anxious to raise the issue. Instead, it poured another $10M last year into the firm. But that's not FMI's problem; the public holds the government accountable for how the money was invested. For now, both FMI and the government hope the public is asleep or will accept a warm fuzzy story of good R&D by a highly competent firm.

Foster-Miller Nets a Product
(May23) Shoot-a-net got a Business Week (May26) story for the national champ ($60M) SBIR consumer. A DARPA project for a shell that fires a Nonlethal Entanglement Technology (such bureaucratic words must fit into a pistol shell) from a fat police pistol. Is that high-tech as envisioned by SBIR's inventors? Close enough; at least it's a product with some sales potential which was the real goal (other than just pushing contract business to a constituency).

Foundation Medicine (Cambridge, MA)

Foundation Medicine  (Cambridge, MA; no SBIR), a cancer diagnostics company, said that it has closed an expanded Series A financing, bringing the total raised in the round to $33.5 million. [ChrisReidy, Boston Globe, Oct 18, 11]

Just a few months after naming new top officers and landing new collaboration deals, Foundation Medicine (formerly Enzo Clinical Labs, Cambridge, MA; no SBIR) has raised $10 million of a planned $20.5 million financing, according to federal documents.  [Rodney Brown, Mass High Tech, Aug 25, 11]

Foundation Medicine (Cambridge, MA) said it has completed a $25 million Series A financing [Boston Globe, Apr 15, 10]

Fractal Antenna Systems (Bedford, MA)

Fractal Antenna Systems (Bedford , MA; one Phase 2 SBIR) says it got its 13th patent, [Mass High Tech, Sep 13]

Free Flow Power

Free Flow Power, a New England startup company, wants to harness the mighty river for a secondary purpose — generating electricity. ... pursuing a $3 billion plan to install thousands of small electric turbines in the river bed, reaching from St. Louis to the Gulf of Mexico that would collectively generate 1,600 megawatts of electricity — enough to power 1.5 million homes. [Jeffrey Tomich, St Louis Post Dispatch, Apr 1, 08] But capitalistic innovations of technology are not free to enter the marketplace without considering any public downside that would have been ignored under Cal Coolidge's "The business of America is business." In this case, taking energy from the river will slow the flow with consequences not immediately apparent. But if the idea gathers enough energy at an acceptable cost, more such installations would follow until the river nearly stopped. The Western gold and silver rushes provide an example of unrestrained extraction.

FTL Solar

Alternative energy startup FTL Solar said  that it is finalizing $15 million of a planned $40 million funding goal, and it is expanding its line of solar-powered shelters. ... formed two years ago after spinning out of FTL Design Engineering Studio, a New York-based pioneer in building integrated fabric structures.   [Austin American Statesman, Nov 6, 08]

Fuel Cell Energy

FuelCell Energy, the state's largest fuel cell manufacturer, is narrowing its losses on its products, but its revenues were down from the third quarter of 2009. [Mara Lee, Hartford Courant, Sep 2, 10]

FuelCell Energy rose 23% [Jun 3, 10], after the company said it will supply power plants to PG&E's California utility for use at two public universities, in deals valued at $12.6 million.  [Wall Street Journal, Jun 4, 10]

Fuel Cell Energy up 11% [Mar 11, 10]

Fuel Cell Energy  up 12% [Feb 22, 10]

Fuel Cell Energy up 11% [Dec 31, 09]

FuelCell Energy up 16% [Dec 29, 09]

Fuel Cell Energy said it has expanded an existing deal with a South Korean power provider that will use the Connecticut company's hardware to manufacture fuel cell stacks. .. the additional demand would justify expansion of its Danbury operations. ... includes an upfront license fee of $10 million and an ongoing royalty, initially set at 4.1 percent of revenues generated by POSCO's sales of the fuel cell stack modules.  [Eric Gershon, Hartford Courant, Oct 31, 09]

Fuel Cell Energy up 11% [Sep 14, 09]

Fuel Cell Energy up 12% [Aug 19, 09]

Fuel Cell down 10% [Jun 10, 09]

Fuel Cell up 19% [Jun 9, 09]

FuelCell Energy said that it is partnering with a South Korean power producer to sell the main components of its fuel cell generators in the country. As part of the agreement, POSCO Power, an independent power producer based in Seoul, has ordered $58 million worth of fuel cell manufacturing equipment -- enough to build 30.8 megawatts of fuel cell power generation in the country. ...  also agreed to buy $25 million worth of FuelCell Energy common stock at $3.59 a share once the licensing agreement is finalized.  [Lynn Doan, Hartford Courant, Jun 9, 09]

Fuel Cell  up 13% [Apr 9, 09]

Fuel Cell Energy  down 17% [Mar 27, 09]

Fuel Cell Energy  up 11% [Mar 23, 09]

Fuel Cell Energy up 15% [Mar 11, 09]

Fuel Cell down 20% [Mar 5, 09]

Fuel Cell down 14% [Mar 2, 09]

Fuel Cell Energy  up 14% [Feb 24, 09]

Fuel Cell  down 12% [Feb 23, 09]

FuelCell Energy said that it has sold a 300-kilowatt power plant to the Marine Corps to be installed at its largest training center.
No price was disclosed. The plant, running off hydrogen fuel and oxygen from the air, will generate electricity to power the combat center at Twentynine Palms, Calif., and feed heat into the base's steam line to provide hot water and space heating.  [Hartford Courent, Feb 24, 09]

Fuel Cell Energy down 10% [Jan 14, 09]

Fuel Cell Energy up 15% [Jan 13, 09]

Fuel Cell Energy down 10% [Jan 12, 09]

Fuel Cell Energy up 10% [Dec 16, 08]

Fuel Cell Energy down 24% [Dec 4, 08]

Fuel Cell Energy up 12% [Dec 3, 08]

Fuel Cell Energy up 21% [Nov 26, 08]

Fuel Cell Energy up 37% [Nov 24, 08]

Fuel Cell Energy up 11% [Nov 21, 08]

Fuel Cell Energy up 12% [Nov 13, 08]

Fuel Cell Energy down 15% [Nov 6, 08]

Fuel Cell Energy up 11% [Oct 28, 08]

Fuel Cell Energy down 12% [Oct 22, 08]

Fuel Cell Energy up 14% [Oct 17, 08]

Fuel Cell up 26% [Oct 16, 08]

Fuel Cell down 15% [Oct 15, 08]

Fuel Cell down 14% [Oct 14, 08]

Fuel Cell up 23% [Oct 13, 08]

Fuel Cell Energy up 23% [Oct 10, 08]

Fuel Cell Energy down 15% [Oct 9, 08]

Fuel Cell down 22% [Oct 8, 08]

Fuel Cell Energy up 16% [Sep 30, 08]

Fuel Cell Energy down 17% [Sep 29, 08]

FuelCell Energy down 10%  [Aug 29, 08]

FuelCell Energy ($3M SBIR) down 13% after the company reported a fiscal third-quarter loss wider than analysts expected. [Wall Street Journal, Aug 29]

Fuel Tech (Batavia IL)

Fuel Tech (Batavia IL; no SBIR; 137 employees) up 17% after winning a $7.2 million contract from a Midwest utility for its "clean-burning" coal technology. [Wall Street Journal, Oct 18]

Fusion Coolant Systems (Ann Arbor, MI)

Genaera (NYC, NY)

MacroChem (Wellesley Hills, MA; three SBIRs) has purchased the license to a treatment for diabetic foot infection. MacroChem executives report the company has exercised an option to acquire exclusive worldwide license rights for pexiganan, a novel, small peptide anti-infective, from New York City-based Genaera Corp (three SBIRs). [Mass High Tech, Oct 4, 07]

Genelabs Technologies (Redwood City, CA)

GlaxoSmithKlineentered into a definitive agreement to buy Genelabs Technologies (Redwood City, CA; $3.5M SBIR)  for $57 million. [Pittsburgh Business Times, Oct 30, 08]  The stock traded as high as 15 in 2004 and under a buck recently.

Gene Logic (Gaithersburg MD)

Gene Logic (Gaithersburg MD; no SBIR) is selling its genomics business for $10M to Ocimum Biosolutions (Hyderabad, India with US HQ in Indianapolis) [Indianapolis Star, Oct 17, 07]  founded 1994; $24M IPO 1997; $248M public stock offering 2000 [company website]; current market cap $33M; total loss for last three years $130M.

General Compression (Newton, MA)

New England energy stimulus money for small biz:  $2.2 million for an energy storage project at Beacon Power  .... $2.1M for Proton Energy (Wallingford, CT; $1.7M SBIR) and Penn State University aim to develop an advanced energy storage device that incorporates a regenerative fuel cell  ....  General Compression, (Newton , MA; no SBIR)  $750K for a novel compressed air energy storage process [Kyle Alspach, Mass High Tech, Jul 13, 10]

General Compression (Newton, MA; no SBIR) said that it has added $3 million to a Series A funding round. ... uses air compression to store energy from wind farms when they produce more power than needed, and release energy during times of peak demand or when the wind is not blowing. The compressed air is pumped into and stored in large underground areas such as salt domes. ..  founded in 2006 and raised $9.9 million in funding in 2007, according to filings.  [Mass High Tech, May 12, 10]  Not exactly high tech,  purely economics-based business risk, which should not be a federal concern.

Generex Biotechnology (Worcester, MA)

Biotech drugmaker Generex Biotechnology (Worcester, MA; no SBIR) reported positive results for a mid-stage study of its experimental cancer vaccine.  [AP, Dec 15, 09]

Genesis Laboratories (Wellington, CO)

Genesis Laboratories (Wellington, CO; $500K SBIR) says it has received a $5.2 million grant from the Bill & Melinda Gates Foundation to develop new methods to control a parasite-caused disease in India.  [Denver Business Journal, Apr 24, 09]

Genetix Pharmaceuticals (Cambridge, MA)

gene-therapy company bluebird bio (Cambridge, MA; $550K SBIR as Genetix Pharma)  has added Arch Venture Partners to its roster of backers for its latest round that brought in $30 million in financing  ...  raised a total of approximately $75 million, the latest being a $35 million round in 2010 ...  In March, bluebird bio entered into a deal, worth up to $4.2 million, with the French Muscular Dystrophy Association (AFM). The agreement focused on the development of LentiGlobin, a treatment intended for beta-thalassemia and sickle cell anemia. [Rodney Brown, Mass High Tech, Apr 20, 11]

Genetix Pharmaceuticals, (Cambridge, MA; $500K SBIR) focused on gene therapy, announced today that it has completed a $35 million Series B financing.  ... to advance current clinical programs, strengthen platform capabilities, and further expand the team," the company said in a press release.  [Boston Globe, Mar 12, 10]

Genex

thanks to Genex Technologies Inc., a company now owned by Markland Technologies Inc. of Providence, RI .. a provider of facial recognition and 3-D imaging technology and intelligent surveillance based in Maryland, will provide Naval center with its OmniEye Cerberus system, a multi-sensor, reconfigurable system designed for long distance infrared and visible detection. [Mass High Tech, Sep 15]  Genex got its early start in 3-D technology with SBIR from, you guessed it, BMDO back in BMDO's venture capital days when founder Jason Geng was one of two employees. In all it has had about $8M in SBIR. Its website claims  nearly 30 employees and impressive annual revenues. Jason no longer appears on either the management team nor the board of advisors  did up until 2004  His name does now show up as a member of the Chinese Academy of Sciences. Before he founded Genex, he was Director of Research and Development at Intelligent Automation, a huge consumer of SBIR, where he won about $800K of DOD SBIR in  the early 90s including a neural network Phase 2 from BMDO.  Markland is a homeland security company with a cross-country history:  incorporated in 1995 as A.P. Sales, Inc. in Colorado, redomiciled to Florida in 1998 under the name of Quest Net Corporation and further changed its name to Markland Technologies, Inc. in 2001 in Ridgefield, CT.  The stock trades for a nickel a share.

Genocea Biosciences (Cambridge,MA)

Genocea Biosciences (Cambridge, MA; no SBIR) working on novel vaccines for diseases like herpes and malaria, has taken a huge second funding round, pulling in $35 million in Series B financing and adding Johnson & Johnson Development Corp. to its roster of backers. ... In August, Genocea named Chip Clark as chief business officer of the vaccine-focused biotech firm in Cambridge. Clark most recently co-founded Rockville, Md.-based Vanda Pharmaceutical Inc., a pharmacogenetics firm where he served as chief business officer and helped secure more than $220 million in funding and landed a licensing deal with Novartis that brought in $200 million upfront, plus $265 million in milestone payments. Founded in 2006, Genocea raised $23 million in Series A financing in February of 2009.  [Rodney Brown, Mass High Tech, Jan 3, 11]

Genomatica (San Diego, CA)

Genomatica (San Diego, CA; $6.3M SBIR) company that’s developed a green technology for chemical production, has filed with federal regulators for [IPO] .... has corralled about $80 million in venture capital and up to $5 million from the U.S. Department of Energy .... has developed a microorganism-based technology platform for producing chemicals used in industrial production. The platform uses biomass, plants or other renewable, non-petroleum sources as the base material to produce chemicals. Today, these chemicals come mostly from crude oil.     [Mike Freeman, signonsandiego, Aug 29, 11]

Genomatica (San Diego, CA; $6.3M SBIR) biotechnology company, which has developed a microbe that makes chemicals from sugar, is getting a big tryout in the corn belt. ..  is announcing that it plans to begin using corn to produce BDO, a chemical usually made from petroleum. BDO is short for 1,4 butanediol. It is used to make elastic fibers, sneakers and insulation.  The worldwide market is $4 billion [Onell Soto, signonsandiego.com, Mar 16, 11]

Genomatica (San Diego, CA; $6M SBIR) says it has successfully scaled up technology that uses genetically engineered microbes to make 1,4-butanediol (BDO)—a solvent and industrial chemical usually made from crude oil or natural gas ... The venture-backed company founded in 2000 is using biotechnology and renewable raw materials to eliminate energy-intensive industrial processes and petrochemicals in making the key intermediate chemical. ...  has raised a total of $38.5 million (including $15 million in March) from investors   [Bruce Bigelow, signonsandiego.com, Jul 13, 10]

Genomic Health

Genomic Health  up 12% [Nov 2, 11]

Genomic Health  up 21% [Nov 9, 10]

Genomic Health   down 18% [May 6, 09]

Genomic Health  down 12% [Apr 15, 09]

Genomic Health down 10% [Oct 15, 08]

Genomic Health up 10% [Oct 13, 08]

Genomic Health up 15% [Feb 6, 08] on better than expected financial results.

Genomic Health up 10% [Jan 14, 08]

GenomeQuest (Westborough, MA)

GenomeQuest (Westborough, MA; no SBIR), a developer of sequence data management software for genome-based research, has  received $3.1 million in an offering of equity and warrants ... “There’s been a 10,000-fold increase in the last three years in the volume of data generated per instrument,” said GenomeQuest CEO Ron Ranauro in a June interview with Mass High Tech. “Now we can interrogate every DNA molecule against all known knowledge bases, when before only a fraction could be sequenced.” [Mass High Tech, Dec 16, 09]

Genoptix Medical Laboratory (Carlsbad, CA)

Genoptix up 26% [Jan 24, 11] as Novartis AG (Swiss) agreed to buy Genoptix (Carlsbad, CA; $1M SBIR), a lab that specializes in diagnosing cancers in bone marrow, blood and lymph nodes, for about $470 million in cash. ... revenue of about $184 million in 2009 and employs about 500 people  [Bloomberg, Jan 24]  Another smart SBIR investment by NIH a decade ago.

Genoptix up 16% [Dec 14, 10]

Genoptix (San Diego, CA; $1M SBIR) was 41st on the new Deloitte Fast 500 list of fastest-growing technology companies [Mike Freeman, signonsandiego, Oct 21, 10]

Genoptix down 11% [Sep 21, 10] said it expects third-quarter revenue and case volumes to decline sequentially due to increasing competition. [Wall Street Journal, Sep 22]

Genoptix down 25% [Jun 16, 10]  after the company cut its 2010 forecast as it gave weaker-than-anticipated earnings estimates for the second quarter. The company said it was hurt by pressure on physician practices and a more competitive market reduced its field-sales productivity. [Wall Street Journal, Jun 17, 10]

Genoptix down 23% [May 7, 10]

Genoptix, (Carlsbad, CA; $1M SBIR) laboratory that helps doctors diagnose certain types of cancer.... has grown rapidly. In a little more than a decade since its founding, it has grown to more than 400 employees with $135.3 million in revenue during the first nine months of last year.... [founder Tina] Nova co-founded San Diego-based life science companies Ligand Pharmaceuticals (San Diego, CA; one SBIR) and Nanogen  (San Diego, CA; $1M SBIR) [Thomas Kupper, San Diego Union Tribune, Jan 11, 10]

Genoptix  (Carlsbad, CA; $1M SBIR) up 15% [Jul 31, 09]  a lab-service provider, reported second-quarter earnings and revenue above Wall Street estimates and boosted its earnings and revenue guidance for 2009. [Wall Street Journal, Aug 1]

Genoptix (Carlsbad, CA; $1M SBIR), that helps oncologists determine the proper treatment for people with blood cancers, topped a list of the region's fastest-growing companies compiled by the Deloitte & Touche accounting firm. [Terri Somers, San Diego Union-Tribune Oct 11, 08]

Shares of laboratory-services company Genoptix (Carlsbad, CA; $1M SBIR) became the latest in a series of health-care-related companies to post large first-day trading gains, increasing 49% from its IPO price. [Wall Street Journal, Oct 31]

 Genoptix Medical Laboratory, (Carlsbad, CA; $1M SBIR) registered for an $86M IPO. [Aug 3, 07]

Genor

Genor up 14% [May 14, 07]  looks born to run ...  the stock market's largest player in embryonic stem cell research -- could feel good long before the company discovers any miracle cures [Melissa Davis, Thestreet.com, May 14]

Gen-Probe (San Diego, CA)

[Swiss giant Novartis] is no longer actively pursuing U.S. medical diagnostic-testing company Gen-Probe  (San Diego, CA; $150K SBIR)., meaning Gen-Probe could end its sales process without a buyer, people familiar with the matter said. Novartis appeared to be the only potential suitor left after other bidders, which included Life Technologies and Thermo Fisher Scientific, dropped out of the race for Gen-Probe last month, these people said. [Gina Chon and Anupreete Das, Wall Street Journal, Jul 20, 11]

medical test maker Gen-Probe (San Diego, CA; three SBIRs) said Thursday that it acquired GTI Diagnostics (Waukesha, WI; three SBIRs long ago), a specialty diagnostics company for $53 million in cash.  ... Gen-Probe bought GTI from Riverside Co., a Cleveland private equity firm that acquired the company in 2008. [signonsandiego.com, Dec 16, 10]

GenSpera (San Antonio, TX)

GenSpera (San Antonio, TX; no SBIR) has been awarded two federal grants totaling $489,000 through the Patient Protection and Affordable Care Act to proceed with clinical trials of two of its prospective [oncology] drug candidates. [San Antonio Business Journal, Nov 4. 10]  Hate Obamacare - take the money. Principles are only for political campaigns.

GenTel BioSciences (Madison, WI)

Gentel Biosciences  (Madison, WI; no SBIR) maker of chips that help researchers test for proteins said Tuesday it has been invited to join a research consortium using novel technologies to gain insight into major diseases of pregnancy.   ... will participate in the development of a protein test with the SCOPE (Screening for Pregnancy Endpoints) Study centers that operate in New Zealand, Australia, the UK and the United States, Gentel said. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 16, 09]

 GenTel BioSciences (Madison, WI; no SBIR) maker of chips that help researchers test for proteins now has a revenue-producing chip on the market. ... after "The product we thought we had, failed in final testing - and a major source of investment dollars ran into some liquidity issues," Vodenlich said. A strategic change was needed  [Kathleen Gallagher, Milwaukee Journal-Sentinel, Oct 17]  Company website says it has been awarded more than $2M in NIH funding for the development of novel protein arrays.

GenVec

GenVec down 16% [May 23, 11]

GenVec (Gaithersburg, MD; $4M SBIR) down 13% agreed to sell $17 million worth of stock and warrants to new and current investors to raise money for operating costs and upcoming clinical trials. [ Baltimore Business Journal, Jun 6, 08]

GenVec dropped 29% after preliminary results from a trial of its TNFerade drug candidate for advanced pancreatic cancer. [Jun 4, 07]

Genzyme

Genzyme said today that it is encouraged by test results for a potential cholesterol treatment it is collaborating on with Isis Pharmaceuticals. [Boston Globe, Aug 4, 10]

Genzyme up 15% [Jul 23, 10] on news of a possible acquisition by Sanofi-Aventis

Life science firms pitch optimism  [CEO] of Alkermes stood before scores of potential investors yesterday and talked about two drugs - for diabetes and opiate dependency - that his Cambridge company expects to get approved in 2010. “This year is going to be a big year,’’ Pops said. ... Henri Termeer defending his leadership at Genzyme  as it scrambles to fix production problems, Biogen Idec’s James C. Mullen avoiding any mention of his recent decision to step down from the company’s top post - the mood was generally upbeat. ...  companies have been raising more money in follow-on offerings than any time in the past decade, about $6 billion in 2009  ...  Another huge market opportunity lies in a drug being developed by Vertex Pharmaceuticals to treat hepatitis C, a largely untreated virus estimated to affect about 3 million Americans and 100 million people globally. “We’re doing a lot to raise awareness of this disease,’’ said new Vertex chief Matthew Emmens.  [Robert Weisman, Boston Globe, Jan 14, 10] from the 28th annual J.P. Morgan Healthcare Conference in San Francisco

Embattled Genzyme [CEO] told investors today that about 80 percent of patients who use Cerezyme, the company's drug for a rare genetic disorder, have resumed treatments after a supply interruption caused by a virus at its Allston Landing plant last year. [Boston Globe, Jan 12, 10]

Genzyme will move all its filling, packaging, and distribution operations out of its Allston drug manufacturing facility because of the latest problems involving contamination at the plant. [Boston Globe, Jan 5, 09]

Genzyme said it is encouraged by early test results of its drug Mozobil as part of a potential strategy to attack blood cancers.  [Boston Globe, Dec 9, 09]

Drug giant Pfizer, mounting a direct challenge to Cambridge biotech Genzyme, yesterday said it will spend up to $110 million to license the global rights to a treatment being developed for the rare genetic disorder Gaucher disease. [Boston Globe, Dec 2, 09]

Isis Pharma  down 17% [Nov 17, 09] An experimental drug from Isis and Genzyme  cut levels of "bad" LDL cholesterol by 25% in patients with a rare genetic disorder that causes extremely high and dangerous levels of cholesterol, according to data presented today at a medical meeting.  [theStreet,com, Nov 17]

Genzyme said it has been included for the first time on the Dow Jones Sustainability World Index. The index tracks companies that practice corporate sustainability, which is defined as a business approach that "creates long-term shareholder value by embracing opportunities and managing risks deriving from economic, environmental, and social developments," according to the index's website. Genzyme said it is one of only three US biotechnology companies to be selected for the index this year.  [Boston Globe, Oct 3, 09]

Just days before a key meeting to consider Genzyme’s application for a new leukemia drug to treat older patients, the Food and Drug Administration released a briefing document criticizing the Cambridge biotechnology company’s clinical study of the drug, called Clolar. [Boston Globe, Aug 29, 09]

Genzyme spent five hundred million dollars developing the drug Myozyme, which is intended for a condition, Pompe disease, that afflicts fewer than ten thousand people worldwide. That’s the quintessential modern drug: a high-tech, targeted remedy that took a very long and costly path to market. Myozyme is priced at three hundred thousand dollars a year. Genzyme isn’t a mining company: its real assets are intellectual property—information, not stuff. But, in this case, information does not want to be free. It wants to be really, really expensive.   [Malcolm Gladwell, The New Yorker, Jul 6, 09]

Genzyme  said today that it has decided to scrap about 80 percent of material used to make the drug Cerezyme that it had been working on at the time a virus was discovered at its Boston manufacturing plant in June. [Boston Globe, Aug 10, 09]

Genzyme continued its descent... to close at its lowest level in more than five years. Goldman Sachs on Friday added the stock to its "conviction sell" list amid uncertainty surrounding the biotech firm's recent manufacturing problems at a large production facility.  [Wall Street Journal, Aug 8, 09]/p>

Genzyme said that regulators have granted one of its drugs marketing authorization for many European countries.  [Boston Globe, Aug 6, 09]

Genzyme spent five hundred million dollars developing the drug Myozyme, which is intended for a condition, Pompe disease, that afflicts fewer than ten thousand people worldwide. That’s the quintessential modern drug: a high-tech, targeted remedy that took a very long and costly path to market. Myozyme is priced at three hundred thousand dollars a year. Genzyme isn’t a mining company: its real assets are intellectual property—information, not stuff. But, in this case, information does not want to be free. It wants to be really, really expensive. [Malcolm Gladwell reviewing Chris Anderson’s, Free: The Future of a Radical Price, The New Yorker, Jul 6, 09]

The virus hunters have arrived at Genzyme. Dozens of decontamination specialists are busy stripping insulation from pipes at the company’s biotech drug plant overlooking the Charles River in Allston. Their prep work involves dismantling equipment, peeling gaskets from the lids of 2,000-liter vats called bioreactors, and scrubbing down every surface in sight with spore-killing bleach. [Robert Weisman, Boston Globe, Jun 25, 09]

Genzyme is shutting down production at its main U.S. plant for several weeks, marking the latest manufacturing misstep for the company, which faces potential shortages of some of its best-selling drugs.  The company said it acted after discovering a virus in one of six bioreactor vats used to develop drugs at the plant, which is the only facility that makes two of Genzyme's top sellers. .... Over the past year, Genzyme has been hit by other manufacturing-related concerns and the company's stock has declined 28% over the past four months. [David Armstrong, Wall Street Journal, Jun 17, 09]  SBIR firms often way underestimate the intense demands of manufacturing their sweet technology for competitive markets. And the government R&D agencies typically aren't much help on the subject.

Genzyme said that the European Commission has approved Renvela in the treatment of some patients with chronic kidney disease.  [Boston Globe, Jun 12, 09]

Genzyme, best known for targeting rare genetic disorders like Pompe disease and Fabry disease, is increasing its investment in drugs to treat broader diseases such as cancer and multiple sclerosis. ....  agreed to acquire the worldwide rights to a potential multiple sclerosis treatment from Bayer HealthCare.  The treatment is called Campath   [Boston Globe, Apr 1, 09]  will acquire a Snohomish County pharmaceutical factory for $75 million to $100 million as part of a multidrug deal with Bayer, the companies said today.  [Seattle Times, Mar 31]

Genzyme  said it received regulatory approval to manufacture one drug on a larger scale in Europe and to market a therapy in the United States.  [Boston Globe, Feb 26, 09]

Genzyme said its experimental oral treatment for Gaucher disease, a rare genetic disorder, met the main goal of a mid-stage clinical trial.  [Boston Globe, Feb 21, 09]

Genzyme CEO Henri Termeer, who marked his 25th anniversary with the Cambridge biotechnology giant this year, says he has no plans to retire. [Boston Globe, Dec 24]

Investing in People. Genzyme spent $770,000 lobbying the federal government in the third quarter, according to a recent disclosure form.  [Boston Globe, Dec 9, 08]

Genzyme  down 10% [Dec 1, 08]  On a stock bloodbath day

Genzyme said it has asked the FDA to approve its leukemia drug Clolar for adults.  The drug is already approved for a form of the disease called acute lymphoblastic leukemia in patients between 1 and 21 years old who have had at least two prior treatments.  [Boston Globe, Nov 24, 08]

a first-ever deal to bring treatments to market based on adult stem cells, Genzyme  has entered into a deal with Osiris Therapeutics, which will see Genzyme investing at least $130 million in Osiris — in a deal worth a potential $1.25 billion.  [Mass High Tech, Nov 4, 08]

Genzyme up 13% [Oct 13, 08]

Genzyme  announced the opening of its new LEED-certified science center in Framingham, today. The $125 million, 180,000-square-foot facility can house 350 employees in a building intended for the early-stage research of cancer, heart disease, genetic diseases, and endocrinology and neurological disorders. [Mass High Tech, Sep 22, 08]

Genzyme and Isis said FDA requirements will result in some delays for Mipomersen, the cholesterol-lowering antisense drug at the heart of their joint venture deal announced in January. The news sent Isis shares down 29% [thestreet.com, Apr 25, 08]

Genzyme plans to construct a 200,000-square-foot facility for research and development in Beijing  [Mass High Tech, Apr 22, 08] Maybe it could get an unadulterated source of its supplies from corner-cutting Chinese factories.

In a decision that shows how difficult it is to copy complex, biologic drugs, federal regulators rejected Genzyme Corp.'s request for permission to sell in the United States a version of its Pompe disease drug, called Myozyme, that is made at its Allston manufacturing plant, the company disclosed yesterday afternoon. [Boston Globe, Apr 22]

Genzyme announced plans today to expand its manufacturing and research facilities in Ireland.  The Irish government said it was offering confidential assistance to subsidize the $200M expansion  [Boston Globe, Apr 1, 08]

Genzyme launched its kidney disease treatment Renvela. FDA approved the drug in October. It’s a new version of the kidney disease drug Renagel, in use since 1998. [Boston Globe, Mar 7, 08]

Genzyme announced a license agreement for exclusive rights to a lung-cancer diagnostic.  [Boston Globe, Jan 16]

Genzyme said its fourth-quarter revenue rose 21%[Jan 8, 08] 

Genzyme and the town of Framingham have asked state officials for a commitment of $12.5 M in state funds toward Genzyme's proposed $260 M expansion of its biologics facility in Framingham  [Mass High Tech, Dec 31,07]

Genzyme reports the U.S. Food and Drug Administration has approved another use for its thyroid cancer medication. [Dec 07]

Genzyme (Cambridge MA; $1M SBIR long ago) has agreed to pay $57M for privately held Canadian Diagnostic Chemicals Ltd.'s diagnostics unit.  [Boston Globe, Nov 10]

An experimental antidiarrhea drug made by Genzyme (Boston, MA: $1M SBIR a decade ago) failed its first large test in humans, the company said yesterday, the second disappointment for the Cambridge biotechnology giant in two days. [Boston Globe, Jul 7]

GeoMed Analytical

By the time the University of Massachusetts at Boston officially opens its Venture Development Center this morning, professor Robyn Hannigan hopes to have her laser system unpacked and her lab's mercury analyzer working.  Hannigan is excited by the prospect of developing her new company, GeoMed Analytical. It will be the first faculty-run firm to be launched in the new $8 million incubator, designed to nurture start-up companies that will turn UMass-Boston research into profitable products.  [Boston Globe, May 1, 09]

Geomagic (RTP, NC)

Ping Fu, the CEO of Geomagic (RTP, NC; one SBIR), recognizes that most entrepreneurs are too busy running their companies to get involved in politics. But when the White House called, she jumped at the chance to provide a voice for small- and medium-size businesses. Fu was one of 50 CEOs who attended a forum Thursday in Washington about using technology to modernize government. ....  she got her main point across: that any stimulus or job-creation money should be aimed largely at smaller companies, which do the bulk of the hiring. ....  she co-founded in 1996 makes 3D software that allows customers such as NASA and Harley Davidson to build realistic digital models of products. ... continues to prosper during the downturn and plans to add to its 100-employee workforce again this year.  [Alan Wolf, Raleigh News & Observer, Jan 15, 10] Does everybody think that what they are doing would be an ideal stimulus target? Where money is on offer,

Geospiza (Seattle, WA)

PerkinElmer has acquired bioinformatics software company Geospiza (Seattle, WA; $3.9M SBIR) for an undisclosed amount, the companies said ... Geospiza's GeneSifter software is used to manage the huge amounts of data flowing out of genetic research.  [Seattle Times, May 6, 11]

Geospiza  (Seatle, WA; $2.8M SBIR) the maker of software for biologists, said that it has been awarded a $1.2 million [NIH SBIR] grant ... along with collaborators at Weill Cornell Medical College and the Mayo Clinic. The grant will support research to help visualize differences in DNA between normal tissue, and samples from tumors, the company said.  [Luke Timmerman, xconomy.com, Feb 9, 11]

Geospiza, a Seattle company that makes software for crunching vast amounts of genetic data, has raised $3 million from private investors to tap the growing market for personalized medicine. [Seattle Times, Dec 1] At least $1.4M of SBIR.

GeoVax Labs (Atlanta, GA)

GeoVax Labs (Atlanta, GA; one SBIR) recent $3.6 million Integrated Preclinical/Clinical AIDS Vaccine Development grant has been boosted to $4.4 million. ... first awarded in 2007 [NIH]. With the latest funding, the program has given GeoVax $20.4 million over the past five years. [Atlanta Business Chronicle, Sep 1, 11]

GeoVax Labs (Atlanta, GA; one SBIR)  phase 2a human HIV vaccine trials are set for sites across North and South America, the company said . [Atlanta Business Chronicle, Dec 1, 08] entered into a $10 million common stock purchase agreement with Fusion Capital Fund II [press release May 08] ... raised $7.5M Aug 07 [press release]

Geron

Geron conducting the world’s first clinical trial of a therapy using human embryonic stem cells said that it was halting that trial and leaving the stem cell business entirely.  [Andrew Pollack, New York Times, Nov 15, 11]

Geron  up 10% [Jul 8, 11]

The California Institute for Regenerative Medicine made history Wednesday by awarding taxpayer funding for the first time to study an experimental stem cell treatment on humans. The $25 million grant went to Geron Corp. of Menlo Park, which last October began injecting immature versions of special neural cells derived from embryonic stem cells into patients paralyzed by spinal cord injuries. [Keith Darce, signonsandiego.com, May 4, 11]

Geron said it will offer 17.4 million shares of common stock in a public offering with expected proceeds of about $87 million. [San Francisco Business Times, Dec 7, 10]

Geron  has begun testing an embryonic stem-cell treatment on a patient with spinal cord injuries, marking the first time such a medical therapy has been used on a human in a government approved study.  [AP, Oct 11, 10]

After an 18-month delay, the [FDA] has given clearance to Geron and the University of California, Irvine, to begin a Phase I study of a human embryonic stem cell therapy for patients with spinal cord injuries. [AAAS, Aug 4, 10]

Geron up 17% [Jul 30, 10]

Geron up 12% [Jan 4, 10]

Geron up 13% [Dec 2, 09]  Scientists can start using taxpayer dollars to do research with 13 batches of embryonic stem cells and the government says dozens more cell lines should be available soon, opening a new era for the potentially life-saving field. [AP, Dec 2]

Geron down 10% [Nov 2, 09]

Geron down 10% [Aug 18, 09]  said U.S. regulators placed its application for a cell therapy to treat spinal-cord injuries on hold.  [Wall Street Journal, Aug 19]

Geron up 15% [Jul 27, 09]

Geron up 15% [Jun 30, 09] agreed to provide stem cells to GE Healthcare for use in tools that will test for the toxic effects of medicines. [Wall Street Journal, Jul 1]

Geron   up 18% [May 5, 09]

Geron  up 10% [Apr 16, 09]

Geron  down 10% [Mar 30, 09]

Geron  up 17% [Mar 9, 09]

Geron down 10% [Feb 27, 09]

Geron    down 11% [Feb 18, 09]

Geron down 18% [Feb 13, 09]

Geron  up 15% [Jan 26, 09]

Geron  up 36% [Jan 23, 09]

first embryonic stem cells in humans ... Just two days after the inauguration of President Barack Obama, who opposed his predecessor’s ban on federal funding for embryonic stem-cell research, the [FDA] authorised  Geron, a US biotech company, to begin clinical trials for patients with severe spinal cord injuries.  [Financial Times, Jan 23, 09]

Geron up 10% [Jan 21, 09]

Geron up 11% [Dec 8, 08]

Geron  down 14% [Dec 1, 08]  On a stock bloodbath day

Geron up 11% [Nov 10, 08]  StemCells reached its highest value in more than a year in U.S. trading on reports that President-elect Barack Obama may reverse the Bush administration's order restricting federal funding for embryonic stem-cell research. Other companies involved in stem-cell development such as Advanced Cell Technology, Geron and Aastrom Biosciences also gained. [San Jose Mercury News, Nov 10]

Geron  down 17% [Nov 12, 08]

Geron down 13% [Nov 5, 08]

Geron up 14% [Nov 3, 08]

Geron up 16% [Oct 28, 08]

Geron up 15% [Oct 20, 08]

Geron up 11% [Sep 16, 08]

Geron up 11% [Jan 29, 08]

Geron up 10%.  [Aug 8, 07]

The patients tolerated Geron's cancer drug, but sadly, so did the leukemia cells.  Down 10% [Jun 12, 07]

 Geron up 15% [May 17, 07] on news that its research partners at the University of Alberta were able to differentiate embryonic stem cells into clusters that secrete insulin in response to elevated glucose levels .. which implies the feasibility of producing therapeutic cells from stem cells to treat diabetes.

GI Dynamics (Lexington, MA)

GI Dynamics (Lexington, MA; no SBIR) reports it has taken in a strategic investment from Minnesota-based medical device giant Medtronic Inc. that will be used to move GI Dynamics’ EndoBarrier Gastrointestinal Liner for the treatment of Type 2 diabetes and obesity toward market approval. ... has secured more than $75 million in venture capital financing since it was founded in 2003  [Rodney Brown, Mass High Tech, Jan 7, 10]

GigOptix

GigOptix, (Palo Alto, CA; $700K SBIR) a supplier of semiconductor and optical components that enable high speed information streaming, has is buying Endwave (no SBIR) for about $24 million of stock. [Patrick Hoge, San Francisco Business Times, Jun 17, 11]

Lumera which is merging with GigOptix  of California, reported that it trimmed its third-quarter loss to $1.5 million, [Puget Sound Business Journal, Oct 21, 08]

Giner  (Newton, MA)

Giner Electrochemical Systems (about $70M SBIR over 27 years)  received $1.5 million to scale up its process for producing a more stable membrane for use in fuel cells. ... part of a nationwide award of $57 million aimed at accelerating the commercialization of clean technologies, and comes from the the DOE’s Small Business Phase 3 “Xlerator” program  [Kyle Alspach, Mass High Tech, Sep 16, 10]

Giner (Newton, MA; 164 SBIR projects) research and development company, has won a $2.3 million SBIR from NIH ... development of a measurement tool to assess human exposure to certain heavy metals such as arsenic, cadmium and lead. The sensor, referred to as a Field-Deployable Monitor to Assess Personal Exposure to Multiple Heavy Metals, is intended as an inexpensive, energy-saving, portable alternative to current heavy-metal analyses conducted in laboratories. [Mass High Tech, Oct 13, 09] Giner's exact total SBIR isn't available since SBA's database has been partly broken for weeks. But 164 Phase 1s and 80 Phase 2s might total something like $70M since 1983. Although both the NIH and the company would no doubt claim high innovation, this latest project sounds an awful lot like a low technical risk engineering service job for data collection by a perfectly competent company. No doubt also that the Massachusetts Congressional delegation finds great merit in an SBIR program that continues to pour zillions into their state. Before the re-authorization struggle ends, Congress will have to decide whether agencies need to be forced into such social programs just to do ordinary R&D that might well have been done even if SBIR never existed.

Giner Electrochemical Systems ( Newton MA) will be bought by Ener1 (Fort Lauderdale FL). Thius Giner is  joint venture of Giner (the SBIR company) and General Motors. Giner, both forms, researches proton exchange membrane (PEM) high-pressure electrolyzers for gas production, regenerative fuel cells, and direct methanol fuel cell (DMFC) stacks and systems. (Jan 05)

Giner formed a joint enterprise, Giner Electrochemical Systems LLC, with General Motors for development of fuel-cell vehicles. Giner has what the SBIR advocates call a strong strong SBIR presence, having been active in the SBIR program from the very earliest days (1983-present). Oh, yeah. Giner is proof that if the government pours enough kerosene, a blaze may start. Giner has had about $26M of SBIR in the last decade with a typical staffing of 25 people. That's about $1M per person (or $100K per year) which is enough to explain what Giner has been doing - contract government research . Whether SBIR should be such a long term research program is a political question of course. Any economic return has yet to show up; this GM deal shows technical confidence but GM has not sold any economic quantity of vehicles and even GM's research is partly supported by the government.

Ginkgo BioWorks (Boston, MA)

 NIST TIP winners  $22 million in funding for nine research projects targeting innovative manufacturing technologies in fields ranging from biopharmaceuticals and electronics to renewable energy sources and energy storage:  Isogenis (Aurora, CO; $4.8M SBIR);  ActaCell,  (Austin, TX; no SBIR);  Engineered BioPharmaceuticals (Manchester, CT; no SBIR); Arsenal Medical  (Watertown, MA; no SBIR); Kent Displays (Kent, OH; $2.6M SBIR); Precision BioSciences (Research Triangle Park, NC; $340K SBIR); Ginkgo BioWorks (Boston, MA; one SBIR); Sinmat (Gainesville, FL; $4.4M SBIR); Polyera (Skokie, IL; no SBIR).  http://www.nist.gov/tip/tip_121510.cfm 

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners:  Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary;  OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems  secondary, twice;  Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

Seven Massachusetts projects will get $22M in [USDOE] research funding ...  to receive $6 million is Ginkgo BioWorks (Boston, MA; one SBIR), which seeks to engineer the E. coli bacterium to harness electric current to convert carbon dioxide and water into isooctane, a component of gasoline  [Boston Globe, Apr 30, 10]  The rest of the money goes to research universities.

GlideLine Systems

Nanohmics (Austin, TX; $16M SBIR)  was among 44 companies nationwide recognized for success in commercializing science and technology innovations with the help of [SBIR] Nanohmics President and co-founder Mike Mayo was at the White House last week to receive the Tibbetts Award, which recognizes companies that have achieve excellence using SBIR. ... founded in 2002, created two new companies to commercialize unique technologies. ... The SBIR program "allowed three first-time entrepreneurs to take the risk of creating a new venture," Mayo said. So far, he said, that has led to the creation of 30 jobs in the Austin area.  Faradox Energy Storage develops high-performance capacitors that can operate in high temperatures. GlideLine Systems develops parachute navigation systems for military special forces personnel.  [Austin American Statesman, Feb 22, 11] Believe what you will about what the Tibbetts Award actually recognizes.  Roland Tibbetts had an interesting idea of an SBIR for NSF which had never funded much small for profit business. But by the time the politicians and the federal agencies captured SBIR for their purposes, the idea had been mangled by self-serving federal management. Nearly thirty years later, it still cannot show any net economic gain over what would have happened if the federal agencies just spent their R&D unmolested by such social programs. Nevertheless, the SBIR advocates hold the principle that anecdote is the singular of data, and if you accept the anecdotes, the whole data must be a mere multiple of them. 

Gliknik (Baltimore, MD)

Gliknik (Baltimore, MD; no SBIR) has raised $1.1 million of a $3.61 million Series A funding round that it will use to pay for research and developing new drugs to treat autoimmune diseases and cancer. [Baltimore Business Journal, Sep 2, 09]

Global Positions (Billings, MT)

Gloucester Pharmaceuticals (Cambridge, MA; no SBIR)  has just raised $1.7 million in a financing round, according to official documents.  ... acquires clinical-stage oncology drug candidates with an eye to getting them through regulatory approval and commercialization. ...  has raised substantial investment dollars in the past. Back in 2004, Gloucester Pharmaceuticals raised $29 million in a Series B financing round .  [Mass High Tech, May 8, 09]

GlucaGo (West Lafayette,IN)

GlucaGo, (West Lafayette,  IN; no SBIR) founded through Purdue University’s Biomedship Program, is among 16 finalists in a Global Business Plan Competition sponsored by Cisco and venture capital firm Draper Fisher Jurvetson.... makes a Chapstick-sized drug injector that is easy to use and allows unstable drugs or vaccines to maintain their stability at room temperature.  [Erika Smith, Indianapolis Star, Jun 23, 10]

GlycoFi

Adimab (Lebanon, NH; no SBIR) has raised $4 million, reports in a regulatory filing. ... [founder] Gerngross, an engineering professor at Dartmouth College, previously founded the biotech company GlycoFi ($2.2m SBIR)., which he sold to Merck & Co. Inc. for over $400 million.  [Mass High Tech, Dec 1, 10]

GlyGenix (Woodbridge, CT)

Apparently spun out of a biotechnology company, startup UCAN (formerly GlyGenix Woodbridge, CT; no SBIR) landed $624,000 of a planned $2.5 million funding round ... focused on marketing a nutritional sports product it calls SuperStarch ... GlyGenix, however is focused on treating and curing Glycogen Storage Disease Type 1a ... GlyGenix took a $1.645 million Series A round of funding in January  [Mass High Tech, Dec 28, 09]

GlySens (San Diego, CA)

GlySens (San Diego, CA; $6.8M SBIR) is seeking [FDA] permission to launch a pilot study testing its implanted wireless sensor in about a dozen people with diabetes. ... a device that constantly monitors blood-sugar levels without painful finger pricks or frequent maintenance  [Keith Darce, SD Union Tribune, Jul 28, 10]

GnuBio

 Harvard University spinout GnuBio (no SBIR). has raised $3 million in an equity offering ...  promises to join together millions of biological samples that are currently siloed at institutes around the world, and to do it using an open source platform. [Mass High Tech, Dec 3, 10]

The race to sequence genomes faster and cheaper has a new entrant — a start-up spun out of a Harvard University laboratory that focuses on emulsions, or mixtures of liquids like those found in mayonnaise and salad dressings. Deciphering the first human genome, a massive technical feat, took more than a decade and cost about $3 billion, but the price and time have been dropping rapidly in the 10 years since — down to about $20,000, powered by new technologies that take days or weeks. The new company, GnuBio, is in the very early stages of its development, but it said last week that its technology could sequence a human genome in hours and for just $30.  [Boston Globe, Jun 7, 10]

Good Start Genetics (Boston, MA)

Good Start Genetics (Boston, MA; no SBIR)  is the first company to repay an accelerator loan from the Massachusetts Life Sciences Center, the center said today. ... has developed a pre-pregnancy test that utilizes an advanced DNA sequencing technology to screen for many genetic disorders.  In May 2009, Good Start Genetics was awarded a $500,000 loan from the center in the first round of the center's accelerator program, which provides working capital to early-stage life sciences companies. ... Earlier this month, Good Start Genetics announced it had completed an $18 million Series A financing. [Boston Globe, Sep 20, 10] 

Good Start Genetics Good Start Genetics; no SBIR) announced the completion of an $18 million Series A financing  [Boston Globe, Sep 10, 10]

Gore Photonics 

More Raincoats, Less Photonics. Gore Photonics, the fiber optics business unit of W. L. Gore dumped its parallel optical business by selling to Optical Communication Products which makes  fiber optic subsystems and modules for metropolitan area, local area and storage area networks. That Gore division started life as Optical Concepts with substantial help from BMDO's SBIR. Gore is the innovative maker of Goretex rainwear. Buying, selling, and trading photonics entities has been going on for a decade during both the boom and bust of the photonics industry.

GPC-Rx (Seattle, WA)

things are looking better: the research-oriented startups seem poised to survive the downturn, and long-awaited clinical results could propel larger companies like Dendreon to stardom. ...  despite the financial crisis, the Accelerator, a local incubator based in Seattle's Eastlake neighborhood, created three firms last year - Recodagen, GPC-Rx and Mirina (none had SBIR) ... "Seattle is really a town of development-stage biotechs," Miller said. ... Light Sciences Oncology (no SBIR), a firm that canceled its initial public offering last February, managed to raise $10 million from venture capitalists in July. Private investors provided Redmond-based Healionics (no SBIR) — which manufactures material for implants — with a $2.6 million boost in December.  In a deal that could yield big results, Bothell-based Acucela  (no SBIR), which is developing therapies to treat blindness, signed a partnership deal in September with Japanese firm Otsuka Pharmaceutical that could potentially bring it $258 million.   [Angel Gonzalez, Seattle Times, Jan 25]

gRadiant Research (Concord, MA)

gRadiant Research (Concord, MA; no SBIR) is trying to make tonsil treatments easier for the patient to swallow, with a new handheld device.  ... received $250,000 in angel funding to pay for preclinical feasibility research, slated for completion by year’s end. Currently, McMillan needs about $3.2 million to develop the first clinical prototype and to do the necessary clinical studies in children and adults. She anticipates being on the market by 2012; the device could potentially garner some $75 million annually in the United States alone.  [Marc Songini, Mass High Tech, May 8, 09]

Graphene Energy (Austin, TX)

Graphic Surgery (Creve Coeur, MO)

Graphic Surgery (Creve Coeur , MO; no SBIR) helps companies contain surgery costs through benefit plan design and patient education. Research by Graphic Surgery shows one out of three health care dollars was spent on surgeries in 2005, ... considers 75 percent of surgeries "discretionary, ...Founder Dr. Patricia Gelnar, a former neurologist, said Graphic Surgery wants to improve communication between patients and physicians, not interfere with it. She started the company to help physicians manage malpractice claims through better communication to patients about surgery's risks. Then, the St. Louis Business Health Coalition learned about the company and thought it could help employers. [Mary Jo Feldstein, St Louis Post Dispatch, Nov 14]

GreatPoint Energy

Great Point Energy (Brookline MA; one SBIR) raised $100M to commercialize its technology, which converts coal into natural gas. Dow Chemical Co. and Citi Sustainable Development Investments led the Series C financing round. [Wall Street Journal, Oct 29]

the company that has been operating the experimental reactor for 18 months now, GreatPoint Energy (no SBIR), has raised $137M from some of the biggest names in industry and venture capital, ... raised its first round of venture finance in 2005 from previous (co-founder) Perlman backers ...  applying a (undisclosed) catalyst directly to the coal and recovering the catalyst from the char ... another lucky break when they found that the Gas Technology Institute had built a $60 M test plant and was looking for revenue after losing government funding from a tax on pipelines. [Daniel Fisher, Forbes, Oct 29]

GreenFuel Technologies

A Cambridge firm developing algae farms to recycle carbon dioxide from industrial emissions and provide feedstock for biofuels and other products said it raised nearly $14 million in venture capital. GreenFuel Technologies , founded in 2001, said it is using the money to further develop its farming technology and move toward commercial scale operations. [Boston Globe, May 16, 08]

GreenTech America

Purdue University says it helped launch 10 startup companies from July 2007 to June 2008, including GreenTech America, Intelliphage and Nutrabiotix. All use Purdue-licensed technologies. Purdue Research Foundation's Office of Technology Commercialization also reported more than $4.1 million in royalties for that time frame.  [Indianapolis Star, Jul 29]

Grove Instruments (Worcester, MA)

The Massachusetts Life Sciences Center, a quasi-public agency, awarded $3.75 million in loans to five early-stage life sciences companies. AesRX (Newton, MA; no SBIR)  biopharmaceutical company focused on the development of sickle cell disease and other orphan drugs; MoMelan Technologies (MA; no SBIR) medical device company; Myomo (Cambridge,MA; one SBIR) focused on helping people move again after a neuro-muscular impairment; ECI Biotech (Worcester, MA $1.6M SBIR) developer and manufacturer of affordable diagnostic sensors that can be incorporated into any consumer product or medical device; and Grove Instruments (Worcester, MA; $400K SBIR) developing a painless, noninvasive technology that accurately measures blood sugar.  [Boston Globe, Mar 23, 11]

GSI Technology

GSI Technology (Santa Clara, CA) filed for an IPO  It provides static random access memory, or SRAM, chips that are used mainly in networking and telecommunications equipment. [San Jose Mercury News, Jan 11]  No SBIRs, and it makes a profit.

GT Advanced Technologies (Merrimack, NH)

GTC Biotherapeutics

GTC Biotherapeutics (Framingham, MA; $5M SBIR) and Ovation Pharmaceuticals (no SBIR) said that they have entered into a collaboration agreement to develop and market a drug treatment called ATryn in the United States. [Chris Reidy, Boston Globe, Jun 24]

GTC Biotherapeutics said it gained orphan status for its treatment ATryn for a rare blood disorder called hereditary antithrombin deficiency. [Mass High Tech, Dec 10, 07]

GTC Biotherapeutics (Framingham MA; $3M SBIR) won FDA fast-track designation  for ATryn, a protein produced in the milk of goats that has anticoagulant and anti-inflammatory properties. [Boston Globe, Sep 5, 07]

GTC Biotherapeutics has entered into a strategic collaboration with French firm LFB Biotechnologies, a wholly owned subsidiary of LFB S.A., to develop recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform. LFB Biotechnologies will purchase $25 million of GTC common and convertible preferred shares, and convertible debt. [Mass High Tech, Oct 2, 06]

GTC Biotherapeutics got a $1.4 M NIH SBIR for its CD137 monoclonal antibody program. The company in-licensed the antibody from the Mayo Clinic in 2004, when it received an initial SBIR grant of $780,000.  ...  It expects to use the new SBIR grant to continue preclinical evaluation of the antibody. [Sep 06]

GTC Biotherapeutics raised another $17M.  Founded in 1993 as a spinout of Genzyme Corp. and originally named Genzyme Transgenics Corp., GTC Biotherapeutics develops and markets therapeutic proteins through transgenic animal technology. In 2005, the company, which employs 130, reported revenue of about $5 million.  [Mass High Tech, Jul 18] At least $3M came from HHS SBIR awards 2003-2005.

GT Equipment (Merrimack, NH)

GT Equipment (Merrimack, NH) claims three new SBIR/STTR awards as a sweetener to being named Environmental Exporter of the Year by the US Export-Import Bank. GT has formerly been called Ferrofluidics and FerroTec, or maybe GT Solar and GT Crystal. Perhaps its  international reputation for delivering high quality, cost effective products that consistently exceed customer expectations will keep it from going down the same photovoltaic tubes as Astropower. 

GTI Diagnostics (Waukesha, WI)

 medical test maker Gen-Probe (San Diego, CA; three SBIRs) said Thursday that it acquired GTI Diagnostics (Waukesha, WI; three SBIRs long ago), a specialty diagnostics company for $53 million in cash.  ... Gen-Probe bought GTI from Riverside Co., a Cleveland private equity firm that acquired the company in 2008. [signonsandiego.com, Dec 16, 10]

Guided Therapeutics (Norcross, GA)

Guided Therapeutics (Norcross, GA; no SBIR)  reported it landed a $2.5 million matching grant form the National Cancer Institute for its “LightTouch” non-invasive cervical cancer detection technology. ... Including this latest grant, the company has taken in $6 million in six consecutive grants from the NCI to develop the new, pain-free test for detecting cervical disease. [Atlanta Business Chronicle, Oct 5, 09]

G-Zero Therapeutics (Chapel Hill, NC )

H2Pump (Colonie, NY)

New York Tech Investment.  H2Pump, a start-up in Colonie NY, will get $395K to develop a 3-in-1 hydrogen pump to separate, pump and compress hydrogen through an electrochemical process. According to NYSERDA, this would avoid high energy-consumptive methods of gas separation, and mechanical pumping and compression.  Plug Power Inc., a Latham fuel-cell developer, will get a $400,000 research grant for membrane technology. [Albany Times Union, Feb 7]

H3 Biomedicine (Cambridge, MA)

H3 Biomedicine (who needs SBIR?) a personalized cancer drug discovery company launched earlier this year,  is opening its new headquarters and 24,000 square feet of laboratory space in Cambridge this afternoon. The privately held company has $200 million in research funding from Japanese pharmaceutical maker Eisai. [Lori Valigra, Mass High Tech, Dec 1, 11]

HNC Software (San Diego, CA)

HNC Bought HNC Software which had some help from SBIR in its younger days will be bought up by consumer credit scoring firm Fair, Isaac for $726M in stock. Fair Isaac says its to give them a better way to find and keep customers.

HNC Software , whose backers include the DARPA, reckons that its new approach to neural networks based on a cluster of 30 Pentium processors is the most powerful and promising approach to artificial intelligence ever discovered. HNC claims that its system could be used to spot camouflaged vehicles on a battlefield or extract a voice signal from a noisy background—tasks humans can do well, but computers cannot. Whether or not its technology lives up to the claims made for it, that HNC is emphasising the use of AI is itself an interesting development. [The Economist, Mar 16]

HNC Software reported earnings. Pro Forma (which means whatever we say it means) profit was seven cents a share. Actual Consolidated Results (which means what the accounting standards require) was a loss of 23 cents a share. The company blamed a continued slowdown in IT spending both in the US and overseas and gave thanks for a flexible business model that allows businesses to opt for payment on either a 'pay-as-you-go' or a one-time 'up-front' model.

A Wall Street Journal piece on passenger profiling says HNC Software is racing to develop an algorithm-based program for the airlines that factors such data as ethnicity, age and travel history into an equation aimed at calculating the probability of a passenger being a terrorist. HNC currently sells risk-assessment tools to insurers and lenders. SBIR gave HNC a little help while it funded lots of neural network companies who never made it public. Since neural nets are a nice clean business, there is no shortage of talent wanting government money to pursue the hobby. SBA reports 857 NN SBIR awards for neural network, of which about half won Phase 2. At an average of only $500K per Phase 2 for 400 awards, that's $200M into an industry out of which only one company went public.HNC had about $5M (2%) of that total. But neural nets is a competitive business and like most competitive industries, you gotta have something better than being good at government R&D to make a business success.

HNC Software , best known for products that help catch credit-card and insurance fraud, said it was developing a program for airlines that would sweep through reservation records for suspicious patterns and help flag potential hijackers. ... developing the software with privately-held PROS Revenue Management which manages revenue systems for major airlines,John Mutch, chief executive of HNC, said he expected the new security software would be delivered within six months. ... ``We will be able to detect patterns -- for instance, if five people of the same origin are traveling together and may use a certain kind of payment, fall between the ages of 25 and 40, and had previously limited credit history,'' Mutch said. The program would deliver a real-time scorecard to airlines, with a range of one to 1,000, which would alert airline personnel of the potential need to increase security. ... Previous suggestions to use data-mining software to sift through corporate records have drawn opposition from civil rights advocates. ...HNC has seen business slow and said it expects third quarter earnings and sales of $58-59M and operating earnings per share 13-15 cents. [Sue Zeidler, Arizona Republic, Oct. 04]

HNC Software took a 9% hit despite a favorable mention by NICK WINGFIELD, Wall Street Journal (Sep 26) of being best known for providing sophisticated software that helps the credit-card and insurance industries detect fraud by monitoring for activity that matches profiles of suspicious behavior. Following the terrorist attacks, the company has been discussing ways of using the technology to identify "high-risk passengers" with a company that installs information systems for airlines, said Joseph Sirosh, an executive director at HNC. Mr. Sirosh said executives at the company had authorized him to look at the company's entire portfolio of products to adapt them for counterterrorism measures. And just a month before the events of Sept. 11, HNC signed a three-year contract with the Defense Department to develop software that could help health-care workers more quickly identify outbreaks resulting from biological terrorism by detecting patterns within bacterial DNA.

In the latest news from HNC Software, the CFO sold 10000 shares. That makes all sales and no buying by insiders for the last year. Lots of options have been exercised at prices above today's prices.

No HNC Didn't Collapse. The apparent cratering of HNC Software, a 75% decline Monday, didn't end the world. Although one brokerage firm reduced its recommendation, the main thrust of the decvline was a distribution of HNC's shares of Retek.How much the distribution actually lowered HNC's share price needs some careful calcualtion.

HNC Acquires Another
(Sep 21) HNC Software (San Diego, CA) announced plans yesterday to acquire Open Solutions, a Connecticut company that makes software to process loans, deposits and other transactions for small banks. Open Solutions' shareholders will receive 3 million shares of HNC stock and options, which values the deal at about $124 million, based on yesterday's closing price. It is the fifth acquisition in less than a year for San Diego-based HNC, which is branching out beyond its original business of predictive software to detect financial fraud. [San Diego Tribune, Sep 17]

SBIR Firm Becomes the Standard
(Aug 17) HNC Software (San Diego, CA)says it is now in the S&P SmallCap 600. HNC was Hecht-Nielsen (Bob Hecht-Nielsen is still chairman and chief scientist) and a winner of neural net contracts from Star Wars in the 80s. Its tiny titbit of SBIR gives SBIR awarders some basis to boast about a tiny something.

Got a Saturday midnight call from your credit card company about an suspicious pattern of your card use? Especially suspicious: consumer electronics purchases in California by an East Coaster who had just bought an airline ticket adjustment, paid a hotel bill, and returned a rental car. Neural nets are watching, including a $150K version from HNC Software (San Diego, CA), says Forbes Jun 2.

HNC to OUTPERFORM
(Mar31) Morgan Stanly's hot-shot HNCS analyst upgraded HNC Software (San Diego, CA) to OUTPERFORM since the "shares traded at a discount to the company's estimated 50% long-term growth rate". The analyst was rated number 1 (of 7) in ability to predict HNCS price and number 5 to forecast earnings with an average historical error of one penny in forecasting earnings and generated "an average excess return of 7.00% when making recommendations for this company". Such a set of statistics in the dog-eat-dog competition on Wall Street. Three significant figures is pretty rich for a company public only two years. Ah well, Wall Street has to have something to talk about since it doesn't create the wealth, only redistributes it. Like politicians. Maybe SBIR program managers could also use statistics more sophisticated than 1-2-3 addition.

Big Profit at HNC
(Jan 24) HNC Software (San Diego, CA) reported a $5.3M quarterly profit on sales of $16.8M. Net profit for the year $6.4M on sales of $54M. Maybe the biggest SBIR success, although the $3M of DOD SBIR must have been no more than a modest contributor to HNC's growth. Return to Index

Spread the Merchandise Management
(Jan 14) Retek Information Systems, a subsidiary of HNC Software (a $600M market cap SBIR user) announced a new addition of software to unite large retail merchandisers' internal operations by Internet. Now Centralized Stores Inc can control all its software centrally. Wait, isn't that bringing management back to the days of the Info Systems priesthood so those pesky individuals can't innovate outside Info's control? One analyst estimates that a PC costs $10-12K per year and a network computer (semi-dumb terminal) only $2-3K per year. George Gilder would probably say, if asked, that such a move violates his theory of the microcosm (essentially infinite decentralization). Management doesn't surrender easily though.

Hold HNCS  A financial house brought HNC Software (San Diego, CA) into its watch portfolio and recommended its listeners hold HNC Software stock even at 81 times next years earnings. HNC had a little SBIR help.

Thinking Against Fraud  Where a new life form arises, there will a new life form also arise to feed on it. Feeding fraudsters applying for credit cards may be discovered by Falcon Sentry's new smart software (ever heard anybody advertise dumb software?) from HNC Software(San Diego, CA). Thus HNC's parade of new neural network product announcements marches on. Its stock price had a nice 15% boost last week also to 38, a stock that's ranged from 10 to 50 in the past year.

Claim Paternity. HNC's commercial victory offers a ripe chance for a federal agency to claim great success for its SBIR program. Such a victory should attract fathers, at least among California politicians. Divide HNC sales by SBIR input, get a large number, and smile. In cold truth HNC would have won without any SBIR, but without any real SBIR program evaluation who would ever throw such cold water on the claim? Everyone has an incentive to accept the claim except the federal career managers who would like SBIR to dry up.

Cardholder Bankruptcy Prediction  HNC Software (San Diego, CA) introduced a neural net prediction system that tells your bank when you're going broke. The scheme, ProftMax Bankruptcy, uses HNC' patented cardholder profiling technology. Such new products are how high-tech innovators keep up their momentum after the first product finds market success. Yogi may say it's not over till it's over, but for high-tech companies, it's never over. HNC got some nourishment from BMDO, both mainline missile defense research (years before it went public) and a small SBIR. 

Neural Nets for Japan Bank A Japanese bank will get neural net software from HNC Software (San Diego, CA) to fight bank card fraud. HNC got a little BMDO money for development in the late 80s and one Phase 2 SBIR for data compression. Its stock has traded many multiples above the 1994 IPO price.

Halozyme San Diego, CA)

biotech  Halozyme (San Diego, CA; no SBIR) said  that it will sell 8.3 million shares of common stock to the public [Keith Darce, San Diego Union Tribune, Sep 9, 10]

Hana Biosciences (South San Francisco, CA)

Hana Biosciences (South San Francisco, CA; one SBIR) plans to raise up to $100 million by selling preferred stock to two investors  ... to prepare and submit a Food and Drug Administration application for its leukemia drug Marqibo. As of March 31, Hana had accumulated a deficit of $140.6 million   [Stephen EF Brown, San Francisco Business Times, Jun 8,10]

Hansen Medical (Mountain View, CA)

Hansen Energy and Environmental (Garland, UT; one SBIR) received $198,500 as part of more than $18 million in Conservation Innovation Grants awarded for 55 projects nationally to develop cutting-edge technologies to help farmers and ranchers conserve natural resources. ...  to demonstrate an economical method to convert methane produced from farm waste products into a liquid fuel.  [Salt Lake Tribune, Jul 16, 09]

Hansen Medical (founded 2002; Mountain View, CA; no SBIR) up 28%  as it signed a new partnership with conglomerate General Electric to promote Hansen's catheter-implanting medical robots, though financial details weren't disclosed.  [Wall Street Journal, May 8, 09]  PO 2006, 208 employees, formerly named AutoCath

Dr. Frederic H. Moll, 56, is a soft-spoken man who can look uncomfortable on stage. Yet his role in founding Intuitive Surgical ($2.5M SBIR), the company that now dominates the field, and his current involvement with three other robotics companies, has kept him in the sights of investors, health care providers and fellow entrepreneurs.  ... He took the idea to his employer, Guidant, a medical device company. Guidant decided that robotic surgery was too futuristic and too risky, so Dr. Moll rounded up backers, resigned, and in 1995, founded Intuitive Surgical. [which] earned $144M last year on sales of $600M .... He’s now best known as chief executive of Hansen Medical  (no SBIR), a publicly traded robotics company focused on minimally invasive cardiac care. But he’s also an investor in and a board member of Mako Surgical (no SBIR), an orthopedics robotics company that recently went public, and he is a co-founder and chairman of Restoration Robotics (no SBIR), a start-up company focused on cosmetic surgery. [Barnaby Feder, New York Times, May 4] 

Harbor Technologies (Brunswick ME)

Harbor Technologies (Brunswick, ME), a provider of innovative and cost-effective composite solutions to the marine infrastructure market, announces that it has received a $418,500 development grant from the Maine Technology Institute to purchase and further develop a machine to produce composite marine pilings in a continuous manner. [Mainetoday.com, Aug 26]

Hardcore Computer (Rochester, MN)

Hardcore Computer (Rochester, MN; no SBIR) start-up's "liquid immersion cooling technology" significantly boosts the performance of high-end computers by reducing the excess heat that these power-sucking machines typically generate.  ....  Since 2007, the company has raised more than $3 million  [Thomas Lee, Minneapolis Star Tribune, Dec 18]

Harvard Bioscience (Holliston, MA)

Harvard Bioscience  (Holliston, MA; $800K SBIR) a medical equipment maker, said it has bought a business unit from a Swedish company that will help to broaden its line of biological research products. .... press release did not include financial details  [Chris Reidy, Boston Globe, Jul 1, 11]

Medical instruments maker Harvard Bioscience (Holliston, MA; $800K SBIR) said it has acquired Coulbourn Instruments (Whitehall, PA; no SBIR) , a private company that makes lab equipment for assessing learning and memory.  Harvard Bioscience estimates the total market for the instruments Coulbourn produces is between $40 million and $50 million. And it expects the company to add about $4 million in annual revenue.  [AP, Aug 23, 10]

Harvard Bioscience (Holliston, MA; one SBIR), that develops, manufactures, and markets a broad range of tools to advance life science research, said it has acquired Denville Scientific (no SBIR) for a purchase price projected to be about $24 million. [Boston Globe, Sep 3, 09]

Harvard Bioscience (Holliston MA; one SBIR), a maker of scientific research tools, reports it plans to repurchase $10M in company stock [Mass High Tech, Dec 7]  Should a company that pays dividends or re-purchases stock be barred from SBIR on grounds that it no longer needs government subsidy because it refuses to use its own $10M (in this case) capital for R&D investment? SBIR was meant as a complement to private capital, not a substitute.

Harvard Bioscience (Holliston, MA; one SBIR) completed the $5M cash purchase of Panlab SL of Barcelona, Spain. [Mass High Tech, Oct 12]

Harvest Automation (Groton, MA)

Harvest Automation (Groton, MA; no SBIR) raised a $4 million tranche of a Series A round of funding, according to a company official. ... founded by ex-iRobot Corp. employees .. developing robots for materials handling, though it’s still stealthy about specific uses markets  [Mass High Tech, Jan 8, 10]

Harvest Power (Waltham, MA)

Harvest Power (Waltham, MA; no SBIR) raised $1.25 million of a targeted $2.25 million new funding round, according to a federal document. ...  making the company’s Series B round worth $58 million in total. ... Founded in 2008, building what it calls North America’s first commercial-scale, high solids anaerobic digestion facility [near] Vancouver BC.  [Rodney Brown, Mass High Tech, Sep 2, 11]

Harvest Power (Waltham, MA: no SBIR) a producer of energy and fertilizer from organic waste, said Wednesday it has received $51.7 million in Series B financing from investors including a firm co-founded by Al Gore. .. said the new funding will allow the company to expand throughout North America and “add to its toolkit of technologies.”  [Mass High Tech, Mar 16, 11]

Healionics (Redmond, WA)

things are looking better: the research-oriented startups seem poised to survive the downturn, and long-awaited clinical results could propel larger companies like Dendreon to stardom. ...  despite the financial crisis, the Accelerator, a local incubator based in Seattle's Eastlake neighborhood, created three firms last year - Recodagen, GPC-Rx and Mirina (none had SBIR) ... "Seattle is really a town of development-stage biotechs," Miller said. ... Light Sciences Oncology (no SBIR), a firm that canceled its initial public offering last February, managed to raise $10 million from venture capitalists in July. Private investors provided Redmond-based Healionics (no SBIR) — which manufactures material for implants — with a $2.6 million boost in December.  In a deal that could yield big results, Bothell-based Acucela  (no SBIR), which is developing therapies to treat blindness, signed a partnership deal in September with Japanese firm Otsuka Pharmaceutical that could potentially bring it $258 million.   [Angel Gonzalez, Seattle Times, Jan 25, 09]

Healionics (Redmond, WA; no SBIR) said it raised $2.6 million in a second round of financing from private investors.  The medical device company manufactures a material for medical implants that's compatible with the body. It recently scored a multimillion-dollar deal to supply TR BioSurgical with material for a veterinary glaucoma implant scheduled for launch in the first quarter of 2009. The company, which spun off from the Ratner Biomedical Group incubator in 2007, raised $1.7 million in its first round earlier this year.  [Angel Gonzalez, Seattle Times, Dec 12, 08]

HealthTronics

Endo Pharmaceuticals completed its $223 million acquisition of HealthTronics (one SBIR) [Philadelphia Business Journal, Jul 15, 10]

Endo Pharmaceuticals has agreed to buy HealthTronics (Austin, TX; one SBIR in Georgia) a provider of urological products and services, for $223 million.   .... a continuation of Endo’s strategy to be a market leader in pelvic health. [John George, Philadelphia Business Journal, May 3, 10]

HealthTronics said it made $31.2 million in the third quarter, down about 7%. [Austin American-Statesman, Nov 8] One 2004 lithotripsy SBIR probably made little difference in a public company with a $236M market cap.  Started life in Georgia and then merged in 2004 with Prime Medical Services.

Hearforward (Colchester, VT)

TheVermont Center for Emerging Technologies has added $1.8 million in new federal stimulus funds, boosting to $5 million the fund the quasi-public technology incubator has at its disposal ...  Returns from investments will be paid back into the 10-year fund and reinvested, [fund manager David Bradbury] said. ... has already made a handful of investments out of miscellaneous funds, including Hearforward, (Colchester, VT; no SBIR) social media analytics software company; Kilawatt Technologies (Shelburne, VT; no SBIR) energy efficiency analytics company; and SemiProbe (Colchester, VT; no SBIR) semiconductor equipment company. [Mass High Tech, Apr 21, 10]

Heartland Robotics

Heartland Robotics, the company founded by MIT robotics expert and iRobot corp. co-founder Rodney Brooks, has landed $20 million in its latest round of funding.  [Mass High Tech, Dec 2, 10]

Heartland Robotics, the manufacturing-focused robotics company founded by iRobot co-founder Rodney Brooks, has taken in $12 million from three investors, and is aggressively hiring engineers, the startup announced  [Mass High Tech, Sep 9, 09]

HeartWare International (Framingham, MA)

Medical devices company HeartWare International (no SBIR) reports it is raising approximately $55 million in a private placement of stock with a group of unnamed institutional investors in the United States, and it is considering a similar placement to Australian investors that would raise another $5 million. ... In February, HeartWare announced plans to be acquired by California medical devices company Thoratec  for $282 million. That deal was called off at the end of July, however, after the U.S. Federal Trade Commission said that Thoratec had a monopoly in the left ventricular assist device market and would allow a suit seeking a preliminary injunction to stop the deal, while the FTC looked at the sale more closely.  [Mass High Tech, Aug 11, 09]

heart pump maker HeartWare International (Framingham, MA; no SBIR) is being acquired by Thoratec (CA; two tiny SBIRs two decades ago) for $282 million  half in cash and half in shares of Thoratec common.  [Mass High Tech, Feb 13]

HeatGenie (Austin, TX)

Self-heating food package maker HeatGenie (Austin, TX, founded 2007 as Ironbridge Technologies; one SBIR) has received $400,000 of a planned $450,000 round of funding. ... Its business model is to generate revenue by licensing the technology to container companies and heat manufacturers  [Austin Business Journal, Jul 6, 10] got $1M from TX Emerging Tech fund

Helicos BioSciences   (Cambridge, MA)

Beleaguered Helicos BioSciences reports it has cut staff levels in half, eliminating 40 positions in the first quarter of the year. The cuts are part of a shift in company focus to concentrating on the diagnostics market for its gene sequencing technology.  [Rodney Brown, Mass High Tech, May 18, 10]

Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon.  Among the fifty most innovative:  A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences.  [MIT Tech Review, M/A10]

Helicos BioSciences  has taken itself off the auction block, the genetic analysis instrument company said  [AP, Nov 11, 09]

Helicos BioSciences said it received a $2.9 million grant from the National Institutes of Health's National Human Genome Research Institute. ... part of the company's genome sequencing technology program. [Boston Globe, Oct 9, 09]

Helicos BioSciences said that it has entered into an agreement with certain investors to raise about $18.6 million in a private placement through the sale of shares of its common stock and warrants. ... focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets.  [Chris Reidy, Boston Globe, Dec 20]

Helicos up 19% [Jan 10, 08]

 Helicos BioSciences (Cambridge, MA; no SBIR)  a developer of genetic analysis systems, has formed a collaboration with a University of Massachusetts Medical School researcher to advance technology for studying RNA... a 2006 net loss of $20.6M on revenue of $160,000. The firm employs 79 workers.  [Mass High Tech, Jan 9, 08] Raised $40M VC Mar 06 and $45M by IPO May 07.

Heliovolt (Austin TX)

HelioVolt (Austin, TX; one SBIR) has raised $8.5 million through the sale of debt securities, in what the company described as "internal financing" to support its operations. [Austin American Statesman, Jan 28, 11]

HelioVolt, a producer of highly-efficient thin film solar products, received a Printed Electronics USA 2007 Award from IDTechEx, a leading independent international consulting firm specializing in printed electronics, RFID and smart packaging. [company press release, Nov 15]

HelioVolt (Austin, TX; one Phase 1 SBIR) has attracted $24M in private investment as it gets ready to build a factory to make advanced solar power panels using thin films of advanced materials. The new money comes in addition to the $77M the company said it raised in August ... has raised a total of $109 M in outside capital. [Austin American-Statesman, Oct 22]

Powered by $77 M in new investment, startup Heliovolt (Austin, TX: one SBIR), will build a factory next year for mass-producing a new type of solar cell [micrometers-thick layer of a copper-indium-gallium selenide (CIGS) semiconductor]  that could, in much of the United States, make solar electricity as cheap as electricity from the grid. [Kevin Bullis, MIT Tech Review, Sep 12, 07]

The 2006 WSJ Silver Medal for Technology Innovation went to HelioVolt (Austin TX) for the fastest and most effective way to manufacture CIS (Copper Indium Selenide), the most reliable and best-performing thin film [photovoltaic] material. One SBIR (Phase I so far from MDA) perhaps created by Ron Gale. VP for Business Development and formerly Chief Technical Officer for Kopin.

Helix Therapeutics (New Haven, CT)

In all, 52 venture capital deals were struck in Connecticut in 2010, with more than $187 million invested, compared with 39 deals and $157.4 million invested in 2009.  In the recent quarter, Helix Therapeutics (New Haven, CT; one SBIR) biopharmaceutical company, received $2.5 million; SeeClickFix (New Haven) firm that develops online and mobile platforms, received $1.3 million; and Affinimark Technologies (New Haven, CT; no SBIR) start-up that develops medical diagnostic products, received more than $1.2 million.  A Guilford-based online advertising start-up, uKnow, received $453,000; Interactive Mobile @dvertising LLC in Norwalk received $275,000; Retail Optimization Inc., a New Haven firm that develops merchandising software, received $250,000; Twigtek Inc., a New Haven company that operates a website for selling or recycling used electronic equipment, also received $250,000. And Semantifi Inc., a Stamford software firm, received $50,000 from Connecticut Innovations Inc., the state's venture capital investing arm.  [Janice Podsada, Hartford Courant, Jan 21, 11]

Helix Therapeutics (New Haven, CT; one SBIR) biopharmaceutical company, has landed $2.5 million in new funding from venture firm Canaan Partners and the quasi-public state funding entity Connecticut Innovations.  ...  to move forward its proprietary targeted gene modification (TGM) technology platform, which the company says can correct certain genetic mutations in blood stem cells of patients with rare genetic diseases such as sickle cell anemia, B-Thalassemia and lysosomal storage disorders.  ...  developed at, and is licensed from, the Yale University School of Medicine. It, uses patented oligonucleotides that bind to the human genome resulting in permanent gene modification.  In January, Helix took in $500,000 in seed funding from CI  [Rodney Brown, Mass High Tech, Nov 22, 10]

HemaQuest Pharmaceuticals (Newton, MA)

small molecule therapeutics startup Hemaquest Pharmaceuticals (Newton, MA; no SBIR)  pulled in $12 million in a Series B funding round ... develops small molecule therapeutics based on its short chain fatty acid derivative technologies to treat anemias and other blood disorders   [Mass High Tech, Apr 21, 10]

HemaQuest Pharmaceuticals (Seattle, WA; no SBIR) has raised $6 million in equity financing out of a round that could be worth as much as $12.7 million, according to a regulatory filing. ... led by former Xcyte Therapies ($1.3M SBIR) CEO Ron Berenson, is pursuing a new treatment for sickle cell anemia. [xconomy.com/seattle, Feb 4, 10]

HemaQuest Pharmaceuticals, a year-old Boston company focused on developing new treatments for blood diseases, said today that its HQK-1001 drug candidate has won orphan drug status from the FDA. [Boston Globe, Nov 5, 08]

Lilly Ventures of Indianapolis, the venture capital arm of Eli Lilly and Co., is giving $20M financing to HemaQuest Pharmaceuticals, [newly launched by two Boston University researchers] in Newton, Mass., that's developing small molecule therapeutics to treat blood disorders such as sickle cell anemia. [Indianapolis Star, Nov 3, 07]  Mass High Tech reports that part of the money came from De Novo Ventures, a California investment group, and Forward Ventures, of San Diego.

Hepregen (Winchester, MA)

Hepregen (Medford, MA; one SBIR) won a $500,000 Phase 2 SBIR [NSF] grant contributing to the company’s total $2 million in federal funding. ... developing a platform to reduce the liver toxicity caused by approved drugs.... co-founded in 2007  [Mass High Tech, Jan 14, 10]  spun out Hepregen Corporation from the Massachusetts Institute of Technology (MIT), with a commitment of a $5-million Series A investment [company website, Feb 09]  The new technology—that Bhatia and HST postdoctoral associate Salman Khetani describe in the Nov. 18 online issue of Nature Biotechnology—arranges human liver cells into tiny colonies only 500 micrometers in diameter that act much like a real liver and reportedly survive as long as six weeks.  To predict how close their model tissue comes to real liver tissue, the researchers evaluated gene expression profiles and found that these profiles are very similar to those of fresh liver cells, “giving us confidence that other [liver] functions are preserved,” Khetani says.  For drug testing purposes, this allows each colony to provide a view into human liver response to a drug without requiring human exposure to the drug in a clinical trial, explains Bhatia. [Jeffrey Bouley, Drug Discovery News, Jan 08]

Hepregen (Winchester, MA; no SBIR) raised a $3 million tranche of a Series A financing of $5 million, according to online reports. The -based firm is a spinout of MIT and is developing a platform to reduce the liver toxicity caused by approved drugs. The platform is based on technology developed by Sangeeta Bhatia, an associate professor in the Harvard-MIT Division of Health Sciences and Technology (HST) and MIT’s Department of Electrical Engineering and Computer Science. The technology is based on engineered “miniature micro liver cells.”  [Mass High Tech, Sep 2, 08]

Herley Industries

Herley Industries dropped 13% [Jun 27, 07] after DOD suspended two of its plants from new government contracts.

Herley Industries rose 20% on news of DOD's lifting its ban on new contract awards at some of its manufacturing sites. [Oct 13, 06]

Herley led the market slide with a 34% one-day loss Tues Jun 13 after the DOD suspended procurement from Herley's factories amid the mess that includes indictment of the former Chairman.

Too Much Profit. Shares of Herley Industries were halted for trading this afternoon after the U.S. Attorney's office for eastern Pennsylvania indicted the company and Chairman Lee Blatt for alleged excessive profits on three defense contracts. ..  designs and manufactures microwave devices for use in high-technology defense electronics [Dow Jones Newswire, Jun 6] No SBA recorded SBIRs.

Hermes Biosciences (Cambridge, MA)

Merrimack Pharmaceuticals (Cambridge, MA; $1M SBIR), which is developing treatments for cancer and autoimmune disease, said it bought Hermes Biosciences (South San Francisco, CA; $600K SBIR) for an undisclosed sum. [Robert Wesiman, Boston Globe, Dec 8, 09]

Hibernaid (Troy, NY)

Hibernaid, (Troy, NY; no SBIR)  drug-discovery company, was named “most likely to be funded.” ... at the 10th Annual SmartStart UNYTECH Venture Forum .... The three-person firm has created a drug to induce hypothermia, a treatment used to treat post cardiac arrest patients, as well as people who have suffered strokes or traumatic brain injuries. [Business Review (Albany), May 19, 10]

High Performance Technologies (Reston, VA)

Histogenics (Waltham,MA)

Cartilage regeneration company Histogenics (Waltham, MA; no SBIR)  announced its closing of a $9 million Series B round of funding. ...  will support development of the company’s NeoCart neocartilage implant, currently in Phase 2 clinical trials, and VeriCart auto-regenerative cartilage matrix, scheduled for Phase 2 clinical trials in 2008. [Mass High Tech, Sep 3, 08]

HistoRx (New Haven, CT)

Connecticut Innovations has announced a $1.5 million loan to HistoRx (New Haven, CT; one SBIR) working on diagnostic solutions for cancer treatment. [Mass High Tech, Mar 15, 10]

Hittite Microwave

Hittite Microwave  up 10% [Nov 30, 11]

Hittite Microwave (Chelmsford, MA; $28M SBIR)  a maker of analog and mixed-signal semiconductors ... [a] core holdings of the two top-performing U.S.-stock mutual funds over the 12 months through September ...  McDowell expects Hittite's part of the semiconductor business, which is less commoditized than the digital semiconductor industry, to continue to grow and for Hittite to boost its earnings by about 20% a year over the next three years as it benefits from a debt-free balance sheet and new products. ....  Over the past few years, it has been one of the most profitable semiconductor investments the fund has seen, says Mr. Beiley [Suzanne McGee, Wall Street Journal, Oct 5, 11]

Hittite Microwave (Chelmsford, MA; $28M SBIR) maker of chips for use in radio frequency, microwave and millimeter wave devices, has acquired Norway’s Arctic Silicon Devices (Trondheim, at 63.5 degrees latitude, north of even Fairbanks AK) for about $12 million in cash and equity. [Mass High Tech, Jan 19, 11]   350 employees, up from one in 1985 at first SBIR.

Real efficiency. NVE is the 4th most efficient company in [Technology stocks]. .. earnings per employee was $230,210 for the last 12 months. That's profits! Hittite Microwave  the 9th most efficient [with] earnings per employee was $140,570 for the last 12 months. [China Analyst, Feb 19 10]  Thanks to Jeff Bond for the info.

Forbes's 2009 list of best 200 small companies includes Aerovironment, American Science and Engineering (paying a dividend and with nearly $600M market cap), Argon ST, Hittite Microwave, II-IV, Meridian Bioscience, Neogen, NVE, and Synaptics. 

Hittite Microwave is down 16%, half as much as the broad market, since I recommended the stock in August 2006. The “fabless” chip maker — one that designs chips but doesn’t fabricate them — has maintained high profitability, and while its recent sales growth might be difficult to sustain, the company looks likely to take share from struggling, capital-intensive peers.  [Jack HOugh, Smart Money, Mar 24, 09]

Hittite Microwave up 11% [Oct 24, 08]

Hittite Microwave down 10% [Oct 14, 08]

Forbes 200 Best Small Companies list for 2008 had several "SBIR involved" companies: Hittite Microwave 12, II-IV 23, Synaptics 33, NVE 39, ATMI 114, Cymer 166. 

A Hittite Microwave founder has led a Series B round of financing for Cambridge drug developer Syndexa Pharmaceuticals (no SBIR), Syndexa reports. Yalcin Ayasli, a founder and former executive and board member at Chelmsford-based Hittite, was the lead investor in the $15 million round of private capital. ... Syndexa was founded by scientists from Harvard University and the University of California San Diego. The firm said it has raised a total of $19 million in private equity.  [Mass High Tech, May 30]

Hittite Microwave up 10% [Mar 20, 08]

Hittite Microwave down 12% [Feb 15, 08]

Hittite Microwave up 12% [Oct 26, 07]

Hittite Microwave has an agreement to license a line of integrated circuit technology from aerospace and defense contractor Northrop Grumman. [Mass High Tech, Oct 19]

Smart Money picked Hittite Microwave as a company doing well in the shade where Wall Street analysts don't follow.

Hittite Microwave jumped 15% after it said it expects earnings to grow 27 -34 % in the first quarter on higher sales. 

Good Profit, Bad Forecast for Hittite Microwave whacked the stock 15% [Oct 27, 06] as the price dropped off its heretofore steady rise to double its starting price a year ago. Hittite had at least 24 Phase 2 SBIRs before being publicly traded.

Hoku Scientific (Kapolei HI)

Hoku Scientific(Kapolei HI, 17 employees; no SBIR), a materials science company focused on clean energy technologies, up 18%after broker Piper Jaffray raised its rating, saying support from solar company Suntech Power Holdings may assist its search for financing. [Wall Street Journal, Sep 5]

Hollis-Eden Pharmaceuticals (San Diego, CA)

Hollis-Eden Pharmaceuticals (San Diego, CA: no SBIR; 66 employees) surged 41% after the drug developer reported promising data from animal tests of a breast-cancer drug. [Wall Street Journal, Sep 8]

Hontek (South Windsor, CT)

Hong had been laid off from his job as a chemist at a Rockville printing plate maker, joining the more than 50,000 Connecticut workers who lost jobs that year ...  wrote a proposal to create a plastic-based coating to protect the blades from erosion.  "It was a long shot. I was just one person working in my basement," Hong said. "These programs are extremely competitive. I sent it in and forgot about it."  Today, Sikorsky Aircraft and the Army are using Hontek's polymer coatings to protect helicopter blades from sand, ice and gravel. He got a 1992 SBIR.  Hontek (South Windsor, CT; $3M SBIR)  grew from two to 10 employees, and in 1997 moved to its present location, a 13,000-square-foot facility.  In 2005, the military needed a new type of coating that would de-ice the blades of helicopters deployed in Afghanistan.  Hontek responded, using private funding to develop a new coating.  ... Last year, the Army decided to use Hontek's coating on its new Black Hawk helicopters. [Janice Podsada, Hartford Courant, Feb 4, 09] He has also had Phase 1 SBIRs in 2006 and 2007. The story doesn't explain why he chose private funding in 2005 after he had established friendly acceptance in DOD's SBIR.  

Hoppe Tool (Chicopee, MA)

Mason Box (North Attleboro, MA) is among several local companies that have been selected to participate in the "Next Generation Manufacturing Initiative, or NGMI, an effort to foster best-in-class manufacturing processes. Other participants in the initiative include Hoppe Tool (Chicopee, MA), Matouk Textiles (Fall River, MA),  Munksjo Paper (Fitchburg, MA), and Spectro Coating (Leominster, MA).  The initiative is a partnership of the Associated Industries of Massachusetts, a nonprofit group representing Bay State employers; MassDevelopment, the commonwealth's finance and development authority; and the Massachusetts Manufacturing Extension Partnership, a group dedicated to helping local manufacturers remain competitive in a global marketplace.  [Chris Reidy, Boston Globe, Jun 19]  No SBIR.

Humacyte (Research Triangle Park, NC)

Humacyte (Research Triangle Park, NC; no SBIR) developing lab-grown blood vessels has attracted one of the most powerful women in business as its CEO. ...  Carrie S. Cox, 53, to lead the company as it expands ... founded in 2004 and based on research at Duke University led by Laura Niklason and two former Duke students ...  employs 15 people who are testing engineered blood vessels designed to be implanted into the arms of dialysis patients [Alan Wolf, Raleigh News & Observer, Sep 9, 10]

three years after forming Humacyte (Research Triangle Park, NC; no SBIR) to pursue their research, the three women are a year or two away from testing their blood vessels in patients.  [Sabine Vollmer, Raleigh News& Observer, Nov 30]

Human Genome Sciences

Human Genome Sciences (Rockville, MD; no SBIR) fell 44%, after it moved high-dose Albuferon patients in two continuing late-stage hepatitis C trials to the low-dose group, citing higher rates of serious lung-related problems in those using the higher dosage.  [Wall Street Journal, Jan 24, 08]

HTSS (Madsion, WI)

The Wisconsin Department of Commerce has qualified two biotech companies to receive investor tax credits, the agency said Thursday. Perscitus Biosciences LLC is developing a molecule that has shown an ability to protect healthy human cells against the harmful effects of chemotherapy and radiation. HTSS LLC, Milwaukee, is developing a technology that analyzes muscle activity to help reduce injuries during exercise regimens. Certain investors in both companies are now eligible to claim tax credits under legislation known as Act 255. [Milwaukee Journal-Sentinel, Jun 27]  No SBIR.

Hybrivet   (Framingham, MA)

Hybrivet Systems (Natick, MA; one 1992 SBIR)  developer of contaminant detection systems, has been acquired by [giant R&D driven] 3M. No financial terms of the deal were disclosed. ...   develops LeadCheck Swabs, a commercially available lead detection tool recognized by the [EPA]. Its other detectors of contaminants and toxins include products for identifying the presence of hexavalent chromium ions, mercury, cadmium, nickel, copper and arsenic.  ....   founded in 1987 by Marcia Stone, has 11 employees. [Michelle Lang, Mass High Tech, Feb 17, 11]

in April, the US Environmental Protection Agency implemented a new rule requiring contractors to use lead-safe work practices and check for lead whenever renovating, repairing, or painting a building constructed before 1978. Hybrivet’s (Framingham, MA; one SBIR in 1992) test, LeadCheck, is one of only a few kits currently recognized by the EPA to check for the substance, which can be extremely toxic even at low levels. All of a sudden, Hybrivet couldn’t make its product fast enough  [Boston Globe, Sep 8, 10]

HYCOR Biomedical (Garden Grove, CA)

Hydra Biosciences (Cambridge, MA)

the increasingly prominent role big pharmaceutical companies are taking during the recession — both to help get new biotech firms off the ground and to prop up those companies with promising technologies, but few financing options. .... MedImmune Ventures, an arm of MedImmune Inc., which is a subsidiary of AstraZeneca plc. The venture arm has $300 million under management and has invested $200 million, including investments in Hydra Biosciences (Cambridge, MA; $250K SBIR) and Inotek Pharmaceuticals (Lexington, MA; $20+M SBIR)    [Mass High Tech, Aug 14, 09]

Hydra Biosciences (Cambridge, MA; two SBIRs) brought in $22.2 million in a fourth venture funding round to advance a number of Hydra’s ion channel drug programs to fight pain, inflammation, and pulmonary disease [Mass High Tech, Jan 16, 09]

Hydra Biosciences (Cambridge, MA; 2 SBIRs) confirmed reports it raised $34M in its third round of venture capital. ... 36 employees, is in the early stages of developing potential treatments for pain management and hopes to begin clinical testing on at least one of them next year.  [Boston Globe, Mar 15]

Hydra Biosciences (Cambridge, MA; two SBIRs) raised $34M in a Series C round of funding. [Mass High Tech, Mar 13, 08]

Hydra Biosciences (Cambridge, MA; two SBIRs) inked a deal potentially worth more than $195M with  Pfizer to develop treatments for pain [Mass High Tech, Jul 26, 07]

HydroCision (North Billerica, MA)

Medical device company HydroCision (North Billerica, MA; no SBIR) said  that new investors have acquired the company ... develops and markets SpineJet, a surgical technology that is designed to allow discectomy and interbody fusion procedures to be performed faster and less invasively than traditional surgical methods. ...  founded in 1994, will focus on several core strategies, and that it plans to invest in U.S.-based research projects to prove the economic value of its products. [James Connolly, Mass High Tech, Sep 16, 10]

Hydrogen Safety (East Hartford,CT)

Six start-up technology firms have received grants as part of the state's small-business incubator program,  ... administered by the Connecticut Center for Advanced Technology ...  $32,000 to $50,000 went to: AllerQuest LLC of West Hartford, Catelectric Corp. of Storrs, Hydrogen Safety of East Hartford, Quadra-Aerrow International of Glastonbury, Revegen Inc. of Farmington and the Center for Network Centric Product Support Research of East Hartford.  [Hartford Courant, Dec 12, 08]  no SBIR for any

Hygeia Therapeutics (Holden, MA)

Hygeia Therapeutics (Holden, MA; no SBIR) reported today that it has completed a $1 million Series A financing. .... founded in 2007, and focuses on developing topical therapies for conditions where localized treatment offers advantages over systemic therapies.     [Mass High Tech, Apr 19, 10]

HyperBranch Medical Technologies (Durham, NC) (Cambridge, MA)

Private investment continues to boost young Triangle companies. Biologics  (Raleigh NC; no SBIR) oncology pharmacy, $20M; . Aldagen  (Durham NC; no SBIR) biotech company, $9 M; HyperBranch Medical Technologies  (Durham NC; one SBIR) medical device startup, $1.5M. [Sabine Vollmer, Raleigh News & Observer, Sep 15] Those who can, do; those who can't or won't depend on government handouts.

Hyperion Therapeutics (South San Francisco, CA)

Hyperion Therapeutics (South San Francisco, CA; no SBIR) raised $60 million in its third round of venture funding. ...  late-stage clinical testing of its drug for urea cycle disorders [San Francisco Business Times, Jul 2, 09]

HyperMed (Waltham, MA)

HyperMed (Burlington, MA; $2.7M SBIR) filed for Chapter 11 bankruptcy protection ... owns over 40 patents related to different medical devices, ... ceased operations and the phone number has been disabled. Online business directories say the private company was established in 1997 and had 21 employees. [Julie Donnelly, Mass High Tech, Dec 23, 09] 

HyperMed (Waltham, MA; $2.7M SBIR) says it has closed on $4M in a new wave of Series A financing to market its hyperspectral medical imaging product, OxyVu,

Hypres (Elmsford, NY)

All digital RF superconductor technology from Hypres (Elmsford, NY; over $40M SBIR), says MDA's Tech Applications Fall 2008 quarterly.  MDA's piece talks the usual talk about marketing, tech benefits, and hopes for the future, but says nothing about whether the company produced any economic effect after $40M SBIR over two decades.  Of course, it's not Tech App's role to evaluate SBIR, only to tell MDA's best stories. We might conclude, though, that if such a project ranks as one of MDA's best stories this year from many tens of millions of SBIR dollars, MDA's SBIR must be paying no heed to SBIR's objective to nurture infant technology with an economic future. Perhaps the SBTC will put some bold lipstick on SBIR by citing MDA's story as another compelling sign of SBIR's success.

Hypres (Elmsford, NY) got some publicity by publishing a self-congratulatory article in IEEE Spectrum Dec 2000. If you like electronics at temperatures below a North Pole Christmas, you'll like the low temperature superconductivity for which Hypres has had something like $20M of SBIR since 1986. The piece concludes with a vision that such electronics may replace conventional microelectronics as they reach "their physical and economic limits. The drivers will be the market's demand for higher bandwidth and for seamless RF and digital integration." Ok, when will the government get a competitive return in its investment? The old SBIR question arises, "how much and how long should a seed program nurse a technology that won't sell?".

Hy-SyEnce (Fall River, MA)

No fewer than four groups in Massachusetts are racing to bring so-called microbial fuel cells to market through a variety of applications. None has been commercialized yet, but industry insiders say microbial fuel cells hold the potential to become a major part of the renewable energy equation. ...  Hy-SyEnce (Fall River, MA; no SBIR) is working to generate large-scale power from the wastewater of food-processing plants, while IntAct Labs LLC (Cambridge, MA; no SBIR)  is applying its technology to similar industrial applications, as well as the possibility of generating power and recycling waste products during space missions.  A research group out of Harvard University, on the other hand, is hoping to provide power for lighting and other systems in developing nations, while Derek Lovley’s Geobactor Project at UMass Amherst is looking to create organic batteries that could one day power computers or even vehicles.  [Mass High Tech, Aug 22]

IAP Research (Dayton, OH)

 IBC Advanced Technologies (American Fork, UT; $0.5M SBIR) a company that develops and sells molecular-recognition technology, received an honorable mention in the chemicals-materials science category at the sixth annual Utah Innovation Awards Program. IBC was lauded for a process that removes bismuth impurity from copper. [Salt Lake Tribune, Jun 28, 08]

Ibis Technology (Danvers, MA)

After stockholders voted earlier this month to shut the company down, Ibis Technology reports that it is officially no longer an operating company in the eyes of the state as of today.  [Mass High Tech, Feb 17]

Ibis Technology said that its stockholders have approved a proposal to complete the liquidation and dissolution of the company. [Boston Globe, Feb 2, 09]

Too Cheap, says NASDAQ about Ibis Technology whose common stock has fallen below the minimum pricing requirements, and risks delisting.

Ibis Technology down another 11% [Nov 6, 07] (already under a buck) on news of the sudden death of its CEO.

Ibis up 12% [May 17, 07]

Ibis jumped 18%.[Nov 17, 06]

Ibis up 11% [Nov 14, 06]

Ibis fell 19% [Oct 26. 06] even though it made $2M profit in the quarter. When you sell an occasional big machine, the profits are lumpy.

Ibis had a big stock day last Friday (Jun 30,06) up 22%.

Ibis rose 12% [Jun 28, 06].

In a whack-em day on Wall Street, the biggest percentage loser was Ibis -20%. [jun06]

Ibis had a cold day [Mar 22] with 11% drop, second sharpest on NASDAQ. When your business sells a huge item infrequently, it's hard for anyone to project earnings and value the company.

Ibis Technology got another juicy $7M order for an Ibis i2000 oxygen implanter from a Japanese manufacturer of silicon wafers. [Mass High Tech, Oct 27]

Ibis got a 17% boost after it reported a $6M order for its  i2000 oxygen implanter in silicon-wafer production.

Someone Knows Something Good. Ibis rocketed 51% yesterday way up to 3% of its Y2K high in the gold old crazy days. No news published - yet. 

Ibis plummeted 45% after reporting soggy financials including a big charge for dropping wafer making.  And II-VI lost 12%. High PEs demand high profit growth rates. 

Ibis took an 18% dive Thursday when it reported that it would throw in the towel on making wafers to focus on SIMOX implanters. CEO Reid made the requisite happy noises about the bad news. 

Ibis reported a $15M loss for the quarter of which $11 was an "impairment charge" on its 200 mm and smaller SIMOX wafer production line. In a world of 300mm wafers, a 200mm line has value only a as scrap (which might actually salvage some real dollars on present booming world scrap markets). Even so, prospects don't seem bleak to stock traders as the price is nearly triple what it was a year ago although down nearly 90% from its info-tech bubble high. 

 Selling an occasional implanter and otherwise making big losses is not the formula for stock market price growth, discovers Ibis as it reports another multi-million dollar loss. Cash to cover the loss and to keep the operations running came from a $13M secondary offering in October. But even with yesterday's 18% hit, the stock is still more than double its price in spring 2003. [Oct 03]

Ibis Up 3/4. Ibis rose 75 cents a share (15% of a depressed price) on news of a deal with IBM wherein Ibis will takes both will develop a better, cheaper wafer-making process. IBM already takes 10% of Ibis's products. 

IBIS Takes a Hit. The stock price of Ibis got whacked 20% Friday (Dec 13) and 30% for th week when a broker advised "hold" the Wall Street equivalent of "sell".  The same broker by contrast has a "strong Buy" on Varian Semi - same industry, different prospects. Ibis stock is at about a third of its 12-mointh high. 

Nearly Breathless Press Release. Ibis Technology shouted a loud headline on its press release: Total revenue up 316% from preceding quarter, includes system sale to Chinese customer; wafer sales up 25% over preceding quarter, marking fifth consecutive quarter of revenue growth. Thereafter followed the ugly facts that losses are still mounting as costs rise faster than revenue. Net quarterly loss $2.2M, and $10M for nine months. Fortunately, cash still exceeds current liabilities although not by enough to withstand many more multi-million losing quarters.

Ibis got an $8M order for its Ibis i2000 oxygen implanter from a "major" semiconductor maker. Which is more than last year's total revenue. CEO Martin Reid claimed it was because of the i2000's ability to produce high quality, 300mm, thin SOI wafers, reliably and cost-effectively. Ibis's stock price jumped 25% which is only 1% of its Y2K high. What claim can you make about the cost-effectiveness of your innovative product?

Ibis to the Birds. Alexander Soule [Mass High Tech, Apr 26] relates Ibis to the bird of that name. He notes that artist and naturalist Roger Tory Peterson once wrote that birds are an ecological litmus paper. And semiconductor equipment manufacturers are the canaries in the coal mines of the technology industry. Last month, Ibis raised nearly $12M for a second generation of SIMOX implanters The North Shore is now home to several companies researching various SOI technologies, including Ibis, and a breeding site for the glossy ibis, a large long curved bill wading bird. Unfortunately, Ibis has not been breeding profits as fast as the birds breed. Its most recent quarter took a net loss of $3.4M following a loss of $2.4M million the year before. This month, the Audubon Society reported spotting about 20 ibises in Ipswich. - just about the number of Ibis machines that exist today. The market last week voted Ibis down 25% in a roller coaster week for semiconductor stocks like ATMI which has been up and down 20% in April.

Ibis sold a $11.7M secondary of 900,000 shares at $13 per share.

Ibis Tech has steadily climbed to more than ten times its mid-September low. On Jan 3 it said that it did the first implants using its next-generation oxygen implanter, the Ibis 2000 for big wafers, both 200- and 300mm.

Ibis Tech jumped 16% as it announced it had shipped an Ibis 1000 oxygen implanter to the Shanghai Institute of Metallurgy (SIM), Chinese Academy of Sciences. Now if all that shipping could actually turn a profit having had only one profitable year in the last five.

Ibis Starts Shipping. Ibis Technology, the leading provider of SIMOX-SOI implantation equipment and SIMOX-SOI wafers to the worldwide semiconductor industry, today announced initial shipments of Advantox MLD-UT wafers, which feature an ultra-thin silicon layer as thin as 300-angstroms and all the advantages of the IBM-developed, production proven MLD process. Ultra-thin SOI wafers have been demonstrated to provide superior results especially in terms of increased power efficiency and heat reduction in the manufacture of fully depleted substrate transistors for next generation semiconductor devices. [company press release] The news shot Ibis up another 17% which makes it doubling in three months although stilll down 90% from its winter 2000 high before the info-tech bubble burst.

Intel Loves Ibis?. Intel calls [it] the TeraHertz transistor because it cycles 1 trillion times per second, could ultimately lead to new applications, such as real-time voice and face recognition, computing without keyboards and ever-smaller electronic gizmos with higher performance and improved battery life. ... "... they've basically invented a new transistor technology that's fundamentally different and manufacturable," said analyst Dan Hutchinson of VLSI Research. "They've completely re-engineering the transistor as we know it." [Reuters, Nov 26] Although Intel has not said anything specific about the substrate, some speculation centers on silicon-on-insulator which could explain a one-day 45% jump in Ibis stock. Notice that Intel wants different and manufacturable, not just better. Government, on the other hand, in SBIR wants only a little different and cares little about manufacturability,mainly because military uses are not cost-sensitive.

Also blown by the swoosh was Ibis Technology which says Total revenues for the quarter were $1,256,000 compared to $5,920,000 reported in the second quarter of 2000. SIMOX-SOI wafer sales decreased to $771,000 from $1,442,000 in the same quarter last year. Equipment revenue, generated from implanter, parts and service sales, was $340,000 for the second quarter of 2001 as compared to $4,224,000 in the second quarter of 2000, which included an implanter sale.

NASADAQ traders dumped (-20%) Ibis Technology when it announced that due to a substantial decrease in wafer forecasts from one of its largest customers, the Company has revised its outlook for the second quarter and full year 2001, lowering its revenue projections. Ibis' customer, one which manufactures optical components utilizing Ibis' wafers, has informed Ibis that it expects to order a very small quantity of wafers in the second quarter and substantially reduced quantities for the remainder of 2001. While the impact on the first quarter is expected to be minimal, the Company is now projecting second quarter total revenue to be reduced by approximately 50 to 60 percent compared to the fourth quarter of 2000. Full year total revenue is still anticipated to be up, although only slightly, compared to fiscal 2000. [company press release, Apr 12]

Ibis shot up a third on news that it has licensed from IBM the right to manufacture and sell SIMOX-SOI (Separation by IMplantation of OXygen / Silicon-On-Insulator) wafers, using IBM's proprietary SIMOX process, to IBM and to all Ibis customers.

Ibis Technology suffered the usual penalty for reporting a loss - a big dip in price. Down 72% from its high of a few months ago when it was making at least a little profit. Ibis blamed lower equipment revenues offsetting a nice business in wafers.

IBIS TECHNOLOGY got to a five-fold rise for the year at 50 on the strenght of its SIMOX-SOI technology is emerging as a key enabling material to drive the technology roadmaps of several leading integrated circuit manufacturers, particularly for high performance computers and low power communications devices,'' said CEO Martin Reid

Two area clean technology startups have won grants under a new local program, U-Launch, that aims to turn university research into commercial cleantech solutions.N12 Technologies (Cambridge, MA) and  iBLogix (Waltham, MA)  Dollar values for the awards were not disclosed. N12 is commercializing advanced materials technology at MIT ...  iBLogix is developing building information software that employs data-aggregation and analysis technology, with the aim of commercializing a system developed to remotely profile the energy performance of buildings. ... U-Launch is partially funded by a three-year, $1.1 million award from the U.S. Department of Energy’s Innovation Ecosystem Development Initiative.  [Kyle Alspach, Mass High Tech, Mar 15, 11]

IBT Laboratories (Lenexa, KS)

Icagen

Icagen is now a wholly owned subsidiary of Pfizer. Icagen's stock ceased trading  [Raleigh News & Observer,Nov 1, 11]

Icagen down 23% [Jul 20, 11]  which was once one of the Triangle's most promising drug-development companies, has agreed to be bought by its larger partner Pfizer for about $56 million. The price of $6 per share disappointed Wall Street investors who had expected more. ...   In 2007, Icagen halted research on an experimental treatment for sickle-cell disease because of disappointing results in clinical tests. It also ran into regulatory hurdles with an epilepsy treatment. Icagen began a partnership with Pfizer in 2007 to develop experimental medicines to treat pain, an agreement that provided much-needed money for further research. The drugs are based on blocking so-called sodium channels and reducing the body's ability to feel pain.   [Alan Wolf, Raleigh News & Observer, Jul 21]

Icagen up 164% [Jun 27, 11] in talks with the pharmaceutical titan  [Pfizer], which already holds a 14.2% stake

Icagen (Durham, NC;$700K SBIR) drug-development company that has struggled financially, is in discussions about a possible takeover by its much-larger partner Pfizer. ...  began a collaboration with Pfizer in 2007 to develop new pain medicines. As part of that partnership, Pfizer has paid Icagen millions of dollars in milestone fees. It also bought more than 1 million Icagen shares and is the company's largest investor, owning a 14.2 percent stake.   [Alan Wolf, Raleigh News & Observer, Jun 24,11]

Icagen up 13% [Feb 1, 11]

Icagen up 30% [Jan 19, 11]

Icagen up 14% [Jan 18, 11]

Icagen shares jumped today after the company announced it has selected an experimental compound for further testing as a potential pain treatment. Icagen is researching pain treatments under a partnership with larger partner Pfizer. Picking the compound for additional clinical testing triggers a $1 million milestone payment from Pfizer, giving Icagen more cash. [Alan Wolf, Raleigh News & Observer, Nov 30, 10]

Icagen developing treatments for pain and epilepsy has received a $3 million payment from larger partner Pfizer. ... Icagen's shares, which began trading publicly in 2005, have fallen sharply as investors worry about the company's financial health and whether it will be able to develop a successful drug [Alan Wolf, Raleigh News & Observer, Jul 29, 10]

Icagen  (Durham, NC; $700K SBIR) hit another setback when its experimental pain medicine didn't help patients during a small test in Britain. ... reported late Monday that the drug did not reduce pain in 24 healthy volunteers who were given simulated sunburns or injected with capsaicin, the active ingredient in chili peppers. ... has seen several experimental drugs run into regulatory roadblocks. ... risks being delisted by the Nasdaq if it doesn't trade above $1 for 10 consecutive days by May. [IPO] 2005 at $8, but have never lived up to investors' expectations. [Alan Wolf, Raleigh News & Observer, Mar 2, 10]

Icagen down ?/% on news that the company plans to stop development of senicapoc due to the asthma drug’s failure in a clinical trial. [Triangle Business Journal, Oct 27, 09]

Drug development company Icagen (Durham, NC; $700K SBIR a decade ago) posted a $3.6 million loss in the third quarter as revenue from its research partners plummeted. [Raleigh News & Observer, Nov 7, 08]

Icagen down 14% [Oct 6, 08]

Icagen ($700K SBIR) is developing three compounds for the treatment of pain disorders, and now Pfizer has obtained exclusive worldwide product rights. Pfizer has already paid Icagen $38 million, including $15 million in equity investments, with a potential $359 million in total periodic payments. [Gene Marcial, Business Week, Mar 10]

Icagen (one Phase 2 SBIR) said it hopes to begin testing an experimental treatment for epilepsy on healthy male volunteers by the end of September. ...  no products on the market and lost about $25M last year ... IPO Feb 05.  [Raleigh News & Observer, Jul 25]

Icagen down 10% [Feb 26, 07]

Icagen rose 21% [Feb 21, 07]

ICx Technologies

FLIR Systems to provide surveillance equipment and technology to the Customs and Border Protection Division working to stiffen the border between Mexico and the United States.
The big prize was a five-year contract worth up to $101.9 million to a FLIR subsidiary via a recent acquisition, ICx Technologies (Arlington, VA).  ....  Also this week, the Defense Department said it had awarded FLIR a $15.9 million, one-year contract to provide 36 night-vision systems and training classes to the Army Aviation & Missile Command [oregonlive.com, Jan 6, 11]

Homeland-security products maker ICx Technologies (no SBIR) rose 14% after saying it has agreed to be acquired by large-cap Flir Systems for about $274 million. [Wall Street Journal, Aug 17, 10]

Idaho Technology (Salt Lake UT)

Ideal Power Converters (Austin, TX)

Ideal Power Converters (Spicewood, TX; no SBIR) received a $2.5 million [DOE] grant ... as part of a $156 million package to encourage cutting edge energy research and projects nationally. ... joined the Austin Technology Incubator in October 2008, develops inverters designed to lower system costs and improve energy efficiency ... received a $1 million grant from the Texas Emerging Technology Fund  [Christopher Calnan, Austin Business Journal, Sep 30, 11]

Photovoltaic inverter developer Ideal Power Converters (Austin, TX; no SBIR) has received a $1 million grant from the Texas Emerging Technology Fund. The Austin-based company is expected to use the capital to accelerate the commercialization of its large-scale photovoltaic inverters, [Austin Business Journal, Dec 30, 10]

IdeaPaint (Boston, MA)

Startup IdeaPaint (Boston, MA) has taken in $5 million in its first venture funding ... has created a patented paint that makes any flat surface into a dry-erase writing surface once applied. ...  Coming out of Babson College’s entrepreneur program [Mass High Tech, Nov 12, 08]

II-VI (Saxonburg, PA)

II-VI down 11% [Oct 25, 11]

II-VI up 10% [Aug 11, 11]

II-VI down 12% [Aug 8, 11]

II-VI down 13% [Aug 2, 11]

II-VI up 23% [Apr 26, 11] after its quarterly results easily topped Wall Street expectations.  ... Fueled by its recent acquisition of near-infrared optics maker Photop Technologies (no SBIR) [Motley Fool, Apr 26]

II-VI is acquiring Philadelphia-basedMax Levy Autograph (no SBIR), a supplier to one of II-VI’s subsidiaries, the company said Tuesday morning. Terms of the deal were not disclosed.  ...II-IV reported 83% percent jump in sales for the first quarter ended Sept. 30, with profit of $18.4 million [Malia Spencer, Pittsburgh Business Times, Dec 7, 10]

Co-founder of optics manufacturer II-VI Carl J. Johnson is retiring from the day-to-day operations of the company he started nearly 40 years ago, but he will remain Chairman of the board  .... under Johnson’s direction, the company went from a few thousand dollars in revenue to sales of $292 million last year and has gone from two employees to 6,000 worldwide.  [Pittsburgh Business Times, May 18, 10]

II-VI  inked a $40 million multi-year agreement with Lockheed Martin to supply components for the Joint Strike Fighter, F-35 Lighting II, the company said .... will be supplying sapphire windows [Malia Spencer, Pittsburgh Business Times, Feb 11, 10]

II-VI made an unsolicited proposal to buy Middlefield, Conn.-based Zygo (Middlefield, CT; one SBIR) according to a release from Zygo. ... Earlier this week, II-VI, which makes specialty optics, closed a deal to acquire the Chinese optics firm Photop Technologies and issued updated guidance for its year-end figures that could see the company break $300 million in profits. [Pittsburgh Business Times, Jan 7, 10]  II-IV had just under $3M SBIR starting in 1984 with 112 employees and ending in 1992 with 220 employees. It now has 1900 employees, revenue of $270M, and a market cap of $930M.

Forbes's 2009 list of best 200 small companies includes Aerovironment, American Science and Engineering (paying a dividend and with nearly $600M market cap), Argon ST, Hittite Microwave, II-IV, Meridian Bioscience, Neogen, NVE, and Synaptics. 

II-VI  up 10% [Apr 9, 09]

II-VI up 20% [Jan 21, 09]

II-IV down 20% [Dec 3, 08]

II-VI up 15% [Oct 13, 08]

Forbes 200 Best Small Companies list for 2008 had several "SBIR involved" companies: Hittite Microwave 12, II-IV 23, Synaptics 33, NVE 39, ATMI 114, Cymer 166. 

Business Week's Hot Growth Class of 2006 has fared relatively well. Weighted by market value, the companies have returned 4.7% over the past two years. That tops the small-cap Russell 2000 index, which dipped 3.9% during the same period. Ninth highest two-year return was II-VI at 71%. [Business Week, Jun 9, 08]

Market pundit Jack Hough likes II-IV as having impressive return on equity and promising growth prospects [Wall Street Journal, May 8, 08]

II-VI down 11% [Apr 22, 08] despite growing profits. Revenue from infrared optics rose 21 percent, while that from military and materials was up 69 percent.  [Reuters, Apr 22]

II-IV named as bargain growth stock on prospects of 20% profit growth in 2008. [Jack Hough, WSJ, Mar 27]

Forbes's annual list of the best 200 small companies had several SBIR awardees: Ceradyne #12, Flir Systems 37, II-IV 58, ATMI 69, ViaSat 90, Surmodics 105, Micrel 149, OPNET Tech 167.

II-VI up 21% after posting a quarter's profit and a gain in yearly profit. [Aug 7, 07]

Among Business Week's 100 hot growth companies were Ceradyne  and  II-VI. [Jun06]

Minor stumble. big overreaction says Motley Fool about II-VI's 17% plunge even though sales were up 25% and profit up 70% and a rough book-to-bill ratio of 1.14 as both numbers fell just short of their targets. ... Looking ahead, the future for lasers is still glowing brightly. Lasers are increasingly replacing machine tools in manufacturing, and new applications in medicine and consumer goods are continually coming online. Not only are more lasers being used but also they are getting more powerful. These new stronger lasers require more valuable optics, and they consume them faster, a good thing indeed for II-VI. [Motley Fool, Jan 20]

"if only" not convincing. Profits up, sales up, so what?  II-VI said, However, orders for near-infrared optics used in semiconductor manufacturing have not yet recovered. If demand from that industry were to improve .. blah, blah. The market was not listening and the stock took a 15% nose dive when the earnings didn't measure up to expectations. Stock prices. after all, are not about present earning, but about future earnings. When a company lets Wall Street raise its expectations, the stock price sinks when the company cannot produce the expected result. So, private companies that don't care about their shareholders getting rich can stay private and work for the 6% profit on government R&D contracts in sheltered political programs like SBIR. 

II-VI avoids telecom battering ram. Eighteen months ago, shares of II-VI were white hot, irrationally buoyed in part by a limited foray into the telecommunications market. They've cooled since then, as telecommunications stocks tanked and the economy headed south. Shares hit a high of $37 in March 2000 and closed Friday at $15.74, ... The company last week posted record fourth-quarter earnings and set new highs for revenue and earnings for its fiscal year ended June 30.... "Our telecom exposure for the next two to four quarters is not good," Chairman Carl Johnson told analysts last week. For the year, II-VI earned $9.5M on revenue of $123M. ... Since late April, II-VI has reduced its work force by about 10% to 1,100 [Len Boselovic, Pittsburgh Post-Gazette, Aug 12]

II-VI makes components for lasers. One is zinc selenide crystals, which are used to make optics that redirect laser beams in carbon dioxide laser systems, a workhorse light source capable of cutting everything from flesh to metal. These lasers are used for industrial applications like cutting fabric or welding metal. II-VI recently bought rival Laser Power, which gave the company a good business supplying the military with parts for missile guidance and infrared imaging devices. At $15, II-VI's shares go for a high 22 times trailing earnings. But we expect earnings per share to grow 29% this year. [Forbes, Jun 11]

II-IV Rockets. II-IV (Saxonburg, PA) jumped 67% to 44 Friday with the only news being a new strong buy recommendation form another broker. II-VI designs, manufactures and markets optical and electro-optical components, devices and materials for infrared, near-infrared, visible light, x-ray and gamma-ray instrumentation and has recently announced new products to serve the telecommunication industry. It has traded between 11 and 74 in the past 12 months.

II-VI made $7M profit for the year, down from $9.5M the previous year. Although revenues were down less than 10%, making a decent profit at all is an accomplishment for a chipster in the info-tech downwash. The stock price is down only a third from its 12-month high. [date??]

II-VI apparently surprised Wall Street with 35% higher earnings, of $2M for the quarter.on record revenues of $19.8M. The trading price jumped 30% in a record NASDAQ up-day. II-VI (Saxonburg, PA), an SBIR minor beneficiary, makes and and sells optical and electro-optical components, devices and materials for infrared, near-infrared, visible light, x-ray and gamma-ray instrumentation and has recently announced new products to serve the telecommunication industry. [company press release, Apr 18, ??]

II-VI ups offer for competitor. , II-VI Inc. turned up the gas this week in its bid to acquire a San Diego competitor. II-VI, (Saxonburg, PA) optical sensor manufacturer formally made a stock-and-cash offer of $4-$5 a share for Laser Power Corp. This offer followed the announcement three days earlier that Laser Power had agreed to merge into Union Miniere S.A., a Brussels-based nonferrous metal producer that already owns almost 10 percent of the Laser Power. One of Laser Power's most attractive features is its military contracts, since military work accounts for less than 10 percent of II-VI's business. II-VI's advantage in the market is that it manufactures its own raw materials, principally zinc selenide, used to make the optics. According to II-VI, acquiring these materials accounts for 10 percent to 15 percent of Laser Power's costs. Imagine that: an SBIR-funded company in a bidding war to acquire a company that adds military business of which it has too little.

II-VI Zooms Yesterday's zoomer was II-VI (Saxonburg, PA) which gapped up 71%.on news of a strong buy rating by a brokerage. Such new recommendations in the info-tech industry seem to work at least temporary miracles. II-VI had about $3M in military SBIR through the 80s starting when it was already a firm over 100 employees. The five Phase 2 projects were relatively modest improvements, or even defensive research, on existing processes. DOD likes to trumpet II-VI as an SBIR success story even though its contribution was clearly minor. OK, victory has a thousand fathers. The company electro-optics products make a nice annual profit for a decade of about 10% net margin on sales that have been steadily rising. Profits per share have declined year-to-year though in 98 and 99.

Ikaria (Clinton, NJ)

Ikaria  (Clinton, NJ; no SBIR) withdrew its IPO [Nov 11, 10] after cutting its size and estimated price range. [Wall Street Journal, Nov 12, 10] ... a fully integrated biotherapeutics company  ... we are positioned to develop and deliver innovative therapeutics and interventions to meet the needs of critically ill patients [company website]

Ikonisys (New Haven, CT)

Ikonisys (New Haven, CT; one SBIR) diagnostics device firm, has raised $3.8 million of a planned $12 million ... Founded in 1999, Ikonisys has developed its CellOptics platform as the basis for automated cell-based diagnostic products. ...  two years ago the U.S. Food and Drug Administration granted approval for the company’s oncoFISH (Fluorescence In Situ Hybridization) HER2 test, intended for the detection of the more aggressive HER2 form of breast cancer.    [Michelle Lang, Mass High Tech, Aug 5, 10] Diagnostics device firm Ikonisys (New Haven, CT; one SBIR) received [FDA] clearance for its oncoFISH (Fluorescence In Situ Hybridization) HER2 test, intended for the detection of the more aggressive HER2 form of breast cancer. ... Founded in 1999, closed a $30 million Series E round of financing in October 2007, bringing the total amount raised by the company to $67.5 million. [Mass High Tech, Oct 29, 08]

Diagnostics device maker Ikonisys  (New Haven, CT; one SBIR) got a $30M VC finance deal. Since its start in 1999, it has raised $67M.  [Mass High Tech, Oct 17, 07]

Illinois Superconductor (Evanston, IL)

Illinois Superconductor (Mt Prospect, IL) completed installation of 15 RangeMaster Systems for Southwestern Bell Mobile Systems, one of the largest cellular providers in the US, which operates in 10 regions and has 5.5 million subscribers. ISCO claims to be a leading supplier of very high performance filters for the wireless telephony industry. The stock market, though, takes a dim view of ISCO's prospects as it trades down near 20% of its 1993 IPO price. Not that any SBIR superconductor company that went public is doing well either. ISCO had a BMDO SBIR, after its VC backing, for a gadget not related to the cellular phone equipment.

Darkness on ISCO
(May 1) With little in the way of solid fundamentals, we are suspending coverage of Illinois Superconductor , said the one Wall Street firm, Grunthal, watching ISCO. Grunthal has recommended selling since last November. The stock has been from 1 to 15 in the twelve months and now rests below 3. ISCO got a start with a BMDO SBIR after it already had VC backing; it has had an imbroglio lately between management and an actively disappointed shareholder.

Diluted or Dead. Shareholders in Illinois Superconductor (Mt Prospect, IL) will have to choose whether to accept the money from new shares sold at way below the IPO price or running out of money. Charges and lawsuits are flying as the firm reports another quarterly loss over $2M.

Illinois Rockets
(Mar 16) Illinois Superconductor stock rose 60% Friday on 2.8M shares (daily average 231K) on top of Thursday's a 119% rise after S&P Equity Group upgraded its prospects. The Dow Jones story, though, said, One industry observer, however, warned of the superconductive electronic device maker's controversial financing agreements and high cash burn rate, or spending on overhead before generating positive cash flow from operations. Nobody's perfect, and 3.5 is still a long haul from the $11 of the 1993 IPO. Back in 1993, superconductors were cool.

Another loss also for Superconductor Technologies. $3.5M in both '96 and '97. The 1988 promise of superconductors has yet to show much economic benefit. The SBIR investments 1988-1992 made sense to give a new technology a chance. But now superconducting has reverted to the long pull of research for which SBIR is not suited.

Never Satisfied
(Nov 24) Illinois Superconductor's largest shareholder filed [another] lawsuit Friday against the company and its directors over a series of recent financing agreements. News of the suit drove down Illinois Superconductor shares nearly 32 percent on the Nasdaq. [Chicago Tribune, Nov 22]

Illinois Superconductor (Mount Prospect, IL) in a dive, down 80% from its high over the last 12 months after a loss of $3M for the quarter. ATMI (Danbury, CT), trading again as ATMI, a lot better off, now 2.5 times its low for the 12 months, even though it is down 20% from the high.

Illinois Super Gets $5M
(Nov 3) Illinois Superconductor (Mt Prospect, IL) got $5M in equity financing for working capital and general corporate purposes. The company said it will use the funds primarily to support sales of its wireless telecommunications filter products. [Chicago Tribune, Nov 1] 

 New Illini Super Product
(Sep 11) Illinois Superconductor (Mt Prospect, IL) unveiled its low-loss personal communications services transmit filter/duplexer as part of its SpectrumMaster line of filters for wireless communications. IS said the PCS transmit filter/duplexer handles over 20 watts of radio frequency power with acceptable intermodulation distortion levels. The company said it plans to begin shipping product in early 1998. [J Fitzgerald , Chicago Tribune, Sep 10] IS got its first SBIR (and one of very few) from SDIO soon after the venture backed company started.

Illinois Superconductor Hires Salomon
(Aug 6) Illinois Superconductor (Mt Prospect, IL) under pressure from its biggest shareholder to lift its share price, hired investment banker Salomon Brothers to evaluate alternative strategies, including selling the firm and strategic alliances. ISC started in 1990 with financial help from the State of Illinois and BMDO SBIR to exploit high temp superconductivity. Lots of firms got such help in the HTSC optimism of 1988-1992. The firm's HTSC radio-frequency filters have been used by several cellular phone firms to reduce interference problems in difficult locations such as O'Hare Airport. But 7.7% shareholder Sheldon Drobny, says, "There is a strong perception right now that they're having trouble selling product. I believe that's untrue, but they are losing the propaganda war." Drobny has been energized by the drop in stock price from $24 to $9. Two other BMDO SBIR HTSC companies, Conductus and STI, have suffered similar shrinkage. [Story by Jon Van, Chicago Tribune, Aug 5]

ISCO's 7.7% Solution A holder of 7.7% of Illinois Superconductor common arranged a kicking upstairs of the CEO. The vocal investor wants management with "extensive operational experience and a Wall Street orientation" now that ISCO has advanced beyond the tech start-up stage. [Wall Street Journal, Jul 9] Out of that nursery.

Raising Another $17M Illinois Superconductor (Evanston, IL) will sell 1M shares in a secondary offering plus another possible 15% if the underwriters exercise their over-allotments. The going price of is around $17. ISCO went public at $11 after getting its first (and almost only) SBIR from BMDO. .

An Illinois Filter, Too While STI shows its HTSC (high temperatures are still cold by human standards) at the big Wireless 97 (where not having something is featured) show in San Francisco, Illinois Superconductor (Evanston, IL) will be showing its filter, too. (You show me yours, I'll show you mine) Indeed two filters that allow20% more coverage by a base station (which at the present rate of expansion will be on every roof) and 25% cell site range extension in networks. ISC got its first SBIR from BMDO for an unrelated HTSC item, a current control switch.

Year's Top Product SpectrumMaster^TM was named one of 12 top products by Microwaves & RF, a telco industry journal. The Illinois Superconductor (ISCO, Evanston, IL) product competed with 5000 new products for the honor. Announced criteria (like SBIR judging) were design practicality, innovative use of technology, and greatest good for the greatest number (the classic utilitarian goal) of industry participants. The product allows (but does not mandate) fewer ugly towers in neighborhoods (NIMBY) because it lets through 35% more voice signal and reduces interference 10,000 times. Product is shipping. Whether neighborhoods see fewer towers is problematical when competition and not technology rules. Illinois had a BMDO Phase 2 SBIR for a current limiting switch (which doesn't seem to generate such press). [Source: Business Wire]

Superconductor Loss Superconductor Loss
Losses of $2M for the quarter and $4.5M for the half were in line with the Company's business plan. How comforting. "In July we achieved the most significant milestone in the Company's history when Southwestern Bell Mobile Systems placed the first commercial order for SpectrumMaster filters". It's at least good to know that someone is benefiting from superconductivity that was the technological rage in 1988. Illinois Superconductor (Evanston, IL) got its first (and one of few) SBIRs from BMDO.

Illumigen Biosciences (Seattle, WA)

Kineta (Seattle, WA; no SBIR) is trying a new approach. ... plans to fund its research step by step, relying on revenue-generating deals to undertake the next step in research. ... started the company last December but unveiled it publicly only this month.  Their new venture quickly came after the $9 million sale of their previous company, Illumigen Biosciences ($2M SBIR)... If Illumigen's research and commercial potential fully pans out, its shareholders could get up to $330 million in additional payments from Cubist. ... Kineta has so far partnered with Cubist for early-stage work on a hepatitis C drug, and has received funding from the National Institutes of Health. But it is also pitching itself to investors.  [Angel Gonzalez, Seattle Times, Dec 23, 08]

Cubist Pharmaceuticals  (Lexington, MA; $5M+ SBIR) lowered its previously reported fourth-quarter earnings to reflect a hefty acquisition charge [relating to buying] Illumigen Biosciences (Seattle, WA; $2M SBIR). [Boston Globe, Feb 13, 08]

Cubist Pharmaceuticals (Lexington, MA; $5+M SBIR) bought Illumigen Biosciences (Seattle,, WA; $2M SBIR) for $9M cash and planned milestone payments.  Cubist, of , will make up to $75M in development payments for Illumigen’s lead product, IB657, now aimed at treating hepatitis C. Development of the compound for other uses could trigger payments of up to $117M. [Boston Globe, Dec 27]

Illumina (San Diego, CA)

Illumina will reduce its global workforce by nearly 9 percent by laying off about 200 employees as part of a restructuring  Keith Darce, [signonsandiego.com, Oct 27,11]

Illumina down 32% [Oct 7, 11]  fell the most ever after dropping its profit forecast because of concerns that research funding will be reduced, sending shares of rival equipment makers down.  .... The weakness in demand may continue as the U.S. government, looking to curtail spending, mulls the research budget for agencies  [Bloomberg, Oct 7]  Indeed, the companies that subsist on federal funding will have a problem as long as deficit reduction is the plat du jour. If SBIR is lucky, Congress won't notice that SBIR's economic return is incalculable (that means nobody knows what it is, if anything).

Illumina down 18% [Jul 27, 11]  investors had very high hopes for screaming growth from the company

Illumina, maker of genetic testing tools, said that it will open on office in Sao Paolo, Brazil, on Feb. 1. [signonsandiego,com, Jan 18, 11]

a French scientist tells me he is moving his startup, Portable Genomics, to San Diego. ...  based on the assumption that it will be possible in another year to completely sequence an individual human genome for less than $1,000—and within three years, for less than $300. This is the promise of the recent announcements coming out of Life Technologies, Illumina, and Complete Genomics, as the speed of genetic sequencing increases and costs plummet. [Bruce Bigelow, signonsandiego.com, Jan 14, 11]

Illumina and Life Technologies [make the machines that separate DNA from samples of saliva, blood, skin and other tissue for genetic analysis. ] both cut their genomics teeth on DNA testing products and sequencing machines designed mainly for human medical research. However, agriculture-related business has become increasingly important to the companies in recent years, executives said.  Crop and livestock customers generated $100 million in sales for Illumina in 2009, or 12 percent of total revenue, said Tristan Orpin, a senior vice president and chief commercial officer ....  Illumina now offers separate commercial chips for testing cows, dogs, pigs, sheep, horses and corn. Each chip sells for between $195 and $295, and the largest one (for cows) tests for 500,000 markers.  In November, Life Technologies began selling a genetic testing kit for quicker detection of viral diarrhea in cows, a costly disease that can spread rapidly in a herd and reduce the body weight, and value, of sick animals. [Keith Darce, signonsandiego.com, Dec 21, 10]

Life Technologies took a step toward lowering the cost of genetic sequencing and expanding the availability of the revolutionary technology by launching its new Ion Torrent Personal Genome Machine. ... acquired the machine in August when it purchased the device’s creator, Ion Torrent (Guilford, CT, no SBIR), in a $725 million deal. .....  among several, including Illumina of San Diego, that are racing to introduce new ways of sequencing genes that expand the use of the technology  [signonsandiego.com, Dec 17, 10]

Sage Science (Beverly, MA; no SBIR), a developer of laboratory and research-related technologies, has taken in $2.02 million in an equity offering ...  Founded in 2005, Sage Science signed a co-marketing deal with Illumina in October to promote sample preparation use of Sage Science’s Pippin Prep in conjunction with Illumina’s DNA sequencing platforms. ... last raised a $2 million round of venture capital funding, with 16 investors, in March. [Michelle Lang, Mass High Tech, Dec 2, 10]

Illumina (San Diego, CA; $9M SBIR) was 130th on the new Deloitte Fast 500 list of fastest-growing technology companies [Mike Freeman, signonsandiego, Oct 21, 10]

Illumina rose 10 percent in after-hours trading after the company reported first-quarter earnings that topped Wall Street estimates. [signonsandiego, May 4]

Illumina up 13% [Apr 29, 10]

Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon.  Among the fifty most innovative:  A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences.  [MIT Tech Review, M/A10]

Illumina has found a famous early adopter for a futuristic personal genome-sequencing service it offers.  The company said Thursday that movie and television star Glenn Close had her genome sequenced last fall, one of about 10 people to have their genetic data compiled since the company introduced the service in June.  While it’s expensive, at $48,000, Illumina says it believes the cost will quickly become a realistic option for many people (with a spare $48K).  [Thomas Kupper, San Diego Union Tribune, Mar 11, 10]

Affymetrix down 14% [Jan 13, 10]  The technology that Affymetrix develops is quickly becoming obsolete, or so analysts believe. ... increased pricing pressures from competitors as its technology becomes quickly outdated by new genetic analysis technology such as Illumina’s sequencing technology. [Lisa LaMotta, Minyanville.com, Jan 13, 10]

Illumina unveiled new technology yesterday that it says will bring the cost of sequencing a human genome below $10,000. It was the latest milestone in the advancement of genetic analysis, from the $3 billion Human Genome Project a decade ago to current systems that can run a person’s genome for around $50,000.  [Thomas Kupper, San Diego Union Tribune, Jan 13, 10]

Illumina up 16% [Jan 12, 10]

Illumina said its board has approved a plan to buy back up to $100 million of the San Diego company’s stock. The buyback program follows a $75 million stock repurchase plan the company announced in August and has recently completed. [signonsandiego.com, Nov 26] 

Illumina down 20% [Oct 28, 09] It swung to a profit, but warned its fourth quarter and year will disappoint. [Wall Street Journal, Oct 29]

Illumina  down 12% [Jul 2, 09]  said revenue for its second quarter would fall below Wall Street estimates after falling short in the first quarter as well. [Wall Street Journal, Jul 3]

Illumina is launching a futuristic service that will give consumers the chance to get their DNA sequenced. But it's not cheap: $48,000. The company, which specializes in DNA research tools for scientists, thinks consumer gene sequencing could become widespread within a few years. That could give patients quick access to personalized information as the role of specific genes in disease becomes better understood.  [Thomas Kupper, San Diego Union Tribune, Jun 11, 09]

Illumina  up 10% [Mar 23, 09]

Illumina   up 21% [Feb 4, 09]

Illumina up 11% [Oct 30, 08]

Illumina down 22% [Oct 22, 08]

Illumina up 10% [Oct 13, 08]

Illumina down 11% [Oct 6, 08]

Illumina (San Diego, CA; $9M SBIR) sold more 4 million shares to the public to raise $343M. [San Diego Union Tribune, Aug 13, 08]

an up kind of day for genetics analysis company Illumina (San Diego, CA; $9M SBIR).  report of a 66% jump in revenue and a $6.1 million increase in quarterly profits. ... would acquire genetics sequencing company Avantome for $25 million upfront and contingent payments of up to $35 million. ... a 2-for-1 stock split. [Terri Somers, San Diego Union Tribune, Jul 23, 08] If the Congress wants to know where and why SBIR seems to succeed, it should explore why most of the economic success stories come from the life sciences and little from the mission agencies - NASA and DOD which have the lion's share of the SBIR money. 

Illumina was up 26% last week and up 79% for 52 weeks. [Jan 14, 08]

Illumina jumped 16% to a record high [Jan 10, 08] after the company settled a patent lawsuit with Affymetrix Inc.

Steady growth and the departure of top executives have driven Illumina (San Diego,CA; $9M SBIR) that does genetic analysis, to reorganize into two operating units. ... As the science at biotechnology companies has progressed over the past few years, there have been increasing demands for the genetic analysis and products developed by Illumina. Meanwhile, technology advances have made the tests performed by Illumina much more affordable. ...  Revenue for the first nine months of 2007 was $254M [San Diego Union Tribune, Jan 5]

Illumina fell 10% despite better earnings. [Feb 2, 07]

IlluminOss Medical (East Providence, RI)

IlluminOss Medical (East Providence, RI; no SBIR, founded 2007), has taken in a $4 million debt financing round, the company noted   ...  develops its Photodynamic Bone Stabilization System used in stabilizing and treating bone fractures. The photodynamic polymer system is intended to replace traditional screws, plates and pins used to stabilize fractured bones. It has been approved in Europe for use in low load bearing bones. [Michelle Lang, Mass High Tech, Nov 30, 11]

IlluminOss Medical  (East Providence, RI; no SBIR) raised $11M in Series B funding, according to published reports. ... develops medical devices for the treatment of bone fractures. [Mass High Tech, Apr 4]

Illumitex (Austin, TX)

Illumitex (Austin, TX, no SBIR; founded 2007)  has received $13.5 million of a planned $25.2 million financing. ... develops light-emitting diode, or LED, technology  [Cristopher Calnan, Austin Business Journal, Jun 13, 11]

The experts say light-emitting diodes are creating the biggest change in the lighting industry since Edison. And a little-known Illumitex, (Austin, TX; no SBIR) says it has developed a way of making LEDs that is more energy efficient than previous methods. The 5-year-old startup unveiled its first LED product line Thursday and said it is working with an array of lighting system manufacturers that like its promise of delivering more highly directed light from smaller diodes that consume less energy. [Austin American Statesman, Apr 1, 10]

Illumitex (Austin, TX; no SBIR) has received $4.3 million of a planned $10 million round of financing. ... develops light-emitting diode technology ... founded in 2007, has been operating in stealth mode ... In June, the company was reportedly in beta production  [Austin Business Journal, Oct 14, 09]

Imaging Biometrics (Elm Grove, WI)

Imaging Biometrics (Elm Grove, WI; $200K SBIR) medical imaging software firm received an $800,000 [NIH SBIR] grant ... to develop and distribute its software to neuroradiologists, oncologists and surgeons [Kathleen Gallagher,  Milwaukee Journal Sentinel, Sep 22] Funding low technical risk projects to reduce business risk does not meet a market failure croterion for government market intervention.  But it does make politicians and beneficiaries happy.  

Imago Scientific Instruments (Madison, WI)

Ametek (Paoli, PA, annual sales of $2.1 billion) announced that it has acquired  Imago Scientific Instruments (Madison, WI; $900K SBIR) manufacturer of three-dimensional atomic probe microscopes. "Imago is a pioneer in the development of 3-D atom probe technology, which is used in advanced materials science to conduct atomic level imaging and analysis. Imago provides us with additional technical capabilities, significantly broadens our customer base and strengthens our global leadership in this high-end technology," said Frank A. Hermance, Ametek's chairman and CEO. Ametek manufactures electronic instruments and electromechanical devices, and reports. [Don Walker, Milwaukee Journal Sentinel, Apr 9, 10]

Immersion

Immersion up 10% [Nov 16, 11]

Immersion  down 11% [Nov 7, 11]

Immersion  down 16% [Nov 4, 11]

Immersion up 10% [Oct 4, 11]

Immersion down 13% [Aug 5, 11]

Immersion up 13% [May 6, 11]  when [sales and profits] numbers exceeded analysts consensus, and were also much stronger than we expected. [Seeking Alpha.com, May 6]

Immersion  up 13% [Dec 30, 10]

Immersion down 10% [Nov 5, 10]

Immersion  up 10% [Sep 30, 10]

Immersion up 10% [Jun 25, 10]

Immersion up 10% [May 10, 10]

Immersion up 11% [Jul 27, 09]

Immersion  down 23% [Jul 1, 09]  is conducting an internal investigation into certain previous revenue transactions in its Medical line of business. [Business Wire, Jul 1]

Immersion   down 10% [May 5, 09]

Immersion  down 10% [Apr 20, 09]

Immersion  up 12% [Mar 23, 09]

Immersion  down 13% [Mar 5, 09]

Immersion down 25% [Mar 3, 09] 

Immersion down 13% [Feb 9, 09]

Immersion down 13% [Jan 20, 09]

Immersion up 14% [Dec 8, 08]

Immersion up 12% [Nov 24, 08]

Immersion down 15% [Nov 14, 08]

Immersion up 10% [Nov 13, 08]

Immersion down 11% [Nov 5, 08]

Immersion up 11% [Nov 3, 08]

Immersion up 12% [Oct 30, 08]

Immersion up 16% [Sep 16, 08]

Immersion down 12% [Aug 1, 08]

Immersion up 15%  [Jun 5, 08]

Immersion up 11% [Apr 29,08]

Immersion climbed 13% amid news that a new CEO and president was appointed [smallcapinvestor.com, Apr 25, 08]

Immersion  up 14% [Jan 31, 08]

Immersion up 14% [Sep 27, 07]

Immersion down 10%. [Aug 15,07]

Immersion dropped 16% after an analyst offered cautious comments on the company's shares ... are pricing in "unachievable" growth opportunities beyond his already bullish assumptions. [Jul 16, 07]

Immersion up 17% [Mar 2, 07]

Immtech Pharmaceuticals

Immtech Pharmaceuticals down 46% after the New York pharmaceutical company said it will discontinue all development for a potential treatment for African sleeping sickness, after the development of kidney and liver abnormalities in a subgroup of volunteers in a safety study of the drug.  [Wall Street Journal, Feb 26] 

Immtech Pharmaceuticals up 15% [Feb 5, 08]

Immtech Pharmaceuticals up 15% [Jan 23, 08]

Immtech Pharmaceuticals down 16%  [Jan 16, 08]

Immtech Pharmaceuticals down 20% [Jan 4, 08]

Immtech Pharmaceuticals up 36% [Dec 28, 07]

Immtech Pharmaceuticals down another 25%  [Dec 27, 07]

Immtech Pharmaceuticals down 51%  [Dec 26, 07]

Immtech Pharmaceuticals up 14% [Dec 5, 07]

Immtech Pharmaceuticals down 10% despite new scientific support for it product. [Aug 14,07]

Immtech Pharma down 10%. [Mar 5, 07]

Immtech Pharmaceuticals up 19% [Dec 14, 06] after its earlier announcement of a Phase 2 trial of a malarial prophylactic.

Immune Control (West Conshohocken, PA)

Immune Control (West Conshohocken, PA; no SBIR) and Arginetix (Baltimore, MD; no SBIR) said they are merging to form Corridor Pharmaceuticals Inc., which will develop novel treatments for vascular diseases with an initial focus on pulmonary arterial hypertension. In conjunction with the merger, Corridor Pharmaceuticals completed a $15 million Series A financing involving previous investors in the two companies.  [John George, Philadelphia Business Journal, Jun 17, 10]

Immune Design (Seattle, WA)

Immune Design   (Seattle, WA; no SBIR), the developer of vaccine technology, said it has pulled in another $11 million through the second tranche of its previously announced Series B venture financing. The company is backed by some prominent VC firms [Luke Timmerman, xconomy.com, Oct 6, 11]

Immune Design (Seattle, WA; no SBIR) said it’s raised $32 million in Series B financing ... developing vaccines and immunotherapies for infectious disease and cancer. ... said it’s raised $50 million since its founding two years ago [Puget Sound Business Journal (Seattle), Jul 26, 10]

Immunetics (Boston, MA)

Infectious disease testing company Immunetics (Boston, MA; $9.2M SBIR) won a three-year, $2.4 million Phase 2 [NIH] SBIR grant. ... aid in bringing its confirmatory test for Chagas’ disease, a potentially fatal parasitic infection, to clinical trials, Immunetics said [Michelle Lang, Mass High Tech, May 3, 11]

Test developer Immunetics (Boston, MA; $7M SBIR) has been awarded a $2.8 million contract as part of a long-term study of blood safety involving HIV and other complications of blood transfusions. [James Connolly, Mass High Tech, May 18, 10]

Immunetics (Boston, MA;  24 workers; $5.5M SBIR) won two federal grants totaling $1.2M to develop a test for antibiotic resistance in bacteria. [Mass High Tech, Jun 6, 08] Company press release [Jun 4] announced [FDA] approval of its test for anthrax infection

Immunex (Seattle, WA)

Pfizer, the world's largest drug company, has agreed to pay up to $632 million to Theraclone Sciences (Seattle, WA; no SBIR) in a research collaboration on antibody drugs for cancer and infectious disease, the companies said ...  The company is led by Steven Gillis, a scientist and venture capitalist who previously co-founded Seattle biotechnology companies Immunex (Seattle, WA; three Phase I SBIRs) and Corixa (Seattle, WA; $4M SBIR).   Amgen bought Immunex for about $16 billion in 2002; GlaxoSmithKline bought Corixa for about $300 million in 2005.  [Duff Wilson, New York Times, Jan 19, 11]  SBIR advocates should calculate the ROI to the government, and the economy, if the government had taken an appropriate equity share for its capital investment. And then insist that future SBIR be managed in such a way to push the investments to such entrepreneurs instead of the life-style companies with no taste for ROI.

ImmuneWorks (Indianapolis IN)

ImmuneWorks (Indianapolis IN; no SBIR) , a life-sciences startup based at Indiana University's Emerging Technologies Center, has developed a therapeutic product it says can help fight IPF and increase the success rate of lung transplants. ... The company last week secured $300,000 in early-stage funding from BioCrossroads' $6 M Indiana Seed Fund 1, and hopes to begin clinical trials by next summer. [Chuck Bowen, Indianapolis Star, Oct 30]

Immunicon

Immunicon slipped 12% after reporting a bigger loss. [Feb 21, 07]

Immunicon down 12% in a soggy week for its stock. [Dec 14, 06]

ImmunoGen   (Cambridge, MA)

Immunogen  up 10% [Nov 30, 11]

Immunogen up 11% [Nov 28, 11]

ImmunoGen is pulling in more milestone payments from Amgen, raking in its second $1 million pay from the company this month.[Mas High Tech, Nov 15, 11]

Immunogen up 13% [Aug 23, 11]

Immunogen up 10% [Aug 9, 11]

Immunogen down 10% [Aug 8, 11]

Immunogen down 11% [Aug 4, 11]

Immunogen up 10% [Jul 6, 11]

ImmunoGen said that it has earned a $2 million milestone payment after its partner in a licensing agreement, Bayer HealthCare Pharmaceuticals, submitted an investigational new drug application.  [Boston Globe, Jun 15, 11]

ImmunoGen has priced a public stock offering of 7 million shares of common stock at $12 per share, expected to bring in gross proceeds of about $84 million [Mass High Tech, May 20, 11]

Immunogen up 27% [Apr 7, 11] on news that its potential therapy for breast cancer achieved positive phase 2 trial results.  [Julie Donnelly, bizjournals,com, Apr 7]

ImmunoGen said it has initiated a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901, for first-line treatment of small-cell lung cancer in patients with extensive disease. [Boston Globe, Nov 30, 10]

ImmunoGen has agreed to work with Novartis on targeted anticancer therapeutics developed using ImmunoGen’s Targeted Antibody Payload (TAP) technology, in a deal potentially worth nearly $250 million – and potentially much more. [Mass High Tech, Oct 11, 10]

Immunogen up 10% [Aug 30, 10]

ImmunoGen  plunged 38% yesterday after US regulators rebuffed a bid to gain fast-track status for a breast cancer drug it is developing with the Genentech unit of Swiss pharmaceutical giant Roche Holding AG. [Boston Globe, Aug 28, 10]

ImmunoGen said it will receive a $1 million milestone triggered by the start of a clinical trial by sanofi-aventis, a global drug maker. [Boston Globe, Jun 25, 10]

Immunogen up 10% [Jun 17, 10]

ImmunoGen said it raised $77.6 million through a stock offering after deducting expenses. [Boston Globe, May 11, 10]

ImmunoGen expanded its planned stock offering, and now expects to raise $67.4 million in net proceeds. [Boston Globe, May 7, 10]

Immunogen  down 12% [May 6, 10]  announced plans to offer at least 8.5 million shares of common stock. [WSJ, May 7]

ImmunoGen reports the [FDA] and the EU Committee for Orphan Medicinal Products has granted orphan drug status to an ImmunoGen compound used to treat Merkel cell carcinoma (MCC).  The compound, IMGN901, has shown effectiveness in treating MCC, a rare aggressive neuroendocrine cancer of the skin that typically occurs on the head/neck, most often in individuals of European ancestry, according to the company.  [Mass High Tech, Mar 10, 10]

Roche and ImmunoGen reported on a "guided missile" combination drug called T-DM1 that shrank tumors by 30% or more in one-third of critically ill, advanced breast cancer patients in a trial. The therapy combines Roche's Herceptin with a second, potent cancer-killing drug from ImmunoGen, with Herceptin acting as the guidance system, using its ability to home in on cancer cells to deliver the treatment directly to its target. [BusinessWeek.com, Dec 17, 09]

ImmunoGen announced a second license granted to Amgen Inc. for its maytansinoid Targeted Antibody Payload technology for an undisclosed target. The deal promises a $1 million upfront payment to ImmunoGen, with up to $34 million in milestone payments and additional royalties [Mass High Tech, Nov 20, 09]

Immunogen down 11% [Oct 30, 09]

ImmunoGen ($1.6M SBIR in the 1990s) today priced its public offering of 5 million shares of common stock and expects proceeds of $33 million. [Boston Globe, Jun 19, 09]

ImmunoGen (Waltham, MA; $1.6M SBIR) has raised $24.7 million through a purchase of 7.8 million shares of common stock. [Mass High Tech, Jun 23,08]

ImmunoGen (Cambridge, MA; $1.7M SBIR) earned a $1.5 million milestone payment in connection with a drug candidate for treating certain types of tumors.  [Boston Globe, Feb 2]

Immunomedics

Immunomedics  up 13% [Feb 17, 10]

Immunomedics  down 11% [Jan 26, 10]

Immunomedics up 24% [Jan 8, 10]

Immunomedics up 13% [Oct 29, 09]

Immunomedics down 11% [Oct 1, 09]

Immunomedics down 15% [Aug 28, 09]

Immunomedics ($4M SBIR) rose 61% after announcing with partner UCB SA that a midstage trial comparing their treatment with placebo for treating lupus over 12 weeks showed "meaningful treatment effect."  [Wall Street Journal, Aug 28, 09]

ImmuRx (Lebanon, NH]

ImmuRx (Lebanon, NH) vaccine developer for cancer and chronic infections, has pulled in $250,000 in seed funding ....  brings additional funding to the $329,000 SBIR grant from the NIH [Mass High Tech, Jun 18, 08]

ImmusanT (Cambridge, MA)

Born from research in Australia, ImmusanT (Cambridge, MA; no SBIR) has launched to commercialize a therapy that aims to treat celiac disease like a simple allergy with regular injections of a therapy. [Mass High Tech, Mar 15, 11]  ...  The company, which said in a press release that it has secured seed financing from angel investors, is calling its drug candidate vaccine Nexvax2. Celiac disease is a lifelong autoimmune disorder that is triggered by foods containing gluten, the main protein in wheat, rye, and barley. [Boston Globe, Mar 15]

Impact Science Technology [Nashua, NH]

Bombs Away.  Impact Science & Technology [Nashua, NH] won the contract for the production and support of 1,100 "vehicle-mounted counter-radio-controlled IED electronic-warfare systems," according to the U.S. Department of Defense. The technology is expected to be produced quickly for use in the field by U.S. troops in Iraq and Afghanistan. [Mass High Tech, Apr 16] No SBIR, and not be confused with Impact Technologies (Rochester, NY) which has at least 30 SBIR Phase 2s in the last decade. IS&T is also now a subsidiary of EDO.

Imperium Renewables (Seattle, WA)

Imperium Renewables formally withdrew its proposed $345 million initial public offering this morning, blaming "unfavorable market conditions." The Seattle-based company, which operates the largest biodiesel facility in the U.S  [Angel Gonzalez, Seattle Times, Jan 3]

Imperium Renewables in Seattle, which is armed with $145 M in VC and private equity funding. Imperium buys practically every drop of oil U.S. algae startups are producing. ... expects startups to be making 100 million gallons a year. At that point, Tobias reckons, the price per gallon will fall to $1.70, from as much as $20 today. [Gail Edmonson, Business Week, Dec 3]

Impinj (Seattle, WA )

Impinj  (Seattle, WA ; no SBIR) a technology company that designs and sells RFID chips used for tracking everything from pants to prescription drugs, filed to raise up to $100 million [IPO]. ... founded 2000 ... has never been profitable  [Sanjay Bhatt, Seattle Times, Apr 21, 11]

Implant Sciences (Wakefield, MA)

Implant Sciences announced a contract totaling approximately $6 million for its Quantum Sniffer(TM) QS-H150 Portable Explosives Detectors and associated support. ... by the Government of India, for use by the Ministry of Defence (MoD) in Force Protection and Public Safety applications throughout the country. [company press release]

Implant Sciences disclosed Tuesday it missed a $7.65 million payment on its convertible promissory notes and is working with its lender to negotiate the financing of the loans. ... for the fiscal year ended June 30 ...,it generated $8.7 million in revenue and $12.8 million net loss. [Jackie Noblett, Boston Business Journal, Dec 23, 09]

Implant Sciences reports it has landed $1.2 million from a government agency in China for its explosive detection technology.  Under the deal, the Wilmington-based defense and homeland security sensor maker will deliver its Quantum Sniffer QS-H150 Portable Explosives Detectors to be used for transportation security applications throughout China.  [Brendan Lynch, Mass High Tech, Aug 14, 09]

Implant Sciences raised $5.6 million in a note and warrant sale on condition that two board members be replaced, including David Eisenhaure, founder of Sat Con Technology. [Mass High Tech, Dec 17, 08]

Implant Sciences reports that its wholly owned subsidiary, Core Systems, has been sold to the group’s management in a $3 million deal.  ...  has been gradually shedding parts of its business since the beginning of the year.  [Mass High Tech, Nov 17, 08]

Implant Sciences has retained the services of an M&A advisory firm to help with “strategic alternatives,” one day after Implant reported a fourth quarter loss of $2.46 million. [Mass High Tech, Oct 16, 08] The stock traders have already marked the company way down below the buck despite its most recent Phase 2 SBIR.

Implant Sciences continues to shed medical IP business assets, this time announcing a sale to Best Medical International The definitive agreement, closing on September 18, ensures that Best pay $100,000 initially to acquire Implant’s intellectual property from its former brachytherapy products business. [Mass High Tech, Jul 30,08]

Implant Sciences reports it has sold equipment used to make coatings for medical products for $750K as part of a plan to withdraw from the medical coatings business.  [Mass High Tech, Jul 3, 08]

Implant Sciences got $2.7 M in contracts for its portable explosives detection systems  [Mass High Tech, May 29,08]

Implant Sciences reports plans to sell Core Systems, the company's wholly owned semiconductor subsidiary. [Mass High Tech, Feb 21]

Implant Sciences is reaching for world markets in its appointment of Richard Meyerhoff as its new Vice President of Sales and Service in the Security Division. He holds a BA in Economics from Universidad Catolica Argentina and an MBA from the University of Michigan. Mr. Meyerhoff speaks several foreign languages and has had responsibility for leading and managing sales operations, distributor networks and business units in the U.S., Middle East, Asia-Pacific, Europe and Latin American regions. [company press release, Nov 26, 07] Notably, the company has five directors: its two founders, two from SatCon Technology, and a former CEO of a medical products company.

Implant Sciences shipped six units of the company's Quantum Sniffer BTS benchtop bomb-finding system to Beijing for the Olympics.

Pulling Up Seeds. Implant Sciences completed the first phase of its plans to get out of the radioactive prostate seeds business. [Mass High Tech, Jul 2, 07] 

Implant Sciences is down to 10% of its stock price three years ago. [Jun 07]

Implant Sciences got a patent for a device used in an automated explosives detector capable of desorbing trapped explosives vapors at speeds of less than 1 millisecond.. [bizjournals.com, Apr 3, 07]

Implant Sciences got a service contract that could be worth up to $1.5M from a big tech company. [Mass High Tech, Jan 31]

Implant Sciences up 10% on news that its quantum sniffer would show up in a prime-time TV show. [Nov 20, 06]

Implant Sciences up 11% [Oct 25, 06] and down 7% the next day.

Implant Sciences jumped 17% after saying it expected a big revenue jump. [Sep 06]

Sniffer Orders Flowing.  Over the past several weeks [Implant Sciences] has received domestic orders from public agencies and private companies that plan to use the detectors for shipboard, cargo and overnight delivery security The latest is New Jersey which brings orders to $20M in the past 12 months. [Mass High Tech, Jun 19]  Unfortunately, all those sales led to a $7M loss. Now if they could make it up in volume.

Implant Sciences shot up 11% Wednesday (Apr 13, 06) on news of a Chinese order for another twenty quantum sniffers.

101 Noses.  Although chemo-explosive detectors don't do as well as dogs, China is buying 101 Quantum Sniffers from Implant Sciences for several million dollars. The stock traders loved it and ratcheted the price up an enthusiastic half before dropping back to +10%.  Implant Sciences led the AMEX percentage gainers with 10%. [7/20/05]

Implant Sciences ships product and wins patents but the stock traders don't seem impressed. two more Quantum Sniffer handheld explosives detection devices overseas to exclusive sales agents in Italy and Kuwait ... a fourth patent for its trace explosives detection technology. The patent, titled “Virtual Wall Gas Sampling for an Ion Mobility Spectrometer,” covers a special form of gas sampling vortex in which a large space is enclosed by spinning air.  [Mass High Tech] Meanwhile, the stock price is down to 20% of its roller-coaster high. 

Implant Sciences got a patent for its explosives detection system's vortex air sampling system used in its Quantum Sniffer explosives detection systems. [Apr 05]

Implant Sciences paid $11.3M to acquire Accurel Systems International - a Silicon Valley commercial laboratory specializing in Failure Analysis Microscopy, Transmission Electron Microscopy and Focused Ion Beam Circuit Repair Services. The unimpressed stock traders hit the stock another 10%, driving the price to below half of its year-ago price. [Mar 10, 05]

Implant Sciences sold $7.8M of stock plus warrants to unnamed institutional investors.CEO Tony Armini said the proceeds will be used for an acquisition.  [Mass High Tech, Mar 9, 05]

Implant Sciences sold a Quantum Sniffer (QS) explosives detection devices to the Pakistan Airport Security Force. [Mass High Tech, Nov 29, 04]

Buying Cash Flow.  Implant Sciences is buying Core Systems (Sunnyvale, CA) to provide a steady cash flow to fund new explosive detection products without needing to dilute shareholders by raising money in the capital markets, says CEO Tony Armini.  Core and Implant compete in semiconductor wafer processing which has become almost a sideline for Implant as it tries to cash in on new explosive detection technology. Sounds like Implant thinks it can get a better return for its $2M cash than simply buying Treasury bonds as semiconductor stocks are wallowing. [Mass High Tech, Oct 14]

Sniffing a Market. Implant Sciences sold a dozen trace explosive sniffers to the Army as the first order for commercial quantities of the Quantum Sniffer. That follows a $1.7M Navy production. contract. The market liked the news and put the stock up 32% last week. [Jun 04]

Implant Sciences up 15% for the week even though the quarterly earnings report emphasized government R&D contract revenue and a $1.1M loss (buried in the fourth paragraph) blamed on the expense of performing those contracts. 

Implant Sciences,  got a $1.7M Navy contract for a test buy of three explosive sniffers. Implant's stock is up 40% in the past month and has quintupled in a year. In a demonstration that a small company with a new technology doesn't need SBIR to succeed, and may be actually held back in development by SBIR, Implant got the Navy attention with a TV appearance of its Quantum Sniffer. Once alerted that there was publicly known technology that seemed to work and that the politicians would soon be badgering the military about it, the Navy instantly found the money for a contract. The moral is that if your gizmo works, get as public a demonstration of it as you can muster. High noon in Times Square if you can arrange it. All the bureau talk about budgeting and program limits and such and such will disappear in a New York minute. The downside is that you take all the R&D risk but then you own the intellectual property and the world will rush to your door in the classic better mousetrap. For those with no money and no courage, keep applying in 25 pages or less to the government for money to develop your unproved ideas such that the government takes all the risk. SBIR is perfect for mediocrity of both company and government.  

Implant Sciences got a $600K deal with TSA to demonstrate its table-top explosive sniffer with the promise (governmental promise, of course) for $400K more if all goes well.  TSA desperately needs  an explosives detection device that can be used in a wide variety of security screening applications, including screening luggage, passengers, cargo or vehicles. Especially cargo. [Oct 03]

Implant Sciences stock has doubled this summer even though the company is still not profitable. Its "Quantum Sniffer" has attracted government attention with a Marine Corps SBIR (Phase 1 only so far)  and live demos at  the ASIS International show for security professionals. The Quantum Sniffer  uses proprietary laser ion mobility spectrometry technology which electronically detects minute quantities of explosive vapor molecules in the air.

The stock price of Implant Sciences has taken a drubbing this year, Friday's 7% decline brought the price to about half its Jan 1 (2003) price. The last good news was a Phase 1 SBIR for $70K in December. Press releases for Phase 1s are not the stuff of confidence.

Implant Sciences got $2.5M convertible financing and an invitation to show its prototype explosives detector at DOT laboratories whereafter it got test and evaluation processing. Since DOT is probably buried in security gizmos, don't wait up for a volume procurement.

Half a minute for a whole company. Implant Sciences says it will become an explosive detector company with its two prototype explosives detectors being readied for a queue of customers. Its laser ion mobility spectrometer sucks up particles from a suitcase and looks for traces of explosive in 5-10 seconds, a practical improvement over 47 seconds per scan. Half an airport minute saved for the frenetic business traveler. CEO Tony Armini says the company is in discussions with government (so are zillions of other potential contractors with new gizmos). [facts by Matthew French, Mass High-Tech, Aug 5] TSA has a long queue in the waiting room with detectors sure to solve the explosive detection problem. Just send money. Implant has been around for 16 years, the last few years as a public company with a variety of sub-critical products on which it can lose a little money. The stock traders were not impressed by the announcement as the stock went down on a big up day.

Implant Sciences finished developing its handheld explosives detection product and plans commercially availablility by 2003. Nevertheless, the soggy NASDAQ market has bit a fourth from the market cap.

More Revenue, Less Loss, says Implant Sciences as revenue rose 37% and losses decreased fir nine months. The press release prattles about the relatively good news nine-month results before getting to the latest quarter in which losses grew to $1M rather than shrunk. With only $1.6M in cash, how much longer can it keep trying to make up in volume what it loses in transactions?

An Explosive Sniffer(Dec 11)Implant Sciences shot up by half, and led the AMEX percentage gainers, when it said on Dec 4 that it had developed a prototype explosives sniffer. Implant said that the sniffer could detect vapor from at least five types of explosives, at airborne concentrations measured in parts per trillion. The system is 100 to 1000 times more sensitive than the capabilities of explosive-sniffing dogs. Which is good because the dogs are getting tired everywhere since Sept 11. Implant has had no Phase 2 SBIRs that sound like the source of this sensor although it has had a smattering of Phase 1s over the decade.

Implant Sciences reported sales up 58% and losses down 42% thanks to the growing sales of I-Plant(TM) radioactive seeds for the treatment of prostate cancer.

More Implant Workers. (Sep 12) Implant Sciences said it would immediately increase its production workforce by half to keep up with growing demand for its radioactive seeds used to treat prostate cancer. It said that demand for its I-Plant Iodine-125 brachytherapy seeds has grown at a compounded rate of 27% per month since it became commercially available last November. With that kind of growth in sales, it might even start to make a profit.

Implant Sciences took in 44% more revenue for the quarter to just equal the loss of $700K in the same quarter last year.CEO Tony Armini said We are extremely pleased with the significant progress .

Implant Deal on Stent
(Mar 23)Implant Sciences (Wakefield, MA) which develops products for the radiation oncology, interventional cardiology and orthopedic markets, announced it has entered into a joint development agreement with CardioTech International to begin a new research program to develop a porous polymer covered vascular stent. This joint research and development program will utilize CardioTech's proprietary porous polymer biocompatible coating technology as a platform for Implant Sciences' proprietary radioactive brachytherapy technology. The total vascular stent market is estimated today to be in excess $2B. The polymer covered stent is expected to reduce restenosis after balloon angioplasty by providing means for either local radiation delivery, drug delivery or gene therapy within the polymer. This porous polymer could also provide a platform for CardioTech's endothelial cell seeding technology. [company press release, Mar 21,00] CEO Tony Armini made the usual cooing noises.

Mass Says OK to Implant Sciences
(Jan 13)Implant Sciences (Wakefield, MA) says that Massachusetts OK'ed a license to make and sell its I-Plant(TM) Iodine-125 brachytherapy seeds that are good for radiation oncology, interventional cardiology and orthopedic marketplaces (love those multi-syllable words). Implant says Permanent implant of radioactive seeds for the primary treatment of prostate cancer is a relatively new technique that is rapidlygaining acceptance as a method of treating early stage prostate cancer. The market liked it, pushing IMX up 11% - back above its IPO price from which it had lost 50% only a few months ago. No, no info-tech involved unless you count the new BMDO SBIR for the world's first ion implanted blue light emitting diode (LED) produced from gallium nitride. Implant has had almost no SBIR support since its founders split from Spire which has had tons of SBIR support.

Implant Moves to AMEX
(Sep 9) An SBIR stock moves to a bigger pond as Implant Sciences (Wakefield, MA) moves to the AMEX. All SBIR companies heretofore have stayed on NASDAQ after going public. CEO Tony Armini, a 1980s escapee from Spire Corp said, The Amex will provide Implant Sciences with heightened visibility, a potentially larger investor base and a more liquid auction market. Which seems an old view in the face of the huge market cap corporations like MSFT and INTC on NASDAQ and likely to stay there. Inmplant's market cap is only $35M but visibility counts for a lot in the capital game.

Implant Comes Out
(Jun 25) After a delay caused by the original underwriter's failure to buy the shares, Implant Sciences (Wakefield, MA) started trading. Priced at 7.50,the stock closed at 8.125 after the first day of trading. Implant has had precious little SBIR even though the firm its founders came from, Spire has had a ton but is now looking for a savior. Tony Armini and Steve Bunker developed a real commercial business in ion implantation to compete with Spire. Officially, Implant's main business is developing medical radiation therapy implant devices. In the line of future business, it has a new Phase 2 SBIR from BMDO for a new version of gallium nitride for blue lasers.

Implant Sciences IPO
(May 4) Implant Sciences (Wakefield, MA) first went public and then pulled it the next day before trading started due to market conditions It had priced 18% of the company at $7.8M. Implant, formed by two escapees from Spire (Bedford, MA), has had 25 Phase 1 SBIRs and one Phase 2 (1991, Army). BMDO just picked Implant for its second Phase 2, no doubt with substantial co-investment by real business partners. Implant has been on the brink of an IPO for months waiting for the right moment.

Implant Sciences IPO Due
(Feb 15) Implant Sciences (Wakefield, MA) is scheduled for IPO this week to raise $8M. Although Implant has had only one Phase 2 SBIR, it is the type of company that would do something commercial with a decent result because SBIR is clearly NOT its business focus. Its founders split from an SBIR multi-multi user, Spire, to do ion implantation its own way.

The IPO of Implant Sciences (Wakefield, MA) to raise $8M for 19% of the equity has been put off to January. The firm plans to make radioactive seeds (awaiting FDA approval) to treat prostate cancer; it also wants to sell coronary stents, catheters, and other devices with radioactive coatings that make them visible when X-rayed. The company currently uses proprietary ion implantation techniques to alter the surfaces of semiconductors and orthopedic devices (thus minimizing friction and wear). [Hoover's] Implant Hopes for IPO
(Nov 9) Implant Sciences (Wakefield, MA) filed Sep 29 for an IPO to raise $7.8M. Says Hoover's Implant Sciences hopes to counter the growth of cancer with the seeds of science. The firm plans to make radioactive seeds (awaiting FDA approval) to treat prostate cancer; it also wants to sell coronary stents, catheters, and other devices with radioactive coatings that make them visible when X-rayed. The company currently uses proprietary ion implantation techniques to alter the surfaces of semiconductors and orthopedic devices (thus minimizing friction and wear). Sales to Biomet and Stryker account for some 48% of sales. Chairman, president, and CEO Anthony Armini will own nearly 27% of the company after it goes public; VP and chief scientist Stephen Bunker will own 14%. Implant has used some SBIR, not enough to get dependent - a little over $1M 1993-97 all Phase 1s.

Impulse Monitoring (Columbia, MD)

ImThera Medical (San Diego, CA)

Houston’s Cyberonics, which makes an implantable neurostimulation device used to treat epilepsy and depression, says today it’s making a $4 million investment in San Diego startup ImThera Medical (San Diego, CA; no SBIR). Cyberonics says its investment could eventually total $12 million, providing that ImThera meets certain milestones. ... has been developing technology that fits neatly with Cyberonics’ core expertise in neuromodulation.  [Bruce Bigelow,, xconomy.com, Oct 56, 11]

ImThera Medical  (San Diego, CA; no SBIR) developer of a neuro-stimulation device for treating sleep apnea, has raised $1 million of a planned $2.2 million round of equity financing,  [Ryan McBride, signonsandiego.com, Nov 19, 10]

i-Nalysis (Concord, MA)

i-Nalysis (Concord, MA; no SBIR) has landed a six-figure round of angel funding and its first customer for the company’s handheld materials analyzer ... X-ray Fluorescence Spectrometer  is a small, light and inexpensive device that identifies the elemental analysis “of almost anything,”  [Mass High Tech, Dec 22, 09]

INC Research (Raleigh, NC)

A private equity firm and a Canadian pension fund have agreed to acquire INC Research, (Raleigh, NC; no SBIR) that assists drugmakers with clinical trials.  [Raleigh News & Observer, Aug 20, 10]

Incelldx (Menlo Park, CA)

In its first round of venture funding, medical test maker Incelldx (Menlo Park, CA; no SBIR) raised $3 million. ... led by CEO Bruce Patterson, M.D., who started it after about a decade of research at both Northwestern and Stanford universities. [Stephen EF Brown, San Francisco Business Times, Jun 8,10]

Incyte  (Wilmington, DE)

Eli Lilly is laying a $90 million bet on an arthritis drug developed by Incyte (Wilmington, DE; no SBIR)  [Jeff Swiatek, Indianapolis Star, Dec 22, 09] Incyte's last five years highly variable revenue with losses totaling $600M against which it has raised $800M from securities sales. [Thomson Reuters]

Indiana Nanotech

 "I knew nothing about teeth." A year-old life-sciences company .. six months away from bringing its first product to market. .. Robert Karlinsey earned a doctorate by studying the way nanoparticles behave when water turns to ice. One day, while waiting for some test samples to freeze, he got to thinking about new applications for his work. By looking at calcium, fluoride and other chemicals at a molecular level, Karlinsey found he could combine them to form a substance with unique properties. [that] actually does a better job than its individual elements of protecting people's teeth from decaying. Indiana Nanotech [no SBIR], founded in October 2006, has raised $300,000 in seed money, [and] hopes to have its first product, a fluoride mouth rinse, to market by February. [Chuck Bowen, Indianapolis Star, Sep 11]

Infinera

Infinera down 11% [Oct 19, 11]

Infinera up 10% [Aug 1, 11]

Infinera down 18%  [Jan 28, 11]

Infinera down 35% [Oct 19, 10] following lowered guidance from the company [Forbes, Oct 19]

Infinera up 31% [Jul 23, 10]

Infinera up 10% [Jul 22, 10]

Infinera down 19% [Jul 20, 09]

Infinera up 10% [Jun 4, 09]

Infinera  down 15% [Apr 22, 09]

Infinera up 11% [Mar 12, 09]

Infinera up 15% [Mar 10, 09]

Infinera  down 18% [Jan 30, 09]

Infinera down 13% [Dec 15, 08]

Infinera  down 16% [Dec 1, 08]  On a stock bloodbath day

Infinera up 10% [Nov 26, 08]

Infinera up 13% [Nov 24, 08]

Infinera up 10% [Nov 17, 08]

Infinera up 14% [Oct 16, 08]

Infinera down 16% [Oct 15, 08]

Infinera up 15% [Oct 10, 08]

Infinera down 14% [Oct 2, 08]

Infinera up 18% [Sep 19, 08]

Infinera down 13% [Sep 9, 08]

Tools for An all-optical Internet. one-centimeter-square chips built at Infinera (Sunnyvale, CA). Each chip contains more than 40 optical devices that are important to managing the transmission of data on light beams; due to be commercialized this summer, they can replace individual components within Internet hubs. And this fall ­Luxtera (Carlsbad, CA) is commercializing a chip that integrates 100 optical components on silicon. [MIT Tech Review, J/A08]

Infinera up 10% [Jul 23, 08]

Infinera down 26% after it cut its full-year revenue forecast and projected third-quarter sales well below analysts' expectations. [Wall Street Journal, Jun 18, 08]

Infinera down 18% [Apr 23, 08]

Infinera down 10% [Mar 10, 08]

Infinera down 10% [Feb 29, 08]

Infinera up 44% [Feb 1, 08] on losing a lot less than expected.

Infinera up 10% [Jan 23, 08]

Infinera down 10% [Jan 15, 08]

Infinera down 12% [Jan 4, 08] on a day of NASDAQ pain that puts it at half its first day price last summer. Intel was down 15% for the week and one wag opined pushed small-capitalization stocks to the brink of a bear market

Infinera expects to raise $240M this week with a secondary. [Oct 07]

Infinera up 12%. [Jun 28, 07]

Infinera up 12% after a big commo provider picked its Digital Optical Network for its regional network.  [Jun 15, 07]

Infinera was up 28% after shooting up 52% the day before above its IPO price. [Jun 8, 07]

Infinera ($2M SBIR) filed to go public. [Feb 07]

David Welch, looking younger than he did a decade ago, graces the story on his new photonic integrated circuit at his start-up Infinera. [story by Kate Greene, MIT Tech Review, J/F 07] David was chief at R&D at SDL which sold itself for uncounted zillions to JDS Uniphase near the top of the IT bubble. He has had at least $1.3M in SBIR to supplement his apparent re-cycling of his profit from SDL.

Infinia (Kennewick, WA)

Infinia (Kennewick, WA; $3.6M SBIR) is raising another truckload of money. ... backed by Paul Allen and Vinod Khosla, has snapped up $11.5 million in new equity financing out of a round that could bring in as much as $75 million over time, according to a regulatory filing. ... developing solar-powered [Stirling] engines to generate large amounts of electricity in a renewable way  [xconomy.com/seattle, Feb 5, 10]

Infinia (Kennewick, WA; $3.5M SBIR)  which is using Stirling Engines to convert the sun’s rays into electricity, has raised $14 million in debt financing, according to a filing with the SEC. ...  part of a $50 million capital raise — follows a massive $50 million venture round  [John Cook, Puget Sound Business Journal, May 22. 09]

Infinity Pharmaceuticals (Cambridge, MA)

Infinity Pharmaceuticals (Cambridge, MA; no SBIR), a cancer drug discovery and development company, said that it has "elected to terminate" a trial of a drug candidate called IPI-504 in patients with refractory gastrointestinal stromal tumors.   [Boston Globe, Apr 16, 09]

Inform Genomics (Boston, MA)

Inform Genomics (Boston, MA; no SBIR, founded 2010) reports it has secured an undisclosed amount of funding from angel investors and individuals, including company founders and members of the board of directors. ....  to move along development of its molecular diagnostic product called ONPART, which uses genomics to predict what side effects a specific cancer patient might encounter with chemotherapy treatments.  [Rodney Brown,  Mass High Tech, Dec 1, 11]

Infoscitex

Infoscitex (formerly Foster-Miller (says SBA), or at least some part thereof, $13M++ SBIR from at least 87 projects since 2005 (SBA database crashes just trying to spit out the data))  landed $49.5 million from the USAF ....   will create modeling, simulation, and analysis tools and techniques for research and engineering for the Air Force...   [Mass High Tech, Mar 19]    Vision and Mission go beyond simple elevator-pitch statements. Our values are the underpinning of our culture and these core values are the primary reasons for our success.   got that?  ...currently employs 80 professionals throughout the U.S. and anticipates revenue of $17 Million in 2008.[company website] got that?

Inframat

 Inframat and its sister company, US Nanocorp...  are idea labs. In 2003 the companies pulled in $3M in revenue, only 10% from commercial sales. The bulk was government research money, the main source of the $20M grants and contracts Reisner has sucked up since 1996, when he started out, from the likes of the Navy, NASA, the National Institutes of Health and other agencies. Private capital abhors abstruse products that can take years to reach the market. Besides, he says, "We would have had to give away half the company for a few hundred thousand dollars."  ...  Reisner, who has three children, quit his job and lived off the income of his wife, who has an ob-gyn practice. ... cranking out nanopowder by the ton. At $35 a pound the stuff will help pay the salaries of all those Ph.D.s. (Some of whom "understand when we miss the payroll by a few days," says Hsiao.) Powder sales have totaled $100K in the last three years. [Thomas Kellner, Forbes, Jun 21] Another SBIR company living on government money until the happy day when the commercial world (or military procurement) cottons on to nanostuff. Could be a long haul to his retirement or bankruptcy. Moral: if you're going to depend on SBIR for your advanced technology dream, marry a doctor with a practice. Meanwhile, the government SBIR people may tout your technology for their commercialization reports without giving you any money. Especially if your payoff to their programs is far in the future.

InfraReDx (Burlington, MA

InfraReDx said it has raised $24.1 million from the sale of equity to existing InfraReDx shareholders. Some of the funding will be used to support the recent launch of a coronary imaging system that can detect coronary plaques.  [Boston Globe, Jun 28, 11]

InfraReDx (Burlington, MA; no SBIR) medical device company announced the completion of a $21 million equity financing. ... support the launch of its LipiScan IVUS Coronary Imaging System.  [Boston Globe, Oct 12, 10]

InfraReDx (Burlington, MA, no SBIR) medical device company, said it has gotten a regulatory clearance to market a coronary imaging system. [Boston Globe, Sep 1, 10]

Until last October, InfraReDx (Burlington, MA; no SBIR) considered itself a symbol of the kind of science-based innovation that creates durable healthcare industry jobs. Now, InfraReDx represents the perils of the recession for small companies working on promising medical technologies that hospitals and insurers see as experimental. The company, which makes a laser-scanning system that locates signs of heart disease, has been through two rounds of layoffs, reducing its work force to 72 from 92. It would have run out of money this month if its investors had not agreed to a new round of investment.  [Barnaby Feder, NY Times, Apr 5, 09]

US regulators approved the first device that lets doctors see fat buildup inside coronary arteries to gauge heart attack risk. ... made by InfraReDx (Burlington, MA; no SBIR).  [Boston Globe, May 1, 08]  a privately-funded, early-stage medical device company with expertise in photonics and medicine. ... founded in 1998 ... to develop novel, photonic-based medical devices that will help improve the diagnosis and treatment of various diseases [company website]

InfraScan (Philadelphia,PA)

InfraScan (Philadelphia, PA; $1M SBIR) has signed a $2 million  [SBIR Commercialization Pilot Program] contract with the U.S. Marine Corps to create a portable device to detect traumatic brain injuries on battlefields and other operational environments. Head wounds, according to military officials, lead to nearly 50 percent of combat deaths. .... The Infrascanner has obtained European marketing clearance and is marketed in Russia, Italy, Romania, Saudi Arabia, Panama, Turkey and India. An application to sell the product in the United States is currently under FDA review   [John George, Philadelphia Business Journal, Jul 19, 10]

Inhibitex (Alpharetta, GA)

Inhibitex up 20% [Nov 29, 11]

Inhibitex up 93% [Nov 21, 11]

Inhibitex up 14% [Nov 7, 11]

Inhibitex up 116% [Nov 4, 11]  after the company released promising new data on its hepatitis C drug candidate. [thestreet.com]

Inhibitex up 13% [Oct 17, 11]

Inhibitex  up 11% [Aug 15, 11]

Inhibitex up 31% [Apr 1, 11] after reporting positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus (HCV). [Business Wire]

Inhibitex up 12% [Mar 31, 11]

Drug developer Inhibitex (Alpharetta, GA; one SBIR a decade ago) down 24% [Dec 13, 10] following news that its potential shingles medication did not test well in a mid-stage clinical trial. [Atlanta Business Chronicle, Dec 14, 10]

Inhibitex (Alpharetta, GA; one SBIR) was dogged again in the third quarter by higher research and development costs. ...  ... a net loss of $4.5 million [Atlanta Business Chronicle, Nov 6, 09]

INI Power (Cary, NC)

INI Power Systems (Cary, NC; $800K SBIR while in IL) raised $4M VC as the company moves closer to marketing methanol-powered fuel systems that could replace batteries in portable electronic devices [Raleigh News & Observer,  May 31]

InnerPulse (Research Triangle Park,NC)

A recent beneficiary of venture capital is InnerPulse, a Research Triangle Park [NC] medical device company that is developing a defibrillator for reviving a heart. A group of venture capitalist firms invested $15.1M in the company in late 2003, even though its technology was unproven. Now, InnerPulse has 40 employees and is on track to test its device -- which would be implanted like a pacemaker -- in humans next year. The company has raised $85M in financing. [David Ranii, Raleigh News and Observer, Mar 21]  No SBIR.

InnerOptic Technology (Hillsborough, NC)

InnerOptic Technology (Hillsborough, NC; $500K SBIR), working on ultrasound equipment that promises to help surgeons, has raised up to $370,000 from private investors and CatoBioventures. [Raleigh News&Observer, Dec 20]  Launched in 2003, InnerOptic is a spin-off of the University of North Carolina at Chapel Hill's pioneering Computer Graphics Department. [company website]